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 1 
I.  INTRODUCTION 
 
A.  Statement of the Problem 
 
Ibuprofen is a prototypical nonsteroidal anti-inflammatory (NSAI) agent, used for 
the treatment of rheumatoid arthritis, post-operative pains, pains associated with common 
colds, etc. (1).  The drug has also been shown to attenuate the effects of modulators of 
inflammation which are implicated in the pathogenesis of Alzheimer’ s disease (2,3). 
Ibuprofen is a poorly water-soluble drug with poor flow and compressibility 
properties (4,5).  Poor compressibility and flowability have continued to present 
considerable challenges in pharmaceutical unit processes such as tableting and filling of 
hard gelatin capsules. Flowability problems also result in poor content uniformity.  Co-
processing of ibuprofen with an excipient into ready-to-use microparticulates (spheroids) 
could potentially be useful to improve flowability, friability, compressibility and content 
uniformity of the drug (6,7).  Moreover, co-processing with less number of excipients 
would reduce the problem of bulkiness usually associated with the multicomponent 
commercial formulations.  In addition, spheroids have been shown to possess lower level 
of gastric irritation and fewer dose-dumping accidents (8).   
In the development of spherical microparticulates or spheroids, extrusion 
spheronization has been the method of choice.  However, it involves four major steps, 
and the process is difficult to optimize, reproduce and scale-up (9,10).  In contrast, rotor- 
disk fluid-bed technology is a one-step closed process that utilizes a rotor, which can also 
be used for spheronization, drying, drug layering and coating.  Moreover, the rotor-disk 
 2 
fluid-bed can be automated, which enhances scalability, batch-to-batch reproducibility 
and reduction of process time and cost (6,11,12).  The fluidization of the particles can 
also lead to cost-effective product with desirable content uniformity. 
The fluid-bed operation is a multivariable process and optimization and scale-up 
of the process are difficult to accomplish (13,14). This is due to interplay of the variables 
and their influence on obtaining products with desirable qualities.  Moreover, achieving 
desirable batch size, drug loading and the use of different particle sizes of the same drug 
to obtain good spheroid qualities were reported as major draw backs of the rotor-disk 
spheronization process, thus limiting the utility of the technology (15,16).  Reports on this 
are limited especially on the optimization and scale-up of rotor-disk fluid-bed technology. 
This is possibly due to the fact that many companies could have proprietary information 
that are inaccessible to the general public.  Therefore, optimization of the process through 
statistically designed experiments would lead to understanding of interplay or interaction 
of variables and their effects on formulation and subsequent scale-up.  
In addition, ibuprofen, being a rapidly absorbed drug with high bioavailability 
(>80%) and short biologic half-life (1.5 - 2 hrs; 17), there is high probability for lack of 
patient compliance.  Therefore, a sustained release formulation will alleviate this problem 
through reduction in dosing. 
Ibuprofen is a potent non-specific cycloxygenase and prostaglandin inhibitor 
which makes it amenable to significant adverse effects, including gastrointestinal tract 
irritation, following the large conventional oral delivery (18).  The adverse 
gastrointestinal side effects of ibuprofen could occur both by local or systemic drug 
contact (19,20).  This effect might be eliminated by coating for sustained release delivery 
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as well as encapsulation of the coated and uncoated microparticulates, which will ensure 
that less drug is in contact with the gastric mucosa per unit time (20,21), and also yield 
effective, safe and stable delivery systems for use in humans. 
Several studies have shown the efficacy of sustained release ibuprofen tablets over 
conventional dosage forms (22-25).  Brufen Retard, a sustained release ibuprofen that is 
marketed in Europe has also been shown to be effective as anti-inflammatory and 
analgesic agents at the recommended dose (26).  However, no sustained release ibuprofen 
formulation has been found to exist in the market in the United States.  
Therefore, the specific aims of this research are as follows: 
1)  Development of spheroids using the one pot rotor-disk fluid-bed technology, 
ibuprofen as the model drug, Avicel as the major excipient and spheronization enhancer, 
sodium lauryl sulfate as lubricant and water as binder. 
2)  Optimization of the formulation and process variables using statistically designed 
factorial experiment.  
3)  Evaluation of the effects of drug particle size, different drug loads and scale-up up to 
intermediate production batch size on the the developed and optimized ibuprofen 
spheroids using the rotor-disk fluid-bed technology. 
4)  Polymer coating and encapsulation of coated and uncoated microparticulates using 






B. Literature Review 
 
1.  Ibuprofen 
 
a.  Therapeutic uses and side effects  
 Ibuprofen (Figure 1) is an acidic drug with a pKa of 4.8 and a molecular weight of 
206.  It is a potent cycloxygenase and prostaglandin inhibitor, an NSAI agent having anti-
inflammatory, antipyretic and analgesic activity in both animals and humans.  It is 
developed in 1960s and has been used for the treatment of rheumatoid arthritis, 
osteoarthritis, post-operative pains, pains associated with common colds, etc. (1).  It has 
recently been implicated in Alzheimer’ s disease (2,3). 
Figure 1:  Structure of ibuprofen (27).  
*: Chiral center constituting the R and S isomers of ibuprofen  
 
As an antinflammatory agent, ibuprofen inhibits cycloxygenase (COX) enzymes, 
thereby inhibiting prostaglandin production (18,19). Two COX enzymes are known to be 
involved in prostaglandin synthesis, COX-1 and COX-2. COX-1 generates prostaglandins 
that maintain normal function in several organ systems, and are involved in the protection 
of gastrointestinal mucosa. COX-2 generates prostaglandins that mediate inflammatory 
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stimulus, and thereby cause inflammation and pain. The adverse gastrointestinal side 
effects of NSAIDs like ibuprofen are therefore related to COX-1 inhibition.  Although the 
therapeutic efficacy of ibuprofen outweighs the severity of its side-effects (28), studies 
have shown an increased tendency of NSAIDs toward gastric irritation at higher doses 
(29). This effect could be regulated by coating and encapsulation of the drug, which will 
minimize the amount of drug that would be in contact with the gastric mucosa per unit 
time (20,21). 
 Ibuprofen has been implicated in the antiinflammatory modulation of Alzheimer’ s 
disease (2,3).  Alzheimer’ s lesion is characterized by the development of -amyloid 
protein deposits and neurofibrillary tangles.  The protein deposits stimulate inflammation 
in the brain, which activates the immune cells and consequently elicit harmful substances.  
These include inflammatory cytokins, proteases and complement proteins that destroy 
nerve cells. Ibuprofen has been shown to interrupt this sequence, and thereby lessen the 
abnormal accumulation of -amyloid (2,3,30). 
Ibuprofen is also used in the prevention of patent ductus arteriosus (PDA; 31).  
The ductus arteriosus is a connection between the aorta and the pulmonary artery.  It is 
part of the fetal pathway that helps to distribute oxygen from the mother to the baby's 
organs.  Thus it facilitates blood flow and by-passes the lungs, which do not require high 
blood flow at this time of the fetal development. At birth, the lungs expand, the baby's 
blood vessels relax to accept more flow, and the ductus arteriosus usually closes on its 
own within the first 15 hours of life. However, sometimes the ductus arteriosus does not 
close on its own; a condition referred to as a patent (open) ductus arteriosus. This 
condition is prevalent in premature babies and can also occur in full term infants.   
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For newborns, NSAID such as indomethacin drug is normally administered which 
helps to constrict the muscle in the wall of the PDA in order to close it. Because of the 
potential side effects of indomethacin that includes a decline in cerebral blood flow and 
cerebral oxygen delivery, surgery is sometimes preferred to tie off the open duct.  Some 
physicians also prefer to use ibuprofen instead of indomethacin, as the former has been 
shown to constrict the duct and also reduce the incidence of PDA in preterm infants, 
without the complications of indomethacin (32,33). 
 
b. Dosage Forms/Dosing 
Ibuprofen is a high dose drug with a short biologic half-life (1.5 - 2 hrs) and is 
therefore administered several times a day orally (34). For the immediate release 
products, the usual prescribed adult dose is 400 - 800 mg three or four times daily, with 
the maximum daily dose not exceeding 3.2 g. For the sustained release formulation, 
Brufen Retard, the recommended once or twice daily dosage (1600 mg) has been shown 
to provide effective control of arthritic symptoms for different patient groups compared to 
baseline, with significant overall improvements in pain and stiffness (34).  Ibuprofen 
pediatric dosage form exist as tablets and suspensions, which range between 5 and 50 
mg/kg daily with the maximum daily dose not exceeding 2.4 g (34).  
 For adults, ibuprofen is available (tablets and caplets) as oral immediate release 
solid dosage form. The most commercially available dosage form is the regular tablets  
(e. g. Motrin®, Advil®), although chewable tablets, liquigel, oral drops and oral 
suspensions exist (35).  Commercially available ibuprofen consist of not less than twelve 
excipients, which often lead to increased bulkiness of the oral dosage form, reduced 
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amount of the active and therefore increased frequency of intake. These factors could 
consequently reduce patient compliance. Intravenous ibuprofen injection also exists but 
as orphan drug (Children’s Motrin®) for the treatment or prevention of patent ductus 
arteriosus (PDA; 31).  
  
b.  Solubility and flowability 
 Ibuprofen powder has a slight characteristic odor and is practically insoluble in 
water.  It also shows poor dissolution and tableting behavior due to its hydrophobic 
structure (5). It is also very cohesive and exhibits poor flow characteristics (36).  The 
physicochemical properties of ibuprofen have been improved by changes in its 
crystallinity and in surface properties (37).  Also drug dissolution has been improved by 
various complexation techniques e.g. with cyclodextrines (38), and by the use of various 
excipients (22), including spray-drying of the drug particles with microcrystalline 
cellulose (MCC; 39).  In the latter study, x-ray diffraction indicated that ibuprofen exists 
as very fine crystals on cellulose particles, which is facilitated by the rapid evaporation of  
the solvent during spray drying.  This restricted crystal growth led to improved  
dissolution (39).  
In a previous study (40), the incorporation of sodium carboxylmethyl cellulose 
(NaCMC) to piroxicam- Avicel® PH-101 formulation (formulation A), or as a co-
processed blend with MCC (Avicel®  CL-611; formulation B) enhanced the release of 
piroxicam at 45 min from 30% (formulation A) to 95% (formulation B).  The use of 
Avicel® RC-581 in a spheronization process has been shown to add plasticity to powder 
blend, thereby facilitating the formation of spherical pellets, and improving the 
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flowability of the formulation (41,42). Therefore, excipients such as MCC or MCC co-
processed with polymers such as NaCMC, have shown good promise in granulation 
processes and could be useful in improving ibuprofen flowability, as well as in the 
development of ibuprofen microparticulates.  
 
2.  Excipients 
 
a. Microcrystalline cellulose/Sodium carboxymethyl cellulose (Avicel®) 
 Microcrystalline cellulose/Sodium carboxymethyl cellulose (Avicel®) products are 
colloidal co-processed mixtures of microcrystalline cellulose (MCC) and sodium 
carboxymethyl cellulose (NaCMC).  They are dispersible in water, and produce 
thixotropic gels at concentrations of >1.2% solids (43,44).  They are also insoluble in 
organic solvents and dilute acids, and partially soluble in both dilute alkali and water. 
They consist of the RC and CL types in which the amount of carboxymethyl cellulose 
present can vary between 8.3 - 18.8% w/w.  The RC-581 grade has lower concentration of 
NaCMC than the CL-611 grade. Both polymers are mostly used in solid dosage forms as 
diluents, lubricants, spheronization enhancers and/or binders (45,46).   
 Several studies (including our previous report in which RC-581 and CL-611 were 
co-processed with ibuprofen; 47) have shown that when used in solid dosage forms, there 
are no significant differences in granule quality obtained from both grades (44).  Major 
differences have nevertheless been observed when used in suspensions due to their end 
product viscosity/gel strength and methods of dispersion required for complete activation, 
and where they exhibit a high degree of thixotropy (43,44).  Additionally, differences 
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have been observed when compared with other Avicel® types (grades that do not contain 
NaCMC), even in solid dosage forms (48). Garcia, et al. showed that in the formulation 
of glipizide microparticulate spheres and tablet dosage forms, the former, containing 
Avicel® PH-101 gave higher drug release than spheres of the same composition but 
prepared with Avicel® RC-581 (48). On the contrary, tableted spherical formulations 
containing Avicel® RC-581 gave higher release rate constants than the formulations of 
the same composition prepared with Avicel® PH-101.  These were attributed to 
differences in porosity of the formulations. Spheres prepared with Avicel® PH-101 had 
more pores than spheres of the same composition prepared with Avicel® RC-581, that 
resulted in swelling of RC-581 and slower drug release.  It is also possible that milling of 
the spheroids required for tableting as well as tablet compression affected the normal 
packing of the polymer in the tablets. This will affect the porosity of the formulations and 
also play a role in determining their amount of water retention, and might have led to 
higher drug release of tablets produced using RC-581. 
 Microcrystalline cellulose (e.g. RC-581) has been used as a processing aid in 
traditional extrusion spheronization.  The MCC acts like a molecular sponge, absorbing 
considerable amount of water and facilitate binding and lubrication of the moistened 
powder mass during extrusion (49-51).  It has also been shown that incorporation of 
surfactants, for example, sodium lauryl sulfate (SLS), to a spheronization system can 
improve particle-particle and particle-liquid interactions, as well as flowability of the 
granules produced (52,53).  These observations justified the continued use of Avicel® and 
SLS in spheronization process. 
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b.  Sodium Lauryl Sulfate 
 Sodium lauryl sulfate is an anionic surfactant that has been extensively used to 
reduce the surface tension of pharmaceutical systems. It has been utilized as anionic 
emulsifier at 0.5 - 2.5%, tablet lubricant and wetting agent at 1 - 2%. It has been used 
widely in traditional extrusion-spheronization as a wetting agent (53,54), and to impart 
plasticity to extrudates (55). Studies have shown that the presence of a liquid binder in the 
formulation is necessary for the formation of pellets by the extrusion/spheronization 
technique (51,56).  The spreading of the liquid can be influenced by viscosity and surface 
tension. The latter affects possible changes in accessibility of the pore structure within the 
powder bed. Both viscosity and surface tension can influence the consistency of the wet 
powder mass, and thereby affect the ability to produce spherical pellets. 
Incorporation of a surfactant to a spheronization system has been shown to reduce 
the contact angle between the solid and ligand, which enhances the interaction between 
the ligand and powder (56).  Also, the addition of surfactants extends the period of 
constant water level slightly, as well as eases the spreading of liquid to a greater extent. 
Larger pellets with narrow size distribution are produced due to particle-particle 
interaction when surfactants are present. The packing of the particles within the pellets is 
also influenced by the presence of surfactants, which results from liquid/solid 
interactions. Although SLS had such commendable influence on water movement, it was 
observed to have less effect on porosity of the granules (56).   
 The effects of three surfactants, namely, sorbitan monolaurate (SML), sorbitan 
monododecanoate (SMD), and sodium lauryl sulfate (SLS) on the physicochemical 
properties of sulfadimidine tablets have been studied (57).  Tablets were compressed 
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from granules processed by the fluid-bed granulation method.  All batches of the 
granulations were compressed to the same weight at constant pressure.  The granulations 
that contained 0.50 SML, 0.20 or 0.50% SMD produced compressed tablets with high 
friability, in contrast to the granulations containing SLS.  With regard to their efficiency 
to improve both tablet disintegration and dissolution, the surfactants were ranked as 
follows: SLS > SML > SMD. 
 In another study using a solution of 0 to 3% polyoxyethylene 20 oleate as a 
granulation liquid, mechanically strong, free flowing pellets were produced with a 
decrease in the amount of fines (58). There was also an increase in the over-sized pellets. 
The shape and the surface characteristics of the pellets were also improved.  For instance, 
the pellets became rounder up to 1% addition of the surfactant, with negligible 
improvement after this concentration. The roughness of the pellet surfaces also decreased 
with an increase in the concentration of the nonionic surfactant.  The results suggest that 
the addition of nonionic surface-active agent improves the wetting and thereby the 
rounding of pellets containing MCC and native maize starch as a co-filler.  
 
3.  Microparticulate Drug Delivery Systems and Spheronization 
 
a. Microparticulate drug delivery systems 
 Microparticulates are drug-loaded small polymeric particles (erodible, non-
erodible or ion-exchange resins) that could be delivered as solids or suspended in a liquid 
carrier medium. They include microspheres, spheroids and/or pellets. Microparticulates 
have been employed in different medical and engineering applications (59-64). In the 
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field of medicine, this delivery system (especially in radiolabeled form) has been used in 
different disorders in form of diagnostic tools for functional imaging of lungs, 
reticuloendothelial system, gastrointestinal system, inflammatory lesions and  
tumors (59).  
Several distinct approaches have been used to formulate drugs as microparticulate 
delivery system for oral, intraocular and topical applications. These include erodible 
microparticulates, swelling mucoadhesive particulates, pH responsive microparticulates, 
nanoparticles/latex systems, ion-exchange resins, etc. (60).  In ophthalmology, ocular 
delivery of microparticulates has been shown to improve bioavailability at the target site, 
and reduce the potential for ocular and systemic side effects (61).  In this regard, the 
delivery system was used topically as controlled drug delivery in vitreoretinal disorders 
(some of the major causes of blindness in the developed world), to reduce frequency of 
intravitreous application (via injection) and optimize intraocular drug levels. This 
minimizes the risk of complications that can occur from frequent intravitreous injection 
(62).  Microparticulates are used therapeutically mostly as spheroids for immediate and 
sustained release drug delivery (59,63,64). 
 Spheroids/pellets are spherical microparticulates of varying diameter depending 
on the application and the goal of the formulator (7). Pellets can be manufactured in 
different ways. These include drug layering (spraying a solution or suspension of a binder 
and a drug onto inert core), hot-melt (hardening of the molten droplets), spray congealing, 
spray-drying a solution or suspension of the drug with subsequent formation of the pellets 
due to the evaporation of the fluid phase, and spraying a binder solution into a whirling 
powder using a fluidized bed (65,66). The most popular method of producing pellets is by 
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extrusion-spheronization technique. This entails the simultaneous control of several 
formulation and process variables.   
 Spheroids/pellets manufactured in the pharmaceutical industry are sized between 
500 and 1500 µm and are commonly filled into hard gelatin capsules (67), but can also be 
compressed in to tablets (68,69). As a drug delivery system, the microparticulates offer 
not only therapeutic advantages such as less irritation of the gastrointestinal tract, but also 
important bulk material processing advantages (8,67,70).  They show better flowability, 
produce less friable dosage form, exhibit biopharmaceutical reproducibility, a narrow 
particle size distribution, low percentage of fines, and are easy to coat and encapsulate 
(6,9).  They are also suitable for dosing as multiple-unit dosage formulations (contrary to 
the single-unit dosage forms) because of their spherical shape, their mechanical properties 
and the ability to readily release their active constituents (71) from hard gelatin capsules, 
tablets, and sprinkles. Additionally, the chance of incomplete absorption of a dose is less. 
For example, if a single-unit tablet fails to disintegrate, the entire dose would be lost, 
however, if few units of the pellets fail to release drug at the desired site, the effect would 
not be altered significantly. 
 The roundness of spheronizedpellets should always be highly considered because 
irregular shapes tend to indicate a process that is out of control. Spheroids with low 
sphericity and agglomerated pellets also have high density and low porosity, which could 
result in poor packaging. Confirmation that the pellets are spherical is obtained using 




b.  Spheronization process  
 Granulation is the process in which primary powder particles are made to adhere 
together to form larger, multiparticle entities called granules. Granulation methods are 
normally divided into two parts: wet granulation methods in which liquid is used in the 
process, and dry granulation methods that use no liquid.  The method and conditions of 
granulation affect the intergranular and intragranular pore structure by changing the 
degree of packing within the granules (73). 
Wet granulation involves the massing of a mixture of dry primary powder 
particles using a granulation fluid, the latter being mostly water for economical and 
ecological reasons (73). Wet granulation methods include wet massing and fluidized bed 
processes. The latter could involve the rotor-disk module in which microparticulates are 
manufactured directly from dry powder by spheronization. 
 
    1. Mechanism of pellet formation  
 Spheronization is a form of granulation process used in pellet formation and thus 
shares the basic granulation mechanism. Like all granulation processes, the mechanism of 
pellet formation involves nucleation, coalescence, abrasion, transfer, breakage and 
layering (74).  Several studies have been performed to study the mechanism of pellet 
formation using high shear mixers (Gral 10 and Gral 25; 75,76), and agglomeration by 
nucleation and coalescence has been found to dominate such systems. Limited 
information is available in literature with regard to the mechanism of pellet formation 
using the rotor-disk fluid-bed process. 
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Although the granulation process of the rotor-disk fluid-bed is different from that 
of the high shear mixer, it has been shown that similar process variables influence the 
product formulation and characteristics in both systems (75-78). In fluid-bed granulation, 
the moisture content in the bed and the speed of the rotating disk are the key parameters 
controlling the pellet qualities, especially the particle size and size distribution (9,44,79-
82).  Similarly, in high shear mixers, the binder concentration and impeller speed are the 
most important variables influencing the mean granule size and size distribution (75,76). 
It is therefore possible that the same mechanism of growth will be applicable to both 
processing systems, as discussed in the subsequent paragraphs.   
 The nucleation or growth mechanism of spherical pellets/spheroids has been 
defined in a high shear equipment using torque measurement (75). Vonk et al. (76), also 
studied growth mechanisms during liquid addition stage in high shear mixers (Figure 2).  
They reported that spheroid formation starts with the formation of large primary nuclei 
that follows particle-particle contact and adhesion due to liquid bridges (nucleation).  
This nucleation process was described by the comparison of the theoretical tensile 
strength of the nuclei and the dynamic impact pressure from the measuring system. The 
primary nucleus is classified as loosed agglomerate with high porosity and low tensile 
strength. The nucleation process is followed by the formation of small secondary nuclei 
due to break-up of the primary nuclei. The secondary nuclei are the starting materials for 
exponential growth, which starts when the solid mass is sufficiently wetted, leading to 
their densification. Due to densification, stronger and spherical pellets are formed that 
survive many collisions, and growth proceeds exponentially by coalescence. Additionally, 
liquid is squeezed to the pellet surface, which contributes to the growth by coalescence,  
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Figure 2: The destructive nucleation growth mechanism of high shear pelletisation (76) 
 
as more particles could adhere to the already formed granule. This liquid addition stage is 
followed by the kneading stage (76). 
 During the kneading stage, net growth diminishes because no more liquid is 
applied, and a steady state is observed. Consequently, spheroid break-up becomes 
considerably important, depending on the final moisture content in the powder bed. 
However, at optimal conditions of binder content, the mean pellet size does not change 
during the final stage of the kneading phase (i.e., there is practically no break-up), which 
results in a well-defined, spherical product, with a reduced porosity compared to the 
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primary nuclei (76). It was therefore concluded that deformation and probably 
densification, and not fragmentation, is the dominant compression mechanisms of pellet 
formulation.  The exponential growth and the final pellet size were linearly related to the 
specific liquid addition rate and the impeller speed.  
 Rashid et al. (77), have described the mechanisms of microcrystalline cellulose 
core formation and growth in a centrifugal granulating process as being similar to the 
spheronizing process of pellets.  Different MCC grades were used as starting materials. In 
such a system, the wetting phase (nucleation region) was followed by combination of 
coalescence between the previously formed nuclei and the layering of the smaller fine 
powder over the nuclei.  At a later stage, layering and abrasion became the predominant  
mechanisms.  Majority of the formulations studied produced granules that were relatively 
spherical, smooth, free-flowing and had good mechanical strength, with desirable narrow 
range of particle size distribution.  
 In another study, the wetting and growth profiles of the granules were investigated 
using a tracer in the binder liquid and the authors reported a linear relation between tracer 
mass and granule mass during the agglomeration stage of the process (78).  The result 
showed insufficient wetting and rewetting of the granules during the early kneading 
stages of the process respectively, which resulted in a decline of granule growth rate, and 
consequently to granule attrition. These growth mechanisms are applicable to those in 
extrusion/spheronization process and spheronization via rotor-disk fluid-bed processing, 




    2.  Extrusion/spheronization 
 Extrusion/spheronization invented by Nakahara in 1964 has been described as the 
most popular method of producing pellets (6,8,79,80) and the methodology of choice in 
the preparation of spherical particles (71).  This traditional spheronization method 
involves four different steps, namely, granulation (preparation of the wet mass), extrusion 
(shaping the mass into cylindrical form), spheronization (breaking up the extrudate and 
rounding of the particles into spheres) and drying of the pellets, as will be elaborated 
below. 
 i. Granulation  
 Different types of granulators are used to perform the mixing of the powder blend 
and the granulation liquid in order to produce plastic mass. The most commonly used 
granulator is the planetary mixer (81), although the use of high shear mixers has also been 
reported (82).  An important problem encountered during the granulation process is the 
evaporation of the granulating liquid probably due to the large amount of heat introduced 
by most of the mixers. The liquid evaporation influences the extrusion behavior of the 
wet mass, especially as a homogenous distribution of the liquid phase throughout the 
granulated mass is highly demanded. Consequently, it was reported that the binder 
(mostly water) would equilibrate throughout the complete mass when the wet mass was 
left for 12 hr in a sealed polythene bag before the extrusion step (83).  However, this 





 ii. Extrusion 
  During extrusion, the wet plastic mass is shaped into long rods. This process is 
used not only in the pharmaceutical industry but also in the food, ceramic and polymer 
industries. Four classes of extruders exist, namely, screw, sieve and basket, roll, and ram 
extruders (7). The contour and position of the screens as well as method of feeding the 
wet mass to extruder differ in each case. Recent modifications have allowed in-process 
control using extrusion forces as these extrusions could be correlated to the final quality 
of the pellets (84). The power consumption of the motor driving the extruder can also be 
correlated to the pellet qualities (76). 
 
 iii. Spheronization 
 During spheronization, the formed cylinders are collected onto the spinning plate 
of the spheronizer, the friction plate, where the extrudate is broken up into smaller 
cylinders with a length equal to their diameter (78), and become rounded due to frictional 
forces from the plates. Two types of spheronization methods have been identified (7).  In 
the first method, the process starts from a cylinder with rounded edges, to dumbbells and 
elliptical particles and eventually to perfect spheres (Figure 3A; 85).  The second method 
reported by Baert and Remon (83) suggests that a twisting of the cylinders occurs after 
their formation resulting in rounded edges that finally results in the breaking of the 
cylinders into two distinct parts (Figure 3B). Both parts have a round and a flat side.  Due 
to the rotational and the frictional forces involved in the spheronization process, the edges 
of the flat side fold together forming a cavity observed in certain pellets. It has been 
suggested that the speed in combination with the diameter of the friction plate (not the 
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Figure 3: Mechanisms of pellet formation in traditional spheronization methods according 
to: (A) I. Cylinder, II. Cylinder with rounded edges, III. Dumb-bell, IV. Ellipse, 
V. Sphere (85). (B) I. Cylinder, II. Rope, III. Dumb-bell, IV. Sphere with a cavity outside, 
V. sphere (83). 
 
absolute speed), should be used to calculate the plate peripheral velocity. These should be 
considered in order to obtain highly spherical pellets (86). 
 
 iv. Drying 
 This is the final stage in pellet formation. The pellets can be dried at room 
temperature (87,88), or at elevated temperature in an oven (70,89,90) or a fluidized bed 
(86).  The use of microwave oven drying has also been reported as the final stage in the 
production of pellets (90,91). 
 
 Several formulation and process variables influence the final quality of the pellets 
derived from the spheronization process. These include the moisture content of the 
granulated mass, the type of liquid binder, type of extruder, extrusion speed, properties of 




these steps affects greatly the quality of the final pellets or spheres (7). Consequently, 
optimization, batch-to-batch reproducibility and especially scaling up to manufacturing 
batch size, that are the ultimate goals of industries in the development of any dosage form 
could be difficult to achieve with this traditional method (7). On the contrary, it has been 
reported that if several variables in a fluid-bed process are fully controlled, good batch-to-
batch reproducibility can be obtained (7,93). 
 
     3. Fluidized bed processes 
 The traditional fluid-bed technology, which was developed over the past 30 years 
for rapid drying, was described for the first time in the pharmaceutical field by Reynolds 
(94) and by Conine and Hedley (68). In the 1990’s, fluidized bed has been extended to 
rotary spheronization process as well as other routine use like agglomeration, air 
suspension coating, powder and solution layering (95).  Nevertheless, the principles of the 
fluid-bed have not changed. 
 
   i. Traditional fluid-bed technology 
 A fluidized bed is essentially a bed of solid particles with a stream of air or gas 
passing through them via a slit created by a plate (inserted into the vessel) and the vessel 
wall. The air-flow is normally strong enough to keep the particles in motion.  
The fluid-bed processing equipment generally consists of the air processing unit, the 
product container, and the expansion chamber for proper fluidization of the powder bed 
(Figure 4; 95,96). It has one or more binary nozzle(s) each comprising of a solution  
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Figure 4: Fluid-bed equipment (97). 
 
delivery system and compressed air to atomize the liquid binder, exhaust filter and 
blower, product temperature probe, filter housing, etc. The latter encloses cartridge filters 
mostly made of polyester or stainless steel materials. These filters retain products in the 
system, which are shaken at pre-determined time intervals to release the retained products 
into the product vessel for spheronization (98).  The conical shape of the expansion 
chamber reduces the velocity of the air in the filter compartment, which helps to keep the 
smaller or fine particles out of the upper filter region.  
 The fluid-bed process has been shown to have several advantages over other 
granulation technologies, especially in the development of extended release products 
(99,100).  In one study, three products were compared in the development of metoprolol 
tartrate extended-release matrix tablet formulations, namely directly compressible, fluid-
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bed or high-shear granulated products (99).  Metropolol tartrate has a tendency to adhere 
to the punch surfaces and has poor flow properties, and all three processes were 
sufficiently sensitive to manufacturing variables.  Despite the various excipients (MCC 
with talc or stearic acid) that were added to address the difficult physico-chemical 
characteristics of the drug, direct compressible materials exhibited poor flow, picking and 
sticking problems during tableting.  High-shear granulation resulted in granules with 
improved granule flow and tableting characteristics but also formed hard granules that 
were difficult to mill. This was attributed to over-massing of the granules by this 
granulation process. On the other hand, the fluid-bed granulation made using various 
binders appeared to be satisfactory in terms of flow and tableting performance.  The fluid-
bed technology was therefore designated as the process of choice for further evaluation of 
critical and non-critical formulation and processing variables.  
 The fluid-bed processes include the top-spray process, the bottom-spray process 
and the tangential-spray process shown in Figure 5 and Table I (96,101). The three fluid-  
bed processes represented offer different advantages and disadvantages. They are 
applicable to both granulation and coating processing, however, the performance  
requirement of the finished product and suitable batch size of the product must be 
considered when selecting them for a particular product.  
The top-spray process is usually used with a conventional granulator-coater, the 
bottom-spray process with a Wurster air-suspension column and the tangential-spray 
technique is used with a rotary fluid-bed granulator (101).  The latter was used for this 




Figure 5: Fluidized bed processes. A. Top-spray method; B. Bottom-spray method;  
C. Tangential-spray method (101). 
 
ii. Rotor-disk fluid-bed 
 1. Equipment and components of the rotor-disk fluid-bed 
 As previously discussed, extrusion/spheronization involves a number of 
successive steps such as moistening, extrusion, spheronization and drying. Rotor-disk 
spheronization, however, reduces the number of processing steps involved in traditional 
spheronization method, and thereby reduces the production time and cost, with good 
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Although rotor-disk fluid-bed comprises of set of processes that depend on each other, 
once optimized, each contributes to the successful transformation of the starting powder 
mixtures into spheroids. 
The components of the fluid-bed processing equipment have been discussed 
previously (Figure 4).  A rotor-disk, which contributes greatly to the spheronization 
process, is inserted in the product container of the rotor-disk fluid-bed. Figure 6 shows 
the product vessel with the rotor-disk insert and the spray gun facing the direction of the 
powder flow.  
 
Figure 6: Rotor-disk fluid-bed product container with rotor-disk insert and spray gun (97). 
 
2. Rotor-disk fluid-bed process Rotor-disk fluid-bed utilizes the tangential-
spray process. This has been described as a method of choice for producing spheroids 
used for immediate release purposes, as well as for producing pellets that could be coated 
for controlled release applications (96,103,104).  The tangential spray process is preferred 
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over the top- or bottom spray methods because spheroids formulated in this equipment 
have a surface morphology (less porous and more spherical) that is more suitable for 
coating than that of spheroids prepared using the other processes.  
 As shown in Figure 7, rotor-disk spheronization is centered around the rotor plate 
insert where disk rotation adds centrifugal force (Fc) to the material on it.  As the powder  
is sprayed tangentially, it is wetted and rolls around the product vessel by the centrifugal 
force into a vertical moving air stream with vertical force (Fv) caused by a gap between 
the vessel wall and the rotor-disk insert.  Because there is no force at the center of the 
plate, the rolling product falls back toward the center of the disk by gravitational force 
(Fg), thereby creating a rope-like motion (95,105). This process has been demonstrated to  
 
Figure 7: Schematic representation of rotor-disk technology using tangential 
spray gun (97). 
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be reproducible at the development and pilot stages, but is difficult to achieve further 
scale-up and optimization steps. 
 
 3. Factors affecting the rotor-disk fluid-bed process and product qualities 
 Several factors affect the characteristics of products produced in the fluid-bed 
spheronization process. These are the formulation, process and equipment variables. 
Formulation variables would include the amount of binder added, moisture content of the 
granulated mass, type of granulation liquid, and physical properties of the starting 
material. Process variables include inlet and outlet air temperatures, binder spray rate, 
spheronization speed, fluidization air velocity and volume. Equipment variables include 
filter shaking, scalability, plate material type and contour, etc. The amount of added 
binder and rotational speed have been identified as the most important variables for 
producing good quality spheroids (44).  
 
  Effect of type and amount of granulation liquid on the spheronization process.  
 In order to initiate the agglomeration and granule growth processes, an optimum 
amount of binder has to be introduced into the granulator (106).  The nature of the 
powder to be agglomerated will influence the selection of binder to be used for the 
granulation process.  Although the amount of binder used in the spheronization process 
has been mostly determined empirically (106), special instrumentation and procedures 
exist for this purpose (107).   
 In the spheronization process, the granulating liquid exerts a lubricant effect, 
which could be affected by the presence of different additives, used in most cases to 
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adjust its properties (108). These include surfactants and polymeric compounds, which 
have been shown to tailor the binder to exhibit specific behavior, thereby allowing fine-
tuning of some binder properties, namely, surface wetting, viscosity, adsorption, and solid 
bridge strength. These directly affect both the spheronization process and the resulting 
product.  
It has been shown that the presence of different additives could change the ease 
and extent with which liquids could be removed (drying) and reabsorbed (wetting) in the 
spheronization process (56).  This was demonstrated using water, a 25% solution of 
glycerol in water, sodium lauryl sulfate below its critical micellar concentration, and 
Pluronic PF68 (a nonionic surfactant at 0.01 and 0.0001%), as granulating liquids. Lower 
levels of saturation were obtained with the glycerol solution and considerably increased 
levels of saturation with the surfactants.  It has also been shown in both traditional 
extrusion/spheronization and rotor-disk processes, that the solubility of materials used 
(both drugs and fillers) plays an important role in the quantity of binder required to form 
satisfactory pellets and on the physical characteristics of pellets (109).  These studies 
emphasize the importance of using minimal number of excipients in dosage formulations, 
as was done in the present study. Additionally, the importance of binder selection for 
specific products in granulation/spheronization processes is implicated. 
 
 Effects of type and amount of granulation liquid on the spheronized products 
 qualities. The spheronizer speed, as well as the initial and final liquid 
contents (at the end of spheronization process) have been shown to exhibit significant 
effects on the qualities of the spheroid (92,110-112).  The qualities mostly affected are 
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sphericity, particle size distribution, and friability. These studies established a correlation 
between the amount of granulating liquid used in the formulation and the shape of pellets. 
For instance, in one of the reports in which traditional spheronization method was used 
(56), pellet shape, a very important spheroid characteristic was demonstrated to be highly 
influenced by the liquid content of the extrudate during spheronization.  In addition, low 
levels of liquid were shown to yield elongated, non-spherical pellets while very wet 
blends produced larger, agglomerated pellets with a wide particle size range and a higher 
porosity.  These were attributed to variations in water content and hence consistency.  
 In another report (113), it was shown that although the mean diameter of the 
granules was influenced by moisture contents at the final stage of spheronization, 
however, the effect of moisture on the granule diameter is cumulative or based on all the 
operational variables in granulation process.  These factors were also considered as 
important scale-up parameters.  
 
 Influence of the spray rate of the granulating liquid on product qualities.  
Liquid distribution by the nozzle influences the pellet growth (78). In addition, the 
spray rate and the mixing of atomization air and binder in the spray zone determine the 
average granule size. There is also a linear relation between the number of droplets that 
comprised a granule and the granule size, especially at the early stage of the process 
(113).  Therefore, there is a requirement for nozzles that produce uniform droplets, which 
allow these droplets to be easily controlled in size independent of liquid- and air-flow of 
the nozzle. Thus, a nucleation ratio factor has been proposed as a useful parameter to 
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describe the binder liquid efficiency (78). This factor depends on the material properties 
of binder liquid and powder particles.  
 
 Effect of plate rotational speed. Spheronization speed affects spheroid 
qualities in both the traditional and rotary fluid-bed processing (14,114,115).  In the 
traditional spheronization, extrudate speed influenced the size and sphericity of the 
pellets, with the best results obtained at intermediate spheronization velocities (116,117).  
In the one-step rotary process, the use of variable speeds of the rotating plate during the 
spheronization run has been investigated in order to achieve optimal spheroid yield (118). 
The study was performed due to the occurrence of material adhesion and formation of 
oversize particles in the product yield that was attributed to the use of a non-optimized 
process speed.   
It was shown that when the plate speed was increased during liquid addition 
(spheronization process), the greater centrifugal forces generated improved liquid 
distribution and the mixing of the moist powder mass, resulting in a decrease in the 
amount of oversize particles formed (118). A "low-high-low" speed variation during 
rotary processing was shown to be necessary to produce spheroids with a narrow size 
distribution and with a minimal amount of oversize particles in the total product yield. 
Based on the mechanism of pellet formation already discussed, and on our practical 
experience, this could be translated as follows:  
 ’Low’ speed at the initial stages of liquid addition when powders are still light in 
weight and could be easily blown into the expansion chambers and filters. This will 
reduce product losses. As more liquid is added to powder bed, the material gets very wet 
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and heavy such that ’High’ speed is needed to improve powder fluidization, and also 
facilitate spheronization. Finally, during the drying period as the powder material bed 
looses its moisture and becomes lighter, ’Low’ speed is needed to avoid attrition and 
losses into the expansion chambers and filter housing. 
 
 Effect of plate contour and plate material type 
 Plate contour.   Rotary fluid-bed spheronization process is centered around a 
rotor-disk insert. The air supplied via a split between the product vessel wall and the disk, 
the disk rotation, and high air pressure of a pneumatic nozzle tangentially mounted on the 
chamber of a conventional fluidized bed granulator impart centrifugal (Fc), vertical (Fv) 
and the gravitational (Fg) forces on the product (Figure 7; 97,119).  These create a 
rotating motion that leads to greater densification and spheronization of the granules than 
with conventional fluidized bed granulation (119,120).  
 The influence of disk surface and its speed on the direct pelletization with rotor 
technology has been previously studied in a series of experiments (98,121).  For each 
experimental set, the process variables were kept constant within specified limits, except 
for the rotational speed of the disk during agglomeration and spheronization steps. Two 
differently textured rotating disks were used, one with smooth and the other with waffle 
surface.  It was shown that both surface textures and rotational speed of the disk have 
influence on shape, surface and size of pellets, with the two textures having opposite 
effects on pellet qualities. 
 In the traditional spheronization process, pellet shape and size have been used to 
describe the influence of different plate geometry on pellet qualities (122).  Under 
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constant spheronization conditions, the extrudates behaved dissimilarly on the two 
spheronizer plates used.  The spheronizer with the rougher surface was shown to apply 
more mechanical energy to the extrudate and wet pellets, which reduced the water content 
necessary for the formation of the desired pellet qualities. Therefore, high differences 
were observed in the quality of the extrudates produced by the two extruders (122). These 
observations could be applicable to using different plate contours in the rotor-disk 
spheronization process (47,121). 
 
 Plate material type. Several authors have demonstrated the use of stainless steel 
disk material in the fluid-bed spheronization and coating processes (123,124).  This plate 
varies in diameter and thickness depending on the size of the fluid-bed, and adds to the 
forces supplied to the fluidizing powder bed. The use of stainless steel disk in fluid-bed 
processes also facilitates product removal and cleanup.  The cleanup step is more feasible 
with smooth textured plates than with the rough/waffle contour plates. The heat 
conduction of the stainless steel material makes it useful for both drying and coating 
processes. It has been shown that heat transfer occurs by a combination of conduction, 
convection and radiation, and is enhanced by vigorous mixing of the powder bed 
(125,126).  The rate of heat transfer to the powder beds during spheronization/coating 
from the stainless steel plate rotor-disk insert is minimized by the addition of cold liquid 
binder or coating solution, which reduces the rate of evaporation of the liquid during 
processing at this stage. This efficient heat transfer would be difficult to be generated 
with other materials such as teflon, which could also be used as rotor-disk insert (47).  
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 Using the stainless steel plate, Balakrishnan et al. (123), reported the coating of 
ascorbic acid with a 10% poly(vinylpyrrolidone) solution in ethanol by a process in which 
a horizontally rotating stainless steel disk was installed in the lower part of a coating 
tower. The latter had a circular horizontal cross-section in which hot air was blown in 
below the disk and was guided upwardly between the coating tower and the periphery of 
the disk.  The flow of air above the disk and the centrifugal force of the disk supplied 
fluidized bed of the particle, enabling it to be efficiently coated.   
 A comparative study on the effects of extrusion/spheronization and rotor direct 
pelletization on pellet quality using a smooth disk shows similarity in physico-
technological characteristics of the produced pellets (127). However, several phenomena 
have been shown to occur successively in the fluid-bed technology and the spheronization 
processes.  Thus, a lot of process parameters should be controlled simultaneously during 
the process (14).   It is therefore important to identify and control the involved process 
and formulation variables and conditions. This can be achieved through experimentally 
designed studies that identify critical and optimum conditions to obtain high quality 
products.  
 
4.  Optimization of Equipment and Process Variables 
 
a.  Factorially designed experiments  
 The effect of multiple factors such as plate contour, binder and surfactant levels 
can be investigated simultaneously using statistical design of experiments (14,128).  
Maximum amounts of information are generated with a minimum number of 
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experiments, which assists to estimate the main effects of each experimental factor of the 
product (129).  Although factorial design has been shown to be effective in predicting the 
properties of granulations prepared at conditions within the limits imposed by the 
equipment or formulation (79), there are limited reported studies on the effects of process 
variables on product quality and characteristics (50). Most of these were confined to 
studying few characteristics (128).  However, none of the studies in both the traditional 
and non-traditional methods has statistically studied the effect of batch-to-batch 
reproducibility on both process variables and spheroid qualities.  Additionally, apart from 
very few studies (9,93) most of them used beads on which drugs were layered, thus 
providing ready-made spheronized cores that initiated the spheronization  
process (129-133).  
Considering the complexities of the spheronization processes, most of the 
processing and formulation variables, especially some critical aspects of granulating 
liquids, scale-up, drug loading, drug particle size, etc. need to be statistically studied and 
validated. This could be achieved using different process and product scales and also 
different aspects of the powder material qualities (129,134).  Optimization studies can be 
based on the results of feasibility studies.  Production and scaling up of spherical pellets 
or microparticulates will then follow (44,135).   
The process variables that could affect scale-up will be discussed in this section, 





b. Scale-up  
 The scale-up of a process or batch is studied to establish the operating conditions 
applicable to large scale production batches, with the goal of obtaining products of the 
same quality based on previously optimized laboratory scale experiments.  Scale-up of 
processes that involve powder handling is especially difficult because the dynamic 
behaviors of powders are not very well understood (136).  Moreover, when applied to 
granulation, the effects of the operational variables on powder properties and granule 
growth are not clearly known. Although scale-up processes of materials in the solid-state 
have been based on dimensional analysis, mathematical modeling and computer 
simulation, most of the work in this field still depends on trial and error and the principles 
of geometric similarity (137,138).  The latter describes the interrelationships among 
system properties upon scale-up, thus, the ratio of some variables in a small scale 
equipment should be equal to that of similar variables in equivalent large scale  
equipment (101). 
 Scale-up of any chemical process is a complex science.  The scale-up of fluidized 
bed processes is likewise complicated because it involves several scientific techniques 
and problems, including those involved in engineering and pharmaceutical fields 
(13,139).  These include the problems of air-flow changes and rate (gas bypassing) and 
poor contact with bed particles, particle flow patterns, dissolution profiles, drug load and 
the physical nature of solid particles that includes the drug particle size. Although most of 
the work published on rotor-disk spheronization focused on small-scale equipment, fluid-
bed systems are designed to maintain critical scale-up factors as constant as possible from 
one unit to another (13,139).  Nevertheless, these studies emphasized that each fluid-bed 
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should operate at identical bed depths, air velocities and air changes as to simplify scale-
up of products from one unit to the other.  Most of these parameters have been recognized 
and incorporated in fluid-bed machinery. 
 Mehta et al. examined the variables that should be optimized in the scale-up of the 
fluid-bed coating process (101). These include, spray rate, powder bed moisture content 
at the end of the spraying cycle, the atomization air pressure, the inlet air temperature, the 
fluidization air volume, the batch size, and the type of equipment. In this study, the 
interplay of various processing parameters presented a great challenge in optimizing the 
coating process in a fluidized bed process. As such, continuing efforts to investigate and 
understand this interplay were reported as extremely important in order to ensure 
reproducible performance of the products. 
 Computerized techniques are becoming popular for the fluid-bed process control 
(140).  These include fuzzy logic, neural networks, and experimental design models. In 
addition, engineering techniques based on particle size population balance modeling are 
under development for both fluid-bed and high-shear granulation processes (140). 
Recently, mathematical model software which utilizes a combination of classical 
equations for transport phenomena in conjunction with effective algorithms and actual 
laboratory, pilot plant, and production data, has been introduced to resolve problematic 
scale-up issues for the pharmaceutical engineer and formulator (141). Nevertheless, some 
authors have maintained that past experience is very much required in handling the 
numerous problems encountered during scale-up in drug development (142). Most 
process and formulation scale-up processes are however based on the principles of 
geometric similarity (138,143,144).  
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    1. The principles of geometric similarity  
 Scale-up from laboratory to production batches is always problematic for the 
development of pharmaceuticals. Deviations in expected results in scaling-up can often 
be evaluated by the principle of similarity. This attempts to represent a physiological or 
chemical process by an unspecified relation between several dimensionless groups, one of 
which contains the unknown variable (138,140).  If the group containing the known 
variables are made to have the same value on the small and large scales, then the group 
containing the unknown variable will also have the same values.  In this form, the 
principle of similarity pre-supposes that the systems to be compared are geometrically 
similar (136).  
Two methods of deriving similarity criteria are available, dimensional analysis 
and differential equations, the latter being preferred where applicable. Alternatively, 
extrapolation by means of a power law relation permits model and prototype to be 
compared under conditions that are not strictly similar (145).  
 Dimensional analysis is an algebraic treatment of variables affecting a process.  
This technique permits the definition of appropriate composite dimensionless numbers 
whose numeric values are process-specific (138).  Experimental data are hereby fitted to 
an empirical process equation that results in scale-up being achieved more readily. This 
indicates that in the scaling up process, any model material system whose dimensionless 
material function in question is similar to that of the original material system may be 
chosen. Block et al. (141), therefore reported that scale-up may be achieved through the 
application of the principles of similarity, wherein effective process translation is based 
on the use of dimensionless ratios of measurements, forces, or velocities i.e., geometric, 
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mechanical, thermal, and/or chemical ratios of scale. Each of these ratios presupposes the 
attainment of the other similarities.   
 According to the theory of similarity, two processes are similar to one another if 
they take place in a similar geometrical space, and if all the dimensionless numbers 
necessary to describe the process, have the same numerical value (138,146).  A complete 
similarity requires a geometrical, material and process-related similarities. However, 
according to the principles of similarity stipulated by the Center for Drug Evaluation and 
Research (CDER) guidelines which state that, “the equipment used to produce test 
batch(es) is of the same design and operating principles as those for scale-up batches.  
The same standard operating procedures and controls as well as the same formulation and 
manufacturing procedures are used on the test batch(es) and on the full-scale production 
batch(es)” (147).  
 The principle of geometric similarity is therefore the driving force when different 
sizes of the same processing equipment are employed in the laboratory, pilot plant, and 
commercial production facilities. Consequently, this principle was adapted to two 
dimensionless numbers of power, namely, Reynold's and Froude's, employed in the 
present studies. 
 
    2. Reynold’s and Froude’s numbers 
 Scale-up in fixed bowl mixer-granulators has been studied by applying the 
classical dimensionless numbers of power, Reynolds and Froude, and a scaling factor, to 
end-point prediction in a range of geometrically similar machines.  When corrections are 
made, data from 25-, 100- and 600 L machines all fall on the same curve, allowing 
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predictions of optimum granulation end-point conditions to be made for production-scale 
equipment from measurements on laboratory-scale equipment and vice-versa (148,149). 
Reynolds’ and Froude’s numbers are dimensionless numbers derived directly from Navier 
Stoke’s equations. These equations, often used as the starting point for the analysis of 
granular systems, mathematically describe the effect of both inertial and viscous forces on 
the motion of fluid elements (150).  For a rotating system like the rotary fluid-bed, 
Reynolds’ number (Re) is defined as shown in Equation 1: 






where ρ and µ are respectively the density and dynamic viscosity of the granular medium, 
w, the angular velocity, and ri the radius to a blade tip. It is generally interpreted as the 
ratio of dynamic to viscous forces. The Froude’s number (Fr) is defined as shown in 
Equation 2: 
2 Eqn.                   
2
g
DNFr =  
where N is the number of revolutions per minute, D the diameter or the impeller or the 
rotor plate (as is applicable to our study), and g the gravitational constant. This number is 
interpreted as the ratio of the centrifugal force generated by the equipment to the 
gravitational force, and is used as a criterion for dynamic similarity. The results obtained 
from these numbers using the high shear mixer often show that, for geometrically similar 
machines, it is possible to calculate the power consumption at a predefined granulation 
endpoint, at any given operating condition and at any scale.  
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 In the present study, these numbers have been used to estimate scale-up effects 
and also to determine important scale-up factors for the rotor-disk spheronization process.  
 
    3. Scale-up parameters 
 i. Rate of addition and amount of liquid binder in powder bed 
 In granulation, an optimal amount of binder solution determined in a laboratory 
scale is often different than that in a production scale (111).  As already discussed, the 
binder solution plays an essential role in the formation of granules with desired physical 
properties in the manufacturing process.  This binder role is closely associated with the 
manufacturing scale. For wet granulation in high-shear mixers for instance, specific 
methods based on the liquid saturation and the consistency of the wet mass have been 
described (140,148). These two parameters can be used to quantify the characteristics of 
the wet granules, and they also relate well with the particle size of the end products. In 
practice, the power consumption of the high-shear mixer is used for monitoring of the wet 
granulation process.  It has also been helpful to use the underlying relationship between 
power consumption and saturation level or wet mass consistency for scale-up purposes.  
 In fluid-bed granulation, the rate of binder addition, the moisture content and the 
air volume in the bed are the key parameters to control (140), and can be used as scale-up 
variables. The rate of binder addition and the moisture content in the bed can be 
monitored in-process through the volume or weight of the binder added per unit time 
interval and by near infrared probes respectively. The moisture content can also be 
obtained through monitoring the loss on drying or by Karl Fisher titration studies (139). 
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The Karl Fisher method determines the total moisture content including the residual 
moisture present in the product.   
The scale-up ratio (SUR) involving rate of addition and amount of binder is 
expressed as shown in Equation 3, which could be applied to several other scale-up 
variables. The air volume in the bed has been mostly monitored using air-volume 
indicators on the fluid-bed machine, as will be discussed below. 
3 Eqn.          
equipment small  in thebinder  of 
equipment  large in thebinder  of 
Amount
AmountSUR =  
 
 ii. Fluidization air volume 
 Besides the rate of spraying and the amount of binder in the powder bed, several 
other variables are involved in the fluid-bed processes.  These must be prioritized during 
the development stages to avoid expending excessive amounts of time during the scale-up 
phase.  The volume of air required to give an adequate fluidization pattern on the specific 
machine is critical to obtain good fluidization pattern necessary to get desired product 
qualities. It is necessary to identify optimum operating air-flow and aeration rates 
accounting for gaseous emissions and bed temperatures (151), as well as for the powder 
bed fluidization. Consequently, air-flow parameter has been used as dimensionless factor 
in scale-up processes (152).  The air-flow rate can be determined in two ways, in relation 
to the spray rate of the binder addition: 
 If both fluid-bed machines, the small scale size (laboratory) from which the 
process is being scaled and the pilot or production sizes have air volume indicators, the 
spray rate multiplier can be determined as the ratio of the two air volumes that are 
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required to give an adequate fluidization pattern in each machine. Alternatively, in cases 
where there are no air volume indicators, an approximation of the spray rate multiplier 
can be made using the ratio of the cross-sectional areas of the product bowl screens or 
plates.  The latter method assumes however that achieving similar fluidization patterns in 
both pieces of equipment will require the same air velocity through the bowl screen. 
Therefore, the former method involving the use of air volume indicators, and which 
relates to the principles of geometric similarity, and is shown in Equation 4, will be 
applied in our scale-up processes. 
 
Where A1 and B1 are the air volume and binder addition rate respectively of the small 
scale while A2 and B2 refer to the same parameters for subsequent scale-up batches.   
 
iii. Rotational speed, centrifugal force and plate radius 
 The Froude’s number defined in Equation 2 entails both a gravitational force and 
diameter variables, with one being inversely related to the other. The centrifugal force 
also relates inversely to the diameter of the impeller/plate. In the rotor-disk module, 
spheronization is achieved by the powder bed rotation caused by both centrifugal and 
gravitational forces during the densification of the powder. It has been reported that for 
high shear mixers, this densification could depend on the impeller rotation speed and also 
on the size of the mixer (140). These relationships have been adapted to the rotor-disk 
module with modifications, to obtain Equations 5 and 6 that formed the bases for scale-up 
in the present studies. 







5 Eqn.                              *
W
RFcV =  
6 Eqn.                            
2*
R
VWFc =  
Where V is the rotational speed, Fc the centrifugal force, R the plate radius and W the 
weight of the powder material.  
 
 In addition to the above process variables involved in scale-up, several product 
variables have been shown to affect both the spheronization and scale-up processes. 
These include the amount of drug present in the system and its mean particle size 
diameter, which also affect the drug release of the products.  
 
5. Product Variables and Drug Release 
 
a.  Product variables 
     1. Drug particle size 
 Drug particle size is an important and challenging factor in the spheronization 
process and therefore needs to be optimized for the success of the process (16).  Studies 
have been performed to describe the effects of interactions observed between powder 
particle size and binder viscosity on the mechanisms involved in agglomerate formation 
and growth using high shear mixers (52,153).  In such systems, agglomeration by 
nucleation and coalescence has been shown to dominate when agglomerating small 
powder particles and binders with a low viscosity. It was also observed that in order to 
produce spherical agglomerates (spheroids), a low viscosity binder has to be chosen when 
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agglomerating a powder with a small particle size, and a high viscosity binder must be 
applied in the agglomeration of powders with large particles. The latter requirement could 
be due to the low agglomerate strength of the large particle sized products that could lead 
to agglomerate breakage. 
 In another report in which three particle sizes of theophylline were used as a 
model drug for fluidized rotor granulation, Sienkiewicz, et al. (16), observed that the two 
finer grades of the drug were substantially more difficult to spheronize than the coarse 
grade of the drug. Only the latter formed the desired spherical product. Additionally, two 
MCC grades with different mean particle sizes were used to demonstrate the effect of 
their particle sizes on the spheronization process and product qualities (115). Although 
both MCC particle sizes gave pellets with good particle size, sphericity, and 
compressibility, under a wide range of spheronization conditions, pellet porosity was 
greater with MCC of larger particle size. It is therefore necessary that a consideration of 
the particle size suitable for the spheronization process should be part of the optimization 
studies performed at the developmental part of a project. 
 
     2. Drug load 
 Drug loading has been shown as a major limitation to the usefulness of the 
spheronization process and the spheronized dosage form, and as a challenging factor in 
the scaling up of fluidized bed processes (16,154).  The influence of type and quantity of 
drugs on spheronization processes has often been studied by varying the quantity of drug 
with respect to the amount of lactose, pure microcrystalline cellulose or different forms of 
Avicel (10,155).  In a previous report using different loads of lactose, the effects of 
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loads applied to agitating powder beds on the particle size distribution was investigated 
(156).  It was shown that at the light load (6.24 g/cm2), smaller particles were produced 
while at the heavy loads (29.2 g/cm2 and 41.9 g/cm2), larger sized particles were 
produced after long mix processing. The latter observation was attributed to a quick 
increase of fine particles and their subsequent agglomeration to form larger particles due 
to the large product load.  Consequently, it was assumed that there was a critical fine 
particle size and critical load quantity under which the physical properties of the powder 
bed change significantly (156). 
 In another study that used theophylline as the model drug, increasing the drug 
loading increased the geometric mean diameter of the microspheres as well as the time 
required to release 50% of theophylline microspheres (T50; 157).   Moreover, the in vitro 
drug release of microparticles with a high drug loading has been shown to be markedly 
faster than those with low drug loading (158).  The latter was partially attributed to a 
more significant initial burst-drug release of the microparticles with a high drug loading. 
Consequently, a proper choice of drug levels could lead to a high degree of control over 
the physical characteristics of products, including their drug release properties. 
 
b. Drug Release  
     1. Immediate Release of drugs 
 Pharmaceutical preparations are formulated to release their actives as immediate 
release (IR) or under modified release (MR) conditions.  For most immediate release 
drugs, including ibuprofen tablet preparations, the United States Pharmacopoeia (USP) 
specifies that the formulation must release at least 75% of its drug content at 30 min 
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(159).  A single time point assessment, called Q20 is also used in which at least 80% of 
the drug is expected to be released within 20 min (160).  Drug release from conventional 
release preparations are often described by Higuchi square root of time relationship 
presented in Equation 7: 
 
where Q is the cumulative amount of drug released per unit surface area at time t and k is 
a constant. 
 
 Drug release is normally intended to be the rate-determining step for absorption of 
the drug substance into the systemic circulation (161).  The release from dosage forms 
and subsequent absorption of the drug are controlled by the physico-chemical properties 
of the drug, the delivery and biologic systems.  The physiological property of the latter is 
also a vital contributive factor.  The essential drug properties for the release process 
include its concentration, aqueous solubility, molecular size, crystal form, protein binding 
and pKa (162).  Consequently, it has been shown that drug release rate could be 
dependent on the equilibrium solubility of the drug, which in turn is dependent on the pH 
of its solution (23,163). 
 The release of drug from a delivery system involves both dissolution and diffusion 
factors.  The release mechanisms can be one of the Higuchi matrix, zero, first or second 
order types, however, most drugs follow either the Higuchi matrix kinetics, the zero or 




first order release kinetics (164,165).  The release kinetics parameters can be calculated 
using the following semi empirical (Peppas) equations: 
8 Eqn.                                               / nktMMt =  
                                 9 Eqn.                          loglog)/log( tnkMMt +=  
 
where Mt/M is the fraction of drug released at time t, k is a characteristic constant of the  
drug and n is indicative of release order. Hence, as the k value increases, the release of  
drug should occur faster. The n value of 1 corresponds to zero-order release kinetics, 
0.5<n<1 means a non-Fickian release model and n = 0.5 indicates Fickian diffusion drug 
model (first-order release kinetics). From the plot of log (Mt/M) vs. log t, the kinetic 
parameters, n and k are calculated. 
 Traditionally, delivery systems do not incorporate a means of controlled release of 
their actives, such that with each dose of a noncontrolled-release drug (conventional), the 
concentration of drug available to the body immediately peaks and then declines rapidly 
(Figure 8). At times, the drug concentration is very high, contributing to adverse side  
 
Figure 8. Types of dosage forms (166). 
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effects. At other times, the concentration is too low to provide therapeutic benefit (Figure 
9). It is desirable to release drugs at a constant rate, thereby maintaining drug 
concentration within the therapeutic range and eliminating the need for frequent dosages. 
These and other problems have led to a shift in the drug delivery technology towards the 
modified/controlled release dosage forms. However, there are some characteristics 
associated with drugs used in sustained release formulations, as will be discussed below. 
 
Figure 9. Drug levels in the blood with immediate ( ) and sustained ( ) 
release profiles (167). 
 
     2. Drugs suitable for sustained drug delivery formulations 
 i. Drugs with short half-lives.  
 The extent of fluctuation in drug concentration at steady state is determined by the 
relative magnitude of the elimination half-life and the dosing interval. If a drug is given at  
an interval equal to the elimination half-life, there exists a two-fold difference between 
the maximum and minimum concentrations at steady state, which normally affects its 
Minimum effective level 
Time Dose 
Therapeutic range 




effectiveness (166).  Drugs with short half-lives and with a clear relationship between 
concentration and response, require to be dosed at regular, frequent intervals in order to 
maintain the concentration within the therapeutic range. These drugs are therefore 
suitable for sustained release delivery, as to reduce the number of daily intakes, and also 
maintain a steady state level that is within its therapeutic concentration. The 
pharmacological effects of these drugs are maintained by various mechanisms, few of 
which will be discussed below.  Conversely, drugs with long half-lives can be given at 
less frequent intervals, and there is generally no advantage in formulating these drugs as 
sustained release formulations. 
 
 ii. Drugs with high toxicity and low therapeutic index. 
 As shown in Figure 8, the conventional oral route of drug administration does not 
provide ideal pharmacokinetic profiles. For drugs that display high toxicity and/or narrow 
therapeutic windows, the ideal pharmacokinetic profile will be one wherein the drug 
concentration reached therapeutic levels without exceeding the maximum tolerable dose, 
and maintains these concentrations for extended periods of time till the desired 
therapeutic effect is reached (Figure 9; 168).  This could be achieved with sustained 
release preparations. Several drugs with short half-lives e.g. ibuprofen, must be dosed at 
frequent intervals and in high doses to achieve this aim. Such therapeutic measures may 
result in higher peak concentrations with the possibility of toxicity. In cases where the 
drugs have wide safety margins, this approach may be satisfactory because although very 
large fluctuations will occur within a dosing interval, no difficulty is generally 
encountered in view of the drugs’ low toxicity (168).  However, some side effects might 
 51 
be deleterious to health. For this class of drugs, the use of sustained drug delivery could 
prevent creating unwanted side effects that occur at very high concentrations and periods 
of inefficiency at very low concentrations. 
 A wide range of drugs is now formulated in a variety of different oral extended-
release dosage forms. However, only those that result in a significant reduction in dose 
frequency (as would apply to ibuprofen) and/or a reduction in toxicity resulting from high 
concentrations in the blood or gastrointestinal tract are likely to improve therapeutic 
outcomes. Consequently, extended release of a formulation has been broadly defined as 
the ability to achieve about two times reduction in dosing frequency usually used for 
conventional dosage form (169).  
 It is also worth noting that in switching a patient from an immediate-release to 
sustained release product, the equivalent total daily dose should generally be the same, 
although in most cases, an effective response has been shown to be achievable with a 
lower dose of the sustained release product (168).  Also, in view of the complexity of 
extended-release products and the potential for greater variability, both inter- and intra-
subject, patients should be monitored at the initial stage to ensure that the anticipated 
benefit of switching to such products is actually obtained. 
  
     3. Pellets and sustained drug release 
 Due to the regular spherical shape and the possibility of incorporation of a high 
drug level, pellets are often the first choice when a sustained release formulation is 
required. In addition, pellets offer flexibility for further release modifications (170).  A 
membrane coat is usually used to achieve release control. Drug release by coated pellets 
 52 
has been achieved by dissolution-control and mostly by drug diffusion, the latter, which is 
governed by the intrinsic pore network of the polymeric membrane (171).  The film coat 
was found to be the major factor controlling the drug release, although both drug and 
filler solubility influenced the diffusion of drug through the membrane. In some other 
reports, soluble co-excipients such as calcium phosphate and lactose have been 
demonstrated to enhance release rates of drugs, including ibuprofen by creating osmotic 
forces that may break the membranous barrier, resulting in higher release rates of drugs 
(172,173).  Such unusual results could only be explained if consideration was given to the 
physical characteristics of both powder and pellets (174).    
In another study in which diclofenac sodium pellets were coated with Surelease® 
polymer, release was dependent on the coating level of Surelease® (175).  At low coating 
level, diffusion of drug was facilitated due to the presence of more pores at the surface of 
the coated pellets, indicating that the rate of dissolution of the drug particles was the rate-
limiting step. However, at high coating loads, drug release was mainly diffusion 
controlled.  It has also been shown that Eudragit® NE 30 D was suitable for coating 
diclofenac sodium:alginate (1:1) microspheres (176).  However, apart from the effect of 
increasing polymer level, the release rate of drug was affected by the size and drug load 
of microspheres.  
 
    4. Sustained release of drugs 
 Controlled drug delivery offers an excellent alternative to multiple administrations 
obtained with immediate release preparations. These systems are capable of delivering 
drugs over longer time periods than conventional formulations (175,177).  Drug release is 
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controlled by a number of variables including drug content, polymer composition and its 
molecular weight, device geometry, and manufacturing process. These variables enable 
sustained release formulations to be fitted to the respective drug release model (178).  
Modern drug technologies have facilitated the production of dosage forms that 
exhibit modified time of release, rate of release, or both. While numerous terms exist for 
defining them, the USP recognizes only two types, namely, extended release (also called 
sustained-, prolonged- or controlled release) and delayed release (also called modified 
release; 168). The delayed release system, e.g. enteric-coated products, involves the 
release of discrete amount(s) of drug at some time other than promptly after 
administration, and exhibit a lag time during which little or no absorption occurs. 
However, they are by definition not extended-release products.  
 Although both sustained and controlled drug release are generally classified as 
extended release preparations, some differences exist between them (168).  Controlled 
release formulation implies a predictability and reproducibility in drug release kinetics, 
and is therefore rate-preprogrammed drug delivery systems. Release of drug molecules in 
these systems has been accomplished by system design, which controls the molecular 
diffusion of drug molecules. Additionally, they mostly exhibit zero order plasma release 
profiles (Figure 8), and Fick’s law of diffusion (Equation 10) is followed (179):   
 
where Jb is the bulk diffusion flux, Db is the bulk diffusion coefficient and (c) the 
concentration of the species. 







 Sustained release products offer several advantages and also some disadvantages.  
The use of extended-release products maintains therapeutic concentrations over 
prolonged periods, thus reducing the frequency of dosing and fluctuations in blood 
concentration (168).  In addition, adverse drug effects related to transiently high 
concentrations are circumvented (180-182) and patient compliance improved (168,183). 
On the contrary sustained release products contain a higher drug load and thus any loss of 
integrity of the release characteristics of the dosage form has potential toxicity problems 
(168).  Moreover, sustained release products should never be crushed or chewed as the 
slow-release characteristics may be lost and toxicity may result. This is particularly 
important in patients unable to swallow whole tablets, a problem commonly affecting the 
elderly or patients with gut motility problems (183).  It is therefore of importance that 
some drug release devices exist to minimize and/or eliminate these possible adverse 
situations, as will be discussed below. 
 
   i. Sustained release delivery systems or devices 
 Several sustained release devices exist and these include diffusion-controlled 
products, dissolution-controlled products, erosion products, osmotic pump systems and 
ion-exchange resins (168,184). Some of these systems will be discussed below. 
 
 1. Dissolution-controlled products  
 These include encapsulated and matrix dissolution products. In these dosage 
forms, the rate of dissolution of the drug (and thereby availability for absorption) is 
controlled by coating the dosage form with slowly dissolving polymers or by 
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microencapsulation. Once the coating is dissolved, the drug becomes available for 
dissolution.  Consequently, by varying the thickness of the coat and its composition, the 
rate of drug release can be controlled (185,186).  In some preparations a fraction of the 
total dose is formed as an immediate-release component to provide a pulse dose soon 
after administration, thus decreasing or preventing the lag time associated with sustained 
release formulations (187).  This is followed by slow release of the remaining part of the 
formulation. 
 
 2. Diffusion-controlled products  
  In these systems, a water-insoluble polymer controls the flow of water and the 
subsequent diffusion of dissolved drug from the dosage form. This mechanism 
encompasses both reservoir and matrix systems (Figure 10; 167).  In the matrix system 
shown in Figure 10A, the drug is homogeneously dispersed throughout a rate-controlling  
    Figure 10.  Delivery of drug from (A) Typical matrix drug delivery system, (B) Typical 




polymer matrix, and the rate of drug release is controlled by diffusion throughout the 
polymer matrix.  This is described in equation 11:  
 
 
where y is the dimensional distance, D is the diffusion coefficient of the drug in the 
polymer matrix, C is the concentration of the drug at any y position and time (t). 
In the reservoir device (Figure 10B) a core of drug (whether solid drug, dilute 
solution, or highly concentrated drug) is coated with a film or membrane of a rate-
controlling material, the polymer, and the rate of drug release is controlled by its 
permeation through this membrane wall. Thus, because the polymer coating is essentially 
uniform, and also possesses a uniform thickness for a specific thickness level, the 
diffusion rate of the active agent can be kept fairly stable (zero order kinetics) throughout 
the lifetime of the delivery system. This system is described in Equation 12: 
 
 
where F is the flux, D is the diffusivity constant of the drug in the coating membrane, K 
the partition coefficient between the coating membrane and the medium, CS is the drug 
solubility, t is the time taken to diffuse through the surface area and L is the membrane 
thickness through which the drug must diffuse.  This equation is used in mathematical 
modeling of drug release from controlled drug release formulations where F represents 
the cumulative amount of drug released per unit surface area at time, t (188).  A plot of F 
vs. t yields a regression equation with the slope of DKCs/L, a zero order constant (ko).  In 
addition to the mathematical modeling of dissolution profiles, some comparison factors 
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have been officially stipulated to control changes that could occur between the different 
drug release profiles. 
  
 ii. Comparison of dissolution profiles 
 In various guidance documents, the Food and Drug administration (FDA) has 
proposed a comparison of dissolution profiles for similarity when data are available for at 
least three dissolution time profiles (189-192).  The recommendations guiding this 
comparison include number of units (12), limit of variability mean dissolution values at 
different time points (10 - 20%), dissolution test conditions for different dosage forms 
(immediate and modified release), etc.  The comparison is achieved either by model 
dependent (curve-fitting) or model-independent (statistical) methods. The former 
involves linear regression of the percentage dissolved at specific time points while the 
model independent analysis involves statistical moment based comparison, repeated 
measure split-plot, two way ANOVA, etc. (190), most of which could be very 
complicated.  The method mostly adopted by the FDA is a simpler model independent 
mathematical approach proposed by Moore and Flanner (189) using two factors, f1 and f2 
shown in the following equations: 
 































where Rt and Tt are the cumulative percentage dissolved at each n time point for the 
reference and test formulations respectively, ∑ is the summation over all time points and 
LOG is logarithm to base 10.   
The factor f1 is directly proportional to the average difference between the two 
profiles, while f2 is inversely proportional to the average squared difference between the 
two profiles, and emphasizes the larger difference among all the time-points. The f1 factor 
measures the difference, while the f2 factor measures the closeness, between the two 
profiles. Because of the nature of measurement, f1 has been described as difference factor, 
whereas f2 is the similarity factor (191). 
Similarity in product performance is a major factor in dissolution studies and 
comparisons.  Thus, regulatory interest lies in knowing the extent of similarity between 
two curves, and in measuring which curve is more sensitive to large differences at any 
particular time point.  Consequently, the f2 comparison has been the focus in Agency 
guidance documents.  When the two profiles are identical, f2 = 50 x log (100) = 100 and 
approaches 0 (50 x log {[1 + 1/nΣ (100)2]-0.5 x 100) as the dissimilarity increases. An 
average difference of 10% at all measured time points results in an f2 value of 50.  FDA 
has therefore set a public standard of f2 value between 50-100 to indicate similarity 
between two dissolution profiles and a point-to-point difference of not more than 10%.  
Although this range is considered wide by some authors, from a public health point of 
view, and as a regulatory consideration, f2 comparison metric with a value of 50 or greater 
is a conservative but reliable estimate to assure product equivalence. Generally, f1 values 
up to 15 (0 – 15) ensure similarity of the two curves being compared. 
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 As already discussed, controlled drug release is mostly achieved using the 
polymeric reservoir and matrix devices.  Cellulose derivatives are commonly used as 
polymeric films in the reservoir systems, while the polymeric matrix material may be 
plastics, e.g. methylacrylate-methyl methacrylate, polyvinyl chloride, cellulose derivatives 
(hydrophilic polymers) or fatty compounds including carnauba wax (a natural wax 
product extracted from the leaves of a Brazilian palm tree, Copernica cerifera (192).  
 
6. Polymeric Membranes and Sustained Drug Release 
  
The use of polymeric film membranes has attracted considerable attention in the 
development of controlled release drug delivery systems in recent years. There has been a 
drastic shift from the originally used solutions of polymeric materials in organic solvents 
to the use of aqueous polymeric dispersions with different commercial names and 
potential applications in sustained release preparations (23). There is also considerable 
shift form the originally coated tablets to the use of sustained release 
multiparticulate/pellet delivery systems (193) using fluid-bed film coating and drying 
equipment. 
 Film coatings are applied to pellet and tablet formulations for several reasons 
including controlled release, taste masking, and improved stability (194).  Pellet qualities, 
especially the shape of pellets, have been shown to influence the deposition of film 
coatings in a fluid-bed process. In a previous report, eight pellet batches were used to 
monitor the pellet shape as a function of the film thickness formed (194). Four of these 
were spherical visually, and the other four batches can be described as ovoids, dumbbells, 
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long dumbbells, and cylinders respectively. The average coat thickness of the pellets 
assessed by cross-sectional measurements did not appear to be influenced by the initial 
shape of the pellets.  
 Among the aqueous polymeric films used in the manufacturing industries, the 
ethylcellulose and polymethacrylic acid based films have been widely employed. This is 
due to their inertness, solubility in relatively non-toxic solvents and availability in resins 
with different properties (195).  Surelease and Eudragit NE 30D are typical examples 
of this class of coating materials. 
 
a. Surelease 
 Surelease is an aqueous polymeric dispersion of ethylcellulose. It is a latex 
coating system of fully plasticized ethylcellulose dispersions with 25% weight/weight 
(w/w) solids content (23). The dispersion contains dibutyl sebacate and oleic acids as 
plasticizers and fumed silica as an anti-adherent, in ammoniated water. Plasticizers 
reduce the minimum film forming temperatures as well as the glass transition 
temperatures, and consequently, increase the flexibility of the film coatings. Surelease 
has been shown to be superior to several other polymers when sustained release (pellet 
and tablet) delivery is required, as well as with the use of the rotor-disk module (175). 
 Although some studies have been reported on controlled release forms of 
ibuprofen tablets (22-25,196) only one such formulation, namely, Brufen Retard, is 
available in the market (26). A study using ibuprofen tablets compressed from ibuprofen 
granulated with different concentrations of Surelease showed that the tablets made from 
polymer-containing granules demonstrated more prolonged release profiles than control 
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tablets that contained no polymer (23). It was also observed that increasing the amount of 
Surelease in the tablets resulted in a reduction in ibuprofen release rate and a 
linearization of the drug release curves.  This was reported to be due to the higher degree 
of imperfection in the formation of the film membrane around ibuprofen by these low 
polymer levels, which might have caused increased diffusion of the drug from the dosage 
forms. In addition, at lower polymer concentrations (1.2 - 3.5%), the release of this acidic 
drug (pKa 4.8) was affected by the pH of the dissolution medium, hence, the release was 
considerably lower at pH 1.2 than at pH 7.5 (Figure 11). The latter results resembled  
 
Figure 11. Release profiles of ibuprofen from tablets granulated with water (control) and 
different levels of Surelease® in pH 1.2 (Upper) and 7.5 (Lower) dissolution media (23). 
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those obtained with both unprocessed pure ibuprofen and processed uncoated drug at both 
pH values used in the study.  These studies indicate that drug release rate from Surelease 
is dependent on the thickness of the coating material, and the equilibrium solubility of the 
drug, which in turn is dependent on the pH of its solution (23).  
 From these and other studies, drug release mechanisms at both pH values were 
reported to be both diffusion and dissolution controlled. However, at the high pH (≥ 7.5), 
the release rates of pellets and tablets coated with higher Surelease levels depended not 
only on the solubility of the drug, but also on the polymer/dissolution medium partition 
coefficient.  
  
b. Poly(ethylacrylate-methylmethacrylate (Eudragit NE 30D) 
 In processing sustained release preparations, usually additional excipients like 
plasticizers and glidants may be required. Modern sustained release dosage forms require 
reliable and minimized number of excipients to ensure a release rate of the active drug 
that is reproducible within a narrow range. Eudragit® polymers fulfill these requirements 
to a very high extent (197), thereby enabling research and development to create tailor-
made solutions. These products are used in the pharmaceutical industry for the 
development of formulations for enteric and controlled-release oral products, as well as 
for providing protective coatings and taste masking for bitter oral dosage forms (194).  
 The Eudragit® RL- and RS-types are based on copolymers of acrylate and 
methacrylates with quaternary ammonium groups as functional groups.  The latter 
determine the permeability and swellability of the films in water.  The Eudragit® RL-
types contain higher amount of the quaternary ammonium groups and therefore form 
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highly permeable films with little delaying action. The RS-types that contain lesser 
amount of the quaternary ammonium functional groups are poorly permeable, swell less 
easily but slow down drug diffusion very noticeably.  The Eudragit® NE-types that 
include the NE 30 grade contain no functional groups but are ethylacrylate 
methylmethacrylate copolymers with a neutral ester group.  They are both permeable and 
swellable in water, and are used for granulation processes and sustained release coatings 
(198).  For the sustained release applications, their usual formulation amounts are 5 - 20% 
calculated on the drug weight, although sufficient release is usually obtained at 14% 
polymer addition (Figure 12). 
  
Figure 12. Coating of potassium chloride crystals with aqueous dispersion of 
Eudragit NE 30 D (199). 
 
Eudragit® NE 30D [poly(ethylacrylat-methylmethacrylat)] is an aqueous 
dispersion of a neutral copolymer based on ethyl acrylate and methyl methacrylate 
polymers, and containing 30% w/w dry polymer substance. Eudragit® NE 30D polymer 
film is water insoluble, permeable, swellable and pH independent (200,201).  The water  
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permeability of the polymer film is critical to drug dissolution profiles; it determines both 
the onset of drug release and the release rates of the drug products. The release profiles 
can be determined by varying mixing ratios and/or film thickness of the product. As  
shown in Figure 12, increasing amounts of polymer has been shown to decrease release 
rate in vitro. 
 Besides ethyl acrylate and methyl methacrylate, the only component in the 
polymer latex dispersion is about 1.5% (on the dry polymer basis) surfactant, nonoxynol 
100 (202).  At higher concentrations, this surfactant has been shown to crystallize out 
from polymer films during storage, and to decrease drug release during aging. Therefore, 
drying of the moistened drug/polymer mixture to a residual water content of <2% is 
necessary to avoid changes on the release profile during storage. 
 For the coating process, Eudragit® NE 30D neither contains nor needs any 
plasticizer, however, stickiness shown by this product can be improved by using glidants 
such as talc or glyceryl monostearate.  It is used in the coating of small particles for 
directly compressed and wet granulated products.  If the coating with this polymer is 
complete, the model represented in Equation 12 (reservoir delivery system) is expected. If 
the coating is not complete (i.e. a more porous membrane exists), a mixed release 
mechanism with both square root of time (Equation 7) and zero order (Equation 12) 
release components, which has recently been proposed (177) could be operating. This is 
represented in Equation 15: 
 






 The pellet dosage forms of diffusion- or dissolution-controlled products can be 
encapsulated using hard gelatin capsules, or prepared as a tablet. In most cases where 
gelatin encapsulation were used, the physical characteristics evaluated included bulk and 
tapped densities, Carr’ s compressibility index, and drug release properties (203,204).  The 
release profiles can be assessed as a mean dissolution time (MDT) and its variance (VDT) 
or by comparison using the similarity factor. The mechanism of dissolution could be 
assessed from the value of the relative dispersion (RD) of the mean dissolution time. In 
some cases where the pellets are tableted, the possible relationship between the properties 
of the pellets and those of the tablets is evaluated by canonical analysis followed by 
multiple regression analysis (205).  In the latter studies, it was found that only about 51% 
of the tablet properties could be predicted from the properties of the pellets.  
 One of the advantages of encapsulated pelleted products is that the onset of 
absorption is less sensitive to stomach emptying (206).  Additionally, because of their 
small size the entrance of the pellets into the small intestine (where the majority of drug 
absorption occurs) is expected to be more uniform than with non-disintegrating extended-
release tablet formulations.  
 
7.  Hard Gelatin Encapsulation and Technology  
 
a. Hard Gelatin Encapsulation  
Most capsules are made from gelatin that is also widely used in many food 
products. Gelatin is a mixture of water-soluble proteins derived primarily from collagen, 
the main naturally-occurring protein constituent of connective tissue (207).  Gelatin is 
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defined as a versatile container that can encapsulate powders, pellets, liquids, semi-solid 
formulations, caplets, tablets and even combinations of these (Figure 13).   
  
Figure 13: Capsules as versatile container for different pharmaceutical  
dosage forms (208). 
 
Capsules are made from pharmaceutical grade gelatin that has met the stringent 
requirements of the United States Pharmacopoeia and other international organizations 
that set standards for products used in medicines. In the body, the water-soluble gelatin 
shell dissolves in the stomach, releasing its contents within the first few minutes of 
swallowing.  
 Both tablets and capsules are well-proven and well-accepted dosage forms. 
However, capsules have the added advantages of masking the taste and/or odor of specific 
medicinal compounds, are easy to swallow, have attractive appearance, color, and can 
also be easily filled and processed (209).  The capsule provides a simple way for the 
patient to take medications or supplements, and many pharmaceutical companies use 
capsule-filling machines as a convenient way to package a pharmaceutical product for 
single or multiple doses.  Additionally, capsules require fewer excipients and have been 
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shown to be more suitable for sustained release dosage forms.  Therefore, capsules can 
promote patient compliance (210). 
 
b. Hard Gelatin Capsule Technology 
 A detailed step-by-step description of hard gelatin capsule production has been 
given (211).  These are manufactured from melted gelatin in demineralized water with the 
addition of any needed additives like dyes and opacifants, in feed tanks that gravity-feed 
the mixture into a dipper section. Herein, the capsule cap and body are molded onto their 
respective stainless steel pin bars dipped into the gelatin solution. Once dipped, the pin 
bars rise to the upper deck allowing the cap and body to set. Then, gently moving air that 
is precisely controlled for volume, temperature, and humidity, dries the capsule halves up 
to a stipulated amount of moisture, while precision controls constantly monitor humidity, 
temperature, and gelatin viscosity throughout the production process. Once drying is 
complete, the pin bars are moved to an automatic table section where the capsule halves 
are stripped from the pins. The cap and body lengths are then precisely trimmed to an 
acceptable tolerance, and joined automatically in joiner blocks. The finished capsules are 
pushed onto a conveyer belt, which empties them into a container.  
 Throughout the production process, capsule qualities, size, moisture content, wall 
thickness, and color, are monitored. Capsules are sorted and often visually inspected on 
specially designed inspection stations. Perfect capsules are imprinted with a particular 
logo on high-speed capsule printing machines, and thereafter sterilized and packaged as 
required. 
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 The most commonly used capsule sizes range from 000 to 5, largest to smallest 
size respectively, and have corresponding fill powder volumes and weights (Figure 14). If 
a greater extent of compression is required in order to fill large dose drugs or to use a 
smaller capsule size, the dosator nozzle principle discussed in a later section usually 
works more successfully for granules, but not necessarily for pellets that do not require 
the formation of firm plugs for filling. 
 
Figure 14. Capsules showing approximate sizes and typical fill weight (212). 
 
c. Capsule Filling Machine Instrumentation  
 Capsule-filling machines generally consist of a through-hole for accommodating 
the cap of a capsule and a body transport member having a body pocket for 
accommodating a body of the capsule (213).  It also comprises of a filling system for 
filling the capsule contents. The contents are typically pharmaceutical products (powders, 
pellets, oils) and foods. The filling system includes a force-feeding screw disposed in a 
chamber, and has a lower end opening above the body transport member. Thus, 
powders/pellets supplied into the chamber are compulsorily force-fed into the capsule 
body by the force-feeding screw. Consequently, even if the substances to be filled into a 
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capsule have low bulk density and inferior formability and fluidity, they can be 
compulsorily force-fed into the capsule body by the screw system. By so doing, filled 
capsule in which a predetermined amount of the contents is filled can be produced with 
certainty. The cap transport part includes a plurality of segments that includes the cap 
pocket.  These segments are individually vertically movable with respect to one another 
and also in a vertical direction away from the body transport member.  
 A modern and ideal capsule-filling machine is designed to fill the material which 
could be very low in bulk density and very inferior in fluidity or formability.  These could 
include crushed substance of weeds, grass or tea leaves or silicon dioxide.  Most of these 
are difficult for a conventional filling machine because of the uncertainty of the expected 
fill amount.  The machines typically form the capsule contents (plugs, pellet dose, etc.) 
once and charge them as such into the capsule body.  Alternatively, vibrations are applied 
to the substances that facilitate their flowing into the capsule body.  It is expected that for 
every capsule filling machine, various products of different qualities could be filled well 
into a capsule reproducibly.   
 There are basically two types of automatic capsule filling machines that are 
commonly used in the pharmaceutical field, based on their mechanisms of filling.  These 
are the dosator and the tamping and dosing disk (tamp filling) machines. 
 
d. Types of Automatic Capsule Filling Machines 
    1. Tamp filling machine  
 The dosing disk consists of a rotating steel plate with precisely bored holes that 
form the dosing chamber.  This machine depends on pushing pins through a powder bed 
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so that a unit dose is transferred into a dosing disk cavity. This dose is then ejected into 
the capsule body.  The important process variables of the tamping capsule filling machine 
include the fill weight, the tamping force, the number of tamps, the operational speed, 
powder bed height, and formulation variables such as the presence or absence of 
lubricants and disintegrants.  These variables have been widely studied and their  
requirements at various filling conditions validated (214,215).   It has also been reported 
that substance flowability affects the filling weight adversely. 
 The operational speed is the operating rate of the machine that has been shown to 
relate strongly with the filled capsule characteristics, especially, the average capsule fill 
weight (216).  Variability in the latter is expressed as standard deviation and coefficient 
of fill weight variation. 
 Recent adaptations of the tamp-filling machine for pellet filling include gravity-
feeding of the pellets from a hopper into main pellet housing.  A male and a female gates 
control the amount of pellet that could be filled into the capsules (Figure 21).  In this case, 
the shuttle speed, which regulates the length of time the gates could remain open, is an 
important variable that affects the capsule fill weight (217).  
 The instrumentation of tamp-filling capsule machine is normally described in 
different ways. In some studies, it was described using strain gauges, by moving an 
instrumented piston from one compression station to the next (218). These revealed 
important relationships between compression force, piston setting, and final fill weight, 
with the latter being a complex interaction of all compression stations.  In another report, 
the instrumentation of a Bosch GKF 400S tamp-filling machine was described using a  
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prototype of a pneumatic tamping head equipped with a piezoelectric force 
transducer (219).  
 During continuous capsule filling, feedback control of capsule fill weight can be 
achieved.  Podczeck (219) established this mechanism by replacing the springs of a 
conventional tamping machine situated between tamping pins and the upper part of the 
tamping head with a pneumatic system. He reported that the air pressure inside the 
pneumatic chamber can be regulated through a feedback switch valve, and that the use of 
the pneumatic tamping head is limited to the control of fill weight during tamping. 
Therefore, major adjustments of fill weight at the set-up stage of the machine should be 
made by alteration of the tamping pin and powder bed height settings.  Although the 
principles of capsule fill weight control by continuous monitoring of tamping forces have 
been established, the transfer of the system to full industrial use requires further 
development by every machine manufacturer.  
 A trend has been observed toward slower dissolution rate with increasing number 
of tamps due to increased compactedness, and also depending on the type of filler used 
(220).  The inclusion of a disintegrant tends to nullify the effects of number of tamps or 
tamping force and enhances drug dissolution markedly. Insoluble fillers appear to cause 
some drugs to follow a diffusion mechanism from insoluble matrix model regardless of 
the number of tamps or their intensity. Using drug plugs, mercury intrusion pore size 
distribution data and other studies suggest that for tamp forces 100 or 200 N, only two 
tamps are sufficient for a good powder consolidation. However, the tamp filling machine 
has also been reported to be very suitable for pellets that do not require plug formation in 
order to be properly filled (215). 
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    2. Dosator filling machine 
 The dosator principle is used by numerous intermittent-motion and continuous-
motion capsule-filling machines. Its instrumentation has been likened to that of tablet 
machines because they both rely on compression process (215).  The compressibility is 
related to the tapped density of the materials, thus, it is suitable for powders that require 
high compressibility for encapsulation.  Very flowable powders and consequently pellets 
have been found difficult to densify and fill using this machine leading to greater 
variation in fill weight. 
 The important variables for this system include the type and level of lubricant and 
the ejection force, powder bed height, piston height, and compression force on the 
ejection forces generated during the filling process. It has been observed that the ejection 
force increased with increasing the powder bed height, piston height and compression 
force (219).  In a study using a Zanasi LZ 64 machine with intermittent operation, the 
effect of the excipient- and machine parameters on the filling of the capsule and the 
dissolution rate using caffeine as model substance was determined (221).  Sufficient 
lubrication of the capsule powder mixture measurable by low ejection forces is critical for 
a uniform fill weight.  However, addition of too much lubricant prevented the compact 
from forming and increased the standard deviation of the fill weight (222).  Another 
report also showed that for an effectively lubricated formulation, a lubricant film is 
formed and maintained on the inside of the dosator nozzle during a run, which maintains 
the ejection force of the process (223).  However, for a less effectively lubricated film, 
where the lubricant film is not formed and maintained, the ejection force increases 
slightly as each slug is ejected.  
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    3. Comparison of the tamp and dosator capsule filling machines 
 A comparison of the effectiveness of the above two commonly used capsule-
filling mechanisms have been made by several authors (204,224).  In one of the studies, 
four different granule size fractions of Sorbitol instant® were filled into hard gelatin 
capsules on a tamp filling (Bosch) and a dosator nozzle machine (Zanasi). An acceptable 
filling performance was always observed and was independent of the machine type 
employed. A direct relationship between the angle of internal flow and the coefficient of 
fill weight variation has also been recorded for both systems (224).  However the tamp 
filling machine was found to be slightly better for the coarser granule size fractions, 
because it does not require the formation of a firm plug.  
 It has therefore been concluded that in situations where a low plug density is an 
essential prerequisite for product qualities including drug dissolution and bioavailability, 
the tamp-filling machine is more suitable. The dosator machine is preferred when higher 
compressiblity is required as to fit large drug doses into small capsule sizes. The 
compressibility issue is however not applicable to the filling of pharmaceutical pellets 
that are normally ≥ 400 µm, especially as it has been shown that particles larger than  
40 µm do not efficiently form a plug (215). Additionally, the dosator machine is not 
suitable for the filling of pellets since their inability to form plugs will lead to loss of 
metered doses from the nozzle during its passage from the hopper to the capsule body. 
 In a previous report, a dosator and a tamping capsule filling machines were used 
to study the relation between variation of filling weight and powder flowability in 
connection with filling mechanism (225).  The angle of repose, the minimum orifice 
diameter and the discharge rate through orifices were measured.  The orifice diameter is 
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the length of a straight line which passes through the center of the orifice, and terminates 
at the circumference. The minimum orifice diameter was closely related to the discharge 
rate through orifices. The angle of repose was used as an index of flowability representing 
the mobility of the particles on the surface of a powder bed, while the minimum orifice 
diameter was used as one representing the mobility of the particles in a powder bed under 
dynamic conditions. In both systems, no good correlations were found between the angle 
of repose and the minimum orifices. However, a good correlation was found between the 
variation of filling-weight and the minimum orifice diameter in a dosator system.  In 
tamping system, the variation of filling-weight was closely related to the angle of repose. 
In this system, a minimum point appeared in the plots of the angle of repose versus the 
coefficient of variation of filling-weight.  This indicated that as the angle of repose 
increases, the variation of filling-weight is governed by both the variation of the powder-
bed-height (an increasing factor) and the amount that escapes the filled capsule (a 
decreasing factor). 
Consequently, the tamp filling machine (Figure 15), which has been shown to  
 
Figure 15: Tamp capsule filling machine with color touch-screen control (left; 226). 
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posses the ability of handling a wider range of products than a dosator machine, including 
medicinal herbs, will be used in our study. 
 
e. Stages of Hard Gelatin Encapsulation Process 
 All capsule-filling machines rectify, separate, fill and join empty capsules that are 
thereafter ejected from the system (227).  Modern capsule fillers are designed to offer 
precise dosing, high speed, and easy changeover and cleanup.  
 
     1. Rectification 
 In order to obtain a capsule product as described above, the cap transport portion 
is placed on the body transport member such that the cap and body pockets are aligned 
with each other. This arrangement can accommodate an empty capsule in which the cap 
and the body are temporarily coupled to each other.  
 
     2. Separation 
  The empty capsule is transported in the formed capsule pocket in an erected 
position, with the cap directed upward.  During transportation of the empty capsule, the 
cap and the body are separated from each other inside the capsule pocket, the cap is held 
in the cap pocket while the body is held in the body pocket.  Thereafter, the cap and body 





     3. Filling 
 The material or medicament is directly force-fed and filled into the body by the 
force- feeding screw.   
 
     4. Joining and ejection 
 Finally, the cap transport member is placed onto the body transport member such 
that they are once more aligned with each other, and then coupled to each other within the 
capsule pocket, to produce a filled capsule product.  
 
f.  Comparison of Hard Gelatin Encapsulation of Various Dosage Forms 
     1. Powder 
 The filling of powders in capsules demands a powder with good 
pharmacotechnological properties for samples to be constant, and to facilitate its transfer 
into the capsule (228).  Thus the powder bulk and tapped densities, its various flow 
angles: repose, internal flow, and friction, as well as some machine variables are of great 
importance (229).  The range of powder combinations that can be filled on the tamp 
filling machine exceeds that applicable to a dosator nozzle system.  However, the latter is 
used very extensively because large doses of highly compressible drugs can be filled into 
smaller capsule sizes. Microcrystalline cellulose (MCC) and silicified microcrystalline 
cellulose (SMCC) powdered formulations are mostly used as fillers in powder capsule 
technology (230), while lactose, Mg stearate, and sodium lauryl sulfate are mostly used as 
lubricants (231,232). 
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 The problems encountered with powder filling are numerous and depend on the 
type of material.  Filling problems due to powder flooding could be solved by increasing 
the powder bed height in the powder bowl.  Inappropriate powder bed height adversely 
affects the capsule fill weight, an effect which increases with decreasing powder flow.  
Tamping pin setting and powder bed height influence capsule fill weight of powders and 
even granulated products having poor flowability.  However, for moderate flowing 
powders and granules, the coefficient of fill weight variation, an attribute of the powder 
distribution into the capsules, appeared to be nearly independent of powder bed height or 
tamping pin setting.  The filling performance of powders with poor flow properties could 
therefore be adjusted by optimizing both machine settings.   
 
     2. Liquids and semi-liquids 
 Liquid and semi-solid formulations in hard gelatin capsules provide alternate 
choice over soft gelatin capsules for improving bioavailability and stabilizing moisture- 
or oxygen-sensitive drugs, processing for low melting point drugs and achieving good 
content uniformity for low-dose drugs. They are also convenient delivery route for 
administering high potency compounds. In addition to high patient acceptability, they can 
also improve product stability (233).  Other advantages of this technology over soft 
gelatin capsules have been demonstrated, especially the flexibility of developing solid 
dispersion and controlled-release formulations. These products include oils, waxes, 
polyethylene glycols, pluronics, surfactants, self-emulsifying system and polyglycolyzed 
glycerides (Gelucire®) with a range of melting point and hydrophilic-lipophilic balance 
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(HLB) values and. Important processing variables include filling temperature, cooling 
rate, and shear rate and should be carefully evaluated (234). 
 
       3. Tablets 
  Tablets are encapsulated for various purposes, including improved stability and 
taste. A fiber-optic probe or an electrochemical device is usually incorporated in the 
system to verify the dosing (226,235).  This is coupled with a reject mechanism that 
rejects capsules with missing tablets. It is recommended that tablet dimensions and 
hardness specifications be maintained within strict tolerance, to assure proper tablet feed. 
Spherical tablets are most suitable for this technology. 
 It has however been shown that in comparison with tablets, pellet encapsulation is 
the technology of choice both for immediate and sustained release formulations. 
Moreover, it is not plausible to compress coated pellets into tablets due to cracking of the 
protective and sustained release coatings. In order to maintain the geometry of pellets, 
coated and uncoated, encapsulation is therefore the preferred method.   
 
       4. Pellets 
 Pellets are very suitable for hard gelatin encapsulation because of their regularity 
of shape, good flowability and other physiological and mechanical qualities. Pellets can 
be filled into hard gelatin capsules using different methods that include feed-frame, 
dosing chamber and vacuum dosator methods. In the feed frame method, most pellet 
formulations are designed with a bulk density to fill the capsule body completely. The 
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vacuum dosator method maintains strictly the dosator mechanism already discussed. The 
dosing chamber method (Figure 16) is widely utilized by many machine types including  
the tamp filling machines, because it allows for partial dosing of the capsule, as well as  
for dosing capsules with two types of pellets or beads.  These pellet formulations must be 
free flowing and free from agglomerations or electrostatic charge that interfere with pellet 
discharge into the capsule body from the dosing chamber. Narrow to uniform particle 
sizes also facilitate accurate dosing.  
   
Figure 16: Tamping pellet filling system (227). 
 
A new automatic ultrasonic control system has been developed for the 
determination of the filling height in pellet encapsulation, and integrated into an 
intermittently operating high output capsule filling machine (236).  Measurement of the 
time required for transmission of several ultrasonic impulses determines the height to 
which each capsule has been filled.  Utilizing this in-line measuring system, it is possible 
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to monitor the fill mass of all capsules without a reduction in throughput.  Furthermore, 
the sporadic occurrence of overfilled or under filled capsules can be detected with a high 
probability and such capsules rejected, contrary to manual in process control methods.  
This new filling monitoring system has been successfully validated and also used   
successfully in routine operation. 
 
 In a previous study (209), film coated and uncoated pellets of different shapes, 
varying from spherical to cylindrical, were filled into hard shell capsules. It was observed 
that when no film coat was applied, the pellets needed not be perfectly spherical in order 
to be filled reproducibly. Thus, an aspect ratio (i.e. the ratio of the maximum and 
minimum dimensions of a particle) of ≤ 1.2 was suitable for encapsulating the pellets into 
hard gelatin capsules, and only very pronounced surface roughness hindered the filling 
process. After coating of the pellets with an ethylcellulose film, none of the batches could 
be filled to an acceptable standard, because electrostatic loading led to a blockage of the 
filling mechanism. The addition of 1% talcum powder was sufficient to remove all 
charges. It is therefore necessary to monitor the surface roughness and pellet shape/aspect 
ratio for efficient encapsulation of coated and uncoated pellets respectively. 
 Pellet encapsulation also leads to reproducible gastrointestinal transit times that 
result in increased efficacy and safety of these dosage forms compared to single unit 
dosage forms or tablets (70). Furthermore, predictable concentration/time profiles can be 
achieved and local mucosa irritations reduced. Using traditional extrusion/spheronization 
process for theophylline, it has been shown that several process steps are necessary to 
obtain the finished encapsulated dosage form.  However, the pharmacokinetic and clinical 
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advantages already mentioned compensated the increased investment necessary for this 
pellet development (70).  The use of the rotor-disk module in both spheronization and 
coating processes will eliminate the several steps involved in the traditional 
spheronization process, thereby leading to a reduction in processing time and cost.  
 To confirm these advantages, two sustained-release (pellets in hard gelatin 
capsules) forms of propranolol have been compared with ordinary sustained release 
propranolol tablets (237).  The bioavailability of the capsules was more acceptable than 
that of the tablets due to improved absorption and efficacy.   
 Despite the several advantages of microparticulate dosage forms and capsules 
over tablets, there are no ibuprofen pellet formulations in the market in both immediate 
and sustained release forms.  Additionally, elaborate studies have not been done to 
elucidate the advantages and drawbacks of the fluid-bed rotor-disk machine. Therefore, 
the specific aims of this research are as follows: 
1)  Development of ibuprofen spheroids from different drug particle sizes and 
different drug loads using the rotor-disk fluid-bed technology and Avicel as the major 
excipient and spheronization enhancer, sodium lauryl sulfate as lubricant and water as the 
granulating liquid. 
2)  Optimization of the developed process and product variables using statistically 
designed factorial experiment.  
3)  Scale-up of process and batch size from development to pilot and eventually to 
semi-production sizes. 
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4)  Polymer coating and encapsulation of coated and uncoated microparticulates 
using hard gelatin capsules for comparative evaluation of controlled and immediate 
release delivery systems. 
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II.  EXPERIMENTAL 
 
A.  Materials and Equipment 
 
 The materials and equipment used in the study are shown in Tables II and III  
respectively. 
 
Table II:  List of Materials 
 
Material Lot/Batch Number Manufacturer/Supplier 
Ibuprofen (20 µ) LPL-4814 Albemarle Corp., Baton Rouge, LA 
Ibuprofen (40 µ) LPL-5810 Albemarle Corp., Baton Rouge, LA 
Avicel RC-581 B106C FMC Biopolymer, Princeton, NJ 
Avicel CL-611 A178N FMC Biopolymer, Princeton, NJ 
Sodium lauryl sulfate S0180 Spectrum Chemicals, Gardena, CA 
HPMC (Methocel) E5LV Dow Chemical Co., Midland, MI 
Talc W47835P09 Spectrum Chemicals, Gardena, CA 
Surelease® E-7-19010 Colorcon, West Point, PA 
Eudragit® NE 30D 1290112016 ROHM Technical Inc., Malden, MA  
Hard gelatin capsules 619067 Capsugel, Greenwood, SC 
Sodium hydroxide S3183 Fisher Scientific, Pittsburgh, PA 
Acetonitrile (HPLC grade) 943286 Fisher Scientific, Pittsburgh, PA 
Glacial acetic acid 903092 Fisher Scientific, Pittsburgh, PA 
Potassium phosphate monobasic 966500 Fisher Scientific, Pittsburgh, PA 
Methanol (HPLC grade) 970703 Fisher Scientific, Pittsburgh, PA 
Triethylamine 920412 Fisher Scientific, Pittsburgh, PA 
Polysorbate 80 A38-500 Fisher Scientific, Pittsburgh, PA 
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Table III: List of Equipment 
Equipment Model Number Manufacturer/supplier 
Fluid-bed Granulator FL-MULTI-1 Vector Corporation, Cranbury, NJ 
Fluid-bed Granulator FL-MULTI-15 Vector Corporation, Cranbury, NJ 
Fluid-bed Granulator FLN-120 Vector Corporation, Cranbury, NJ 
Glatt Fluid-bed WSC-5 Glatt, Binzen, Germany 
Capsule filling machine K150i Romaco/Index, Pompton Plains, NJ 
Liquid Chromatography system LC-10AS Shimadzu Scientific Instruments, 
Columbia, MD 
Auto Injector SIL-10A Shimadzu Scientific Instruments, 
Columbia, MD 
UV-VIS Detector SPD-10A Shimadzu Scientific Instruments, 
Columbia, MD 
System Controller SCL-10A Shimadzu Scientific Instruments, 
Columbia, MD 
Precolumn LUNA 5 C18 Phenomenex, Torrance, CA 
Column IB-SIL 5 C18 Phenomenex, Torrance, CA 
Ezchrom® Software Version 3 Shimadzu Scientific Instruments, 
Columbia, MA 
Vander Kamp Tap Density 
tester 
10705 Van-Kel Industries, Edison, NJ 
Computrac® Moisture Analyzer Max 200 Arizona Instrument, Las Vegas, NV 
Image analyzer Quantimet 500 Leica Cambridge LTD., Cambridge, UK 
Image analysis software QWIN Leica Cambridge LTD., Cambridge, UK 
Microscope Microstar IV Bordersen Instrument Co., Valencia, PA 
Sieve Shaker 18480 CSC Scientific Co., Inc., Fairfax, VA 
Mettler moisture analyzer Mettler Pm 100 Mettler Toledo Inc., Columbus, OH 
Denver Instruments balance B077193 Denver Instruments Company,  
Arvado, CO 
Dissolution Apparatus VK-600 VanKel Industries, Inc., Edison, NJ 
JMP® software Versions 3.0 & 4.0 SAS Institute, New York, NY 
Scanning electron microscope  Hitachi S510 Hitachi, Tokyo, Japan 
Scanning electron microscope Philips XL 30 FEG Holland, Nederlands 
Cressington Sputter Coater  108 Franklin Electric, Bluffton, IN 
Hummer Sputtering System LO.2 ANATECH Ltd., Alexandria, VA 
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B.  Methodology 
 
The methodology is divided into four phases: 
1.  Feasibility studies in the spheronization and scale-up of ibuprofen microparticulates 
using the fluid-bed rotor-disk technology and also using only Avicel® as spheronization 
enhancer, sodium lauryl sulfate as lubricant and water as binder. 
2.  Optimization of the developed process and product variables using statistically 
designed factorial experiment.  
3. Evaluation of the effects of drug loading, particle size and intermediate size scale-up 
using the fluid-bed rotor-disk technology. 
4.  Coating of spheronized ibuprofen microparticulates and encapsulation of coated and 




Feasibility Studies To Evaluate the Spheronization and Scale-up of Ibuprofen     
Microparticulates 
 
a.  Blending and spheronization 
 
    1. Spheronization of 0.75 kg trial batch 
 Preliminary spheronization was performed in FLM-1 fluid-bed granulator, VPS 
Corporation, Cranbury, NJ (Figure 17) using a teflon plate (9”) and 0.75 kg batch of 
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ibuprofen and Avicel® RC-581 (1:1), with 1% SLS.  Spheroids were successfully made. 
The moisture content of the powder bed was checked at regular intervals using a Mettler 
moisture balance (Mettler Pm100 and LP16, Mettler Toledo Inc., Columbus, OH).  
  
 Figure 17. Components of Vector FL-Multi 1 fluid-bed granulator. (1) Pulse 
valve, (2) Cartridge filters, (3) Sample port, (4) Process air heater, (5) Exhaust blower, (6) 
Air flow station, (7) Inlet air filter, (8) Interchangeable processing inserts, (9) Spray gun,  
(10) Control panel, (11) Solution pump, (12) High Efficiency Particle Arresting  
(HEPA) filters (97). 
 
It was observed that, the amount of water needed to provide appropriate 
consistency was between 50 and 52% of the dry powder blend.  Based on this 
observation, FLM-15 (Figures 4 and 18; 12" plates), together with the conditions stated 
on Table IV were used for initial batches of 1 kg, which were later scaled up to 5 kg and 
10 kg pilot batches using 19" plate. 
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Table IV. Spheronization Conditions and Process Parameters 
 
 Equipment FLM-15 
 Parameters    
Batch size  1 kg 5 kg 10 kg 
Plate size  12” 19” 19” 
Centrifugal force 
(N) 
 41,667 41,667 41,667 
 SS/smooth SS/smooth SS/smooth Plate material  
type/contour 
 Tef./waffle Tef./waffle Tef./waffle 
Spraying     
 Air volume (cfm) A1  
and A2 values 
50 90 140 
 Plate gap (mm) 0.8 3.5 6 
 Spray rate (g/min)  
B1 and B2 values 
50 90 140 
 Rotor speed (rpm) 500 300 200 
 Inlet air temperature (oC) 25-30 25-30 25-30 
 Product temperature (oC) 18-22 18-22 18-22 
 Atomization air pressure 
(psi) 
45  45  45 
Drying     
 Air volume (cfm) 85 145 220 
  Plate gap (mm) 1.3 5.0 8 
 Rotor speed (rpm) 150 124 124 
 
SS/smooth: Stainless steel smooth; Tef./waffle: Teflon waffle 
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 Figure 18. Components of the Vector FLM-15 equipment. (1) Top exhaust vent  
(2) Filter chamber (3) Filter access doors (4) View windows (5) Temperature probe 
(6) Product container (7) Spray gun ports (8) Sample port (9) Inlet air plenum  
(10) product container cart (11) Support frame (12) Inspection light windows (97). 
 
     2. Spheronization of 1 kg batches 
 Several formulation (Table VA) and process (Table VB) variables resulting in the 
development of eleven different batches were used to determine those parameters that 
will yield spheroids with acceptable characteristics. These preliminary parameters are 
shown in Table VI.  
 Ibuprofen (20 µm) and Avicel RC-581 or CL-611 were sieved through a size 16 
(1,180 µm) mesh sieve. Weighed amounts (1:1) of the sieved ibuprofen and Avicel  
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Table VA. Formulation Variables 
 
Variables Batch size 
 1 kg 5 kg 10 kg 
Avicel type RC-581 RC-581 RC-581 
 CL-611   
Binder Water Water Water 
 HPMC   
SLS (1%) Present Present Present 
 Absent   
Talc (3%) Present Absent Absent 
 Absent   
PEG (25%) Present Absent Absent 
 Absent   
 
Table VB. Process Variables 
 
Variables Batch size 
 1 kg 5 kg 10 kg 
Stainless steel/Waffle plate Used Not used Not used 
 Not used   
Stainless steel/Smooth plate Used Used Used 
 Not used   
Teflon/Waffle plate Used Used Used 
 Not used   
500 rpm Used Used Used 
 Not used   
650 rpm Used Not used Not used 
 Not used   
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RC-581 or CL-611 were blended with and without 1% SLS, and spheronized in FLM-15 
using water or HPMC solution as binders. The other formulation and process variables 
are shown in Tables VA and VB. The inlet and exhaust flaps were kept open and a 
frequency drive device was used to adjust the control of the air-flow. Fluidization of 
powder blend was achieved by centrifugal, vertical and gravitational forces, as well as 
heated air drawn through a gap around the rotor-disk and also by the nozzle  
pressure (47,95).  
 The air volume and velocity of air can be adjusted with the gap-adjustment ring 
below the disk.  This aids in air distribution while the rotor-disk is spinning in a 
clockwise direction. The fine powders lifted up by the fluidization air are restricted by 
polyester air filters (in the upper part of the equipment chamber) that are intermittently 
cleaned or cleared by a pulsating jet of air, enabling them to be returned to the batch (98). 
Spheronization end point was visually assessed, based on experience and the fluidization 
pattern that has been observed to correspond to moisture content of 50 - 52%. 
 Drying was performed at gradual inlet temperature increases of 10 °C every 5 min 
up to 60 °C.  This staged drying was done to prevent case hardening of the spheroids. The 
end point for drying was achieved when the product temperature reached 50 °C. The 
moisture content at the end of spheronization and drying periods were measured to 
determine loss on drying (LOD; 139) using the moisture balance at 85 °C and the result 
was recorded when the value became constant. The 85 °C was chosen to achieve optimal 
moisture loss with the product remaining intact.  
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 Table VI. Variables Involved in the Preliminary Trial Batches 
Trials 1 2 3 4 5 6 7 8 9 10 11 


























1 % SLS: surfactant and wetting agent 
Avicel® RC-581: filler, binder 
Plate material type: stainless steel 
Plate contour: waffle 
500/SS: rotational speed/stainless steel 
Water: granulating liquid 
PEG: Polyethylene glycol.
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Consequent to data analyses of the eleven spheronized batches and the resultant 
product characteristics (yield, particle size, size distribution, sphericity, etc.), eight of 
these 1 kg batches were replicated twice and analyzed further (Table VI, trials 1-8).  Two 
of the replicated formulations (trials 4 and 7) were used to make two batches each of 5 
kg, 10 kg pilot scale-up trials (trials 12 - 15).  
 
     3.  Spheronization of Pilot scale batches (5 kg and 10 kg batches) 
 Scale-up was based on geometric similarity using the plate radius (R) and 
centrifugal force (Fc) as similarity factors, as shown in equations 5 and 6 for rotational 
speed (V) and centrifugal force (Fc) respectively. These equations are modifications of 
the Froude’s number equation as reported by Horsthuis, et al. (137).  
5 Eqn.                              *
W
RFcV =  
6 Eqn.                       
2*
R
VWFc =  
Using known values of weight (1 kg), rotational speed (500 rpm) and plate radius 
(6"), the centrifugal force was calculated to be 41,667 Newtons.  Using this value, the 
rotational (rotor) speeds during spheronization phase for 5 kg and 10 kg batches were 
calculated from equation 6 to be 300 and 200 rpm respectively (Table IV).  The Froude’s 
numbers for 1 kg, 5 kg and 10 kg batches were of 72.00, 41.04 and 18.24 respectively. 
 For drying of the scale-up batches, a reduced rotor speed was used.  The two plate 
types and contours used for these two batches are shown in Figure 19. The principle of 
geometric similarity was also applied to other process variables using the results of the  
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1 kg batches as well, and also using the air volume indicator present on the equipment 
(101). The air volume that gave the desirable fluidization for the scale-up batches was 
obtained visually by tuning the frequency drive of the exhaust blower in order to balance 
the air volume and velocity.  This correlated with an increased air volume of 10 cfm for 
each additional kilogram powder (Table IV).  The spray rate multiplier for the scale-up 
batches was determined as the ratio of the two air volumes needed for fluidization of both 







       
Figure 19. Rotor-disk plates for fluid-bed machines, stainless steel/smooth (A); 
teflon/waffle (B) (97). 
B 
A 







b. Physical Characteristics of Developed Microparticulates 
 Acceptance criteria were set for the physical qualities of the spheroids based on 
literature (6,9) and FDA guidance for immediate release dosage forms (147). These 
included high product yield: ≥ 85%, adequate sphericity: ≥ 0.85, high drug content:  
≥ 90%, good dissolution profile: Q20 ≥ 80JRRGIORZDELOLW\ ≤ 30o, granule size 
distribution in the range between 250 and 850 µm [(20/60 mesh) chosen as our usable 
fraction]: ≥ 85 % of the total product.  This tight fraction was chosen to achieve 
homogenous surface area, in order to account better for any differences in drug 
dissolution profiles. 
 
    1. Yield of microparticulates 
 The yield of the granules was taken as a percentage of the ratio of the total output 
obtained from batch processing and the initial weight of the powder blend (1 kg).  
 
    2. Particle size distribution 
 The particle size of ibuprofen was determined using an image analyzer 
(Quantimet 500, Leica, USA) interfaced with a microscope (Reichert, Bordersen 
Instrument Co., Inc., Valenca). This is based on transfer of a two-dimensional image of 
the representative pellet sample to a video screen and computation of the area and 
equivalent circle diameter (µm) of the individual particles (78). The ibuprofen powder 
was dispersed in water by gentle vortexing for adequate dispersion and accurate analysis. 
The computed equivalent circle diameter represents the particle size of the mounted 
sample. An average of 30 particles was taken. 
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 Microparticulate size distribution was determined using conventional sieve 
analysis performed once per replicate batches of each formulation.  Spheroids weighing 
100 g were placed on the uppermost of nested sieve with mesh sizes 16, 20, 40, 60, 80, 
and corresponding to mean pore sizes of 1,180, 850, 425, 250, 180 µm, respectively.  The 
sieve-nest was vibrated in a shaker for 5 min and the weight of each sieve was measured 
before and after, to calculate the weight of granules retained on each sieve. The frequency 
is the percentage of granules obtained in the different sieves to the total weight (100 g) of 
the particles used for the analysis. Using the frequency data, the log-normal distribution 
on a probability scale was plotted and the geometric mean diameter dg, and the geometric 
standard deviation δg were calculated.  The results reported are the means of two replicate 
batches and their corresponding geometric standard deviations (Tables XXA and B).   
 The usable fraction (UF) is the percentage of the total fraction of spheroids 
obtained from the 20 - 60 (granules with size ranges between 250 and 850 µm) mesh 
sizes and the initial weight used for particle size analysis (100 g). 
 
    3. Density of the granules  
 7UXHGHQVLW\ ZDVGHWHUPLQHGIURPWKHVDPSOHPDVVDQGYROXPHXVLQJD
Quantachrome multipychnometer® (Vincentown, NJ).  The system and samples of known 
weight were purged of contaminated gas, moisture and vapor for a minimum of 20 min by 
placing the latter in the instrument using helium gas.  Sample volume (Vs) was calculated 
from cell and reference volumes (Vc and Vr respectively) obtained by calibration of a 




where P1 and P2 are the pressures obtained from the reference and cell volumes 
respectively. 
 
    4. Drug content and HPLC assays 
 i. Sample preparation 
 Standards were prepared in triplicates using a concentration range between 2.5 
and 300 µg/ml of methanol.  The determination of ibuprofen in the granules was 
conducted by extracting the drug twice from known sample weight of the product using  
3 ml methanol.  
 
 ii. HPLC assay 
 Fifty microlitre of standards was directly injected into the HPLC (Shimadzu 
Scientific Instruments, Inc., Columbia, MD), consisting of C18 reverse phase column (100 
x 4.6 mm, 5 µm, Phenomenex, MD).  The HPLC method (238) is a modification of Tsao 
and Savage (239), in which the mobile phase consisted of acetonitrile:water:glacial acetic 
acid:triethylamine (600:400:1:0.2).  The mobile phase was vacuum filtered and degassed 
simultaneously using a Branson 3200 ultrasonicator (Branson cleaning equipment, CT).  
Ibuprofen was monitored by UV detector at 265 nm wavelength, and the results were 
reported as the means of data from nine replicates of standards analyzed on three different 
days.  A calibration curve was set up and the method was validated for both accuracy and 








inter-day reproducibility, namely, coefficient of variation, using Equations 17 and 18. The 
regression equation was linear with a correlation coefficient (R2) of 0.9996. 
 
 The samples were also analyzed as stated for the standards, however, known 
concentrations of ibuprofen standard were injected separately and analyzed 
simultaneously with them.  The results were reported as the means of data from six 
replicates obtained from two different batches. 
 
    5. Dissolution 
 The dissolution of the produced microparticulates was carried out using the USP 
apparatus I at a rotation speed of 100 rpm.  Known amount of sample was weighed into 
3x2-cm diameter stainless steel minibaskets with 40-mesh screens that held each sample 
in the six flasks.  Simulated intestinal fluid (USP) containing 0.02% Tween 80 (enzyme 
grade) at pH 7.4 ± 0.05 was used as the dissolution medium with a temperature of 37 ± 
0.1 °C.  One milliliter sample was collected at specific intervals and filtered immediately 
using a 5 micron hydrophilic nylon filter membrane (B. Braun Medical Inc., PA, USA).  
The removed volume was not replaced in the dissolution vessel, but was factored into the 
calculation during the data analysis. Fifty microlitres of the samples and known standard 
concentrations were analyzed by HPLC with ibuprofen concentration monitored by UV 
17 Eqn.                          100  x 
ionconcentrat Expected
ionconcentrat Measured
    Accuracy  % =
18  Eqn.               100 x 
ionconcentratMean 
deviation  Standard
    (CV)  variationoft coefficienInterday  % =
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detector at 265 nm, as already stated.  The results were reported as the means of data of   
9 - 12 dissolution vessels from replicate batches. 
 
    6. Flowability 
 7KHDQJOHRIUHSRVH DQG&DUU
VFRPSUHVVLELOLW\LQGH[40) were used to 
GHWHUPLQHWKHIORZDELOLW\RIWKHVSKHURLGV9DOXHVRI OHVVWKDQo as well as values of 
Carr’s index below 15% were considered good product flowability. 
 
 i.  Angle of repose 
 Weighed amount of granules was gently poured into an 8 oz funnel that was 
mounted on a stand and with the orifice covered.  The covered end was gently opened so 
that the granules flowed freely on a dark surface.  The diameter and height of the granules 
were measured and the angle of repose calculated using the following Equation: 
 
where H and R are the height and radius respectively formed by the granules.  The results 
reported are the means of six replicates of two batches. 
 
 ii. Carr’s index determination 
The bulk and tap densities of the pellets were determined with Vanderkamp Tap 
density tester (Van-Kel Industries Inc., NJ). The Carr’ s compressibility index was 
calculated using the following Equation: 
 
19 Eqn.                    tan)( 1−= RHθ
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where C is the compressibility index while DT and DB are tap and bulk densities 
respectively.   
 
    7. Granule friability test 
 The friability tester of tablets was used to test the resistance of the pellets to 
abrasion.  Size fraction of 250-850 µm placed in the Roche friabilator was subjected to a 
falling shock for 15 min at 30 rpm, sieved for 10 min and the weight loss was recorded. 
 
    8. Sphericity and roundness of granules 
 Sphericity and roundness were determined using a Quantimet image analyzer 500 
interfaced with a microscope in which the roundness, perimeter (Pm) and the particle 
projected area (A) were measured (78).  These were used to calculate sphericity (S), a 
reciprocal of the roundness factor, as shown in the equation 21 below (241):  
 
A perfectly spherical particle will have a value of 1.0 while non-spherical particle will 




21 Eqn.                          142.34 2Pm
AS ∗=






    9. Scanning electron microscopy (SEM) 
 The samples were placed on a sample stub containing double-sided transparent 
adhesive tapes. They were then coated under reduced pressure (~0.8 mbar) with gold for 
2 min using a Cressington Sputter Coater 108 (Franklin Electric, Bluffton, IN) and 
observed under a scanning electron microscope (Hitachi S510, Tokyo, Japan) at 10 kV. 
 
c. Statistical analysis 
 The influence of the independent variables on the pellet characteristics was 
analyzed by standard deviation and relative standard deviation, while the yield variable 
was also analyzed by one-way ANOVA and student’s t-test techniques using the JMP IN 
version 3.2 statistical software. 
 
Phase 2 
Optimization of the Developed Process and Product Variables Using Statistically 
Designed Factorial Experiment. 
 
a.  Experimental Design 
 The results of the feasibility studies showed that two formulation (binder and 
surfactant levels) and one process (plate type-contour) variables were critical to the 
quality of the spheroids prepared in the rotor-disk fluid-bed equipment (47). Based on 
these results, a 2x2x3 full factorial design was generated using a JMP IN based software 
and consisting of two binder levels (X1), two surfactant levels (X2), and a three level 
plate type (X3) in which two-two level factors were collapsed into a single three level 
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factor.  An additional blocking effect was studied in which every experiment in each 
block was randomly replicated, to access the effect of batch replication on the chosen 
product qualities and on the main factors.  This increased the statistical power of our 
design in that the experimental runs were increased from twelve to 24 and the 
randomization ensured that each of the experiments had one over twelve (within each 
block) chances of being run at any given time. This design allows the estimation of 
statistical significance of the effect and interactions of the three product and process 
variables (X1 - X3) on several spheroid qualities in the generated experimental runs.  The 
experimental design matrix is shown in Table VII, and the different levels of the three 
factors shown in Table VIII.  In Table VII, the levels for each of the formulation 
parameters are represented by a (-) sign for the low and a (+) sign for the high levels.   
 In the matrix of the factorial design shown in Table VII, each line identifies the 
experimental condition for each batch (X1 - X3), and each experiment gives a result (Y). 
From these, and applying factorial design mathematical model, one obtains a general 
linear analysis (242,243): 
22    Eqn.                 ijkleklcdjlbdiladldjkbcikackcijabjbiaijklY +++++++++++= µ  
where Yijkl is the response variable, µ is the mean value, ai, bj, ck and dl are the main effect 
coefficients (binder level, surfactant level, plate type and block respectively), while abij, 
acik, bcjk, adil, bdjl, and cdkl are the second level coefficient of interactions, and eijkl the 
error value.  
 Previous studies have shown that higher order interactions are generally not likely 
to exist, and also are uninterpretable even when they are significant (112,244).  
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Table VII: Experimental Design Matrix for Optimization Studies 
 
X1: Binder level; High (1), Low (-1) 
X2: Surfactant level; High (1), Low (-1)  
X3: Plate type; Stainless steel waffle (-1), Stainless steel smooth (0), Teflon waffle (1) 
 
 Consequently, interactions of three or more factors were confounded with       
two-factor interactions and were assumed to be insignificant for the purposes of this 
design.  Moreover, because blocking (dl) had no statistically significant effect on eleven 
out of the twelve response variables (Y), and consequently yielded statistically 
insignificant interactions with the main effects [(ai, bj, ck) results not shown] their  
                 B l o c k  1     
X 1 X 2 X 3
- 1 1 - 1
- 1 - 1 0
1 1 0
1 - 1 1
- 1 1 0
1 1 - 1
- 1 - 1 1
1 - 1 - 1
- 1 1 1
1 1 1
1 - 1 0
- 1 - 1 - 1
                 B l o c k  2     
X 1 X 2 X 3
- 1 - 1 0
- 1 1 - 1
1 1 - 1
- 1 - 1 1
1 - 1 0
1 - 1 1
- 1 1 0
- 1 1 1
- 1 - 1 - 1




Table VIII: Experimental Design for Optimization Studies 
Runs Batch name* Binder level Surfactant level Plate type 
1 Formulation 1a 1200 20 SS-Waf 
2 Formulation 2a 1200 10 SS-Sm 
3 Formulation 3a 1350 20 SS-Sm 
4 Formulation 4a 1350 10 Tef-Waf 
5 Formulation 5a 1200 20 SS-Sm 
6 Formulation 6a 1350 20 SS-Waf 
7 Formulation 7a 1200 10 Tef-Waf 
8 Formulation 8a 1350 10 SS-Waf 
9 Formulation 9a 1200 20 Tef-Waf 
10 Formulation 10a 1350 20 Tef-Waf 
11 Formulation 11a 1350 10 SS-Sm 
12 Formulation 12a 1200 10 SS-Waf 
13 Formulation 2b 1200 10 SS-Sm 
14 Formulation 1b 1200 20 SS-Waf 
15 Formulation 6b 1350 20 SS-Waf 
16 Formulation 7b 1200 10 Tef-Waf 
17 Formulation 11b 1350 10 SS-Sm 
18 Formulation 4b 1350 10 Tef-Waf 
19 Formulation 5b 1200 20 SS-Sm 
20 Formulation 9b 1200 20 Tef-Waf 
21 Formulation 12b 1200 10 SS-Waf 
22 Formulation 8b 1350 10 SS-Waf 
23 Formulation 3b 1350 20 SS-Sm 
24 Formulation 10b 1350 20 Tef-Waf 
*: The "a" and corresponding "b" of each number are random replicates of the same 
formulation and give the mean of the dependent variables presented in Table XX below.  
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interaction factors (adil, bdjl, and cdkl) were eliminated while their degrees of freedom 
were added to that of the error factor, thereby increasing the statistical power of the 
design. The new linear equation is represented in Equation 23: 
 
b. Blending and spheronization 
 This was performed as already described above (pp 88 - 92) and also in our 
published report (47), except that both 1 and 2% SLS were used, and spheronization was 
performed using fixed amount (120 or 135% of the starting material) of water as binder 
solution (Table VIII).  Drying was performed till 50 °C product temperature was reached 
and moisture content was used as a measure for loss on drying (LOD).  The granulation 
end-point was obtained at the set binder content values (Table VIII). 
 
c. Physical characterization of spheroids   
 These were performed as already described in the feasibility studies.  The yield of 
the granules was taken as a percentage of the ratio of the final weight obtained after the 
production processes and the initial weight of the powder blend.  Microparticulate size 
distribution was determined using conventional sieve analysis and the geometric mean 
diameter and geometric standard deviations calculated.  Usable products were considered 
as granules with size ranges between 250 and 850 µm (20/60 mesh size), and were used 
in the different analyses to obtain the response variables (Y).  The drug content and the 
dissolution assays were analyzed using the HPLC reversed phase column and ibuprofen 
was monitored by UV detector at 265 nm wavelength. However, the samples were 
23 Eqn.                      ijkleldjkbcikackcijabjbiaijklY ++++++++= µ
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filtered using 0.45 micron hydrophilic wolven nylon filter membrane (B. Braun Medical 
Inc., PA, USA).  The sphericity and roundness of the spheroids were determined using an 
image analyzer (Quantimet 500, Leica, USA) interfaced with a microscope (Reichert, 
Bordersen Instrument Co., Inc., Valenca). Spheroid friability, flowability, Carr’s index, 
tap and bulk densities were performed exactly as described earlier.  
 
     Scanning electron microscopy (SEM) 
 The samples were placed on a sample stub with double-sided carbon tapes, 
evacuated, back-filled with argon under reduced pressure (0.1 torr).  They were then 
coated with palladium using a Hummer Sputtering System LO.2, (ANATECH Ltd., 
Alexandria, VA), and observed under a scanning electron microscope (Philips XL 30 
FEG CDUTM LEAPTM, Holland, Nederlands) at 1 kV. 
 
d. Statistical analysis 
The influence of the independent variables on the characteristics of microparticulates was 
analyzed by the ANOVA method using the JMP software. Pareto charts were used to 
show the scaled estimates of the effects of the studied product and process variables on 
the physical characteristics of spheroids (245). The effect of a factor or an interaction is 







Drug Loading, Particle Size Effects. Scale-up to Intermediate Scale Using the 
Fluid-bed Rotor-disk Technology 
  
 The results from the optimization studies indicated that higher binder content 
caused higher yield of the spheroids while stainless steel smooth plate gave more 
consistent product quality especially with respect to yield, drug content, sphericity and 
usable fraction.  Additionally, higher binder content in combination with the lower 
surfactant level yielded more acceptable spheroid characteristics as specified in the set 
acceptance criteria (page 94).  The formulation consisting of high binder level, low 
surfactant level (1%), and made with stainless steel smooth plate was therefore chosen for 
the studies in this section. 
 
a. Effects of drug particle size and drug loading on the characteristics of ibuprofen 
microparticulates 
 
    1. Experimental design 
 Drug particle size and drug load have been shown as among the limitations of the 
rotor-disk fluid-bed technology (15,154).  In order to investigate these observations, a 2x3 
full factorial design was generated using a JMP IN based software and consisting of two 
drug particle sizes (X1) and three drug loads (X2).  The experimental runs were replicated 
to access the effect of batch replication on the chosen product qualities and on the main 
factors. The replication also increased the statistical power of our design by increasing the 
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experimental runs from six to twelve. Additionally, this design allows the estimation of 
statistical significance of the effect and interactions of the two product variables (X1 and 
X2) on several spheroid qualities in the generated experimental runs.  The experimental 
design matrix is shown in Table IX, and the different levels of the two factors shown in 
Table X. In Table IX, the levels for each of the formulation parameters are represented by 
a (-) sign for the low, and a (+) sign for the high levels.   
 
Table IX: Experimental Design Matrix for Drug Particle Size and Drug Load 
Effects on Spheroid Characteristics 
Number of runs Replication X1 X2 
1 -1 -1 -1 
2 1 -1 -1 
3 -1 -1 0 
4 1 -1 0 
5 -1 -1 1 
6 1 -1 1 
7 -1 1 -1 
8 1 1 -1 
9 -1 1 0 
10 1 1 0 
11 -1 1 1 
12 1 1 1 
 
X1: Drug particle size (µm); 20 (-1), 40 (1) 
X2: % drug load; 50 (-1), 65 (0), 80 (1) 
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In the matrix of the factorial plan represented in Table IX, each line identifies the 
experimental condition for each batch of the factors (X1 and X2), and each experiment 
gives a result (Y) that will be applied to a general linear model based on the algorithm of 
Yates, as shown in equation 24: 
24    Eqn.                                   ijkejkbcikackcijabjbiaijkY +++++++= µ  
where Yijk is the response variable, µ is the mean value, ai and bj are the main effect 
coefficients (drug particle size and drug load) respectively, while ck is the replication  
 
Table X: Experimental Design for Drug Particle Size and Drug Load Effects 
on Spheroid Characteristics 
Number of runs Batch name Drug Particle Size (µm) % Drug Load 
1 Ibu 20-50a 20 50 
2 Ibu 20-50b 20 50 
3 Ibu 20-65a 20 65 
4 Ibu 20-65b 20 65 
5 Ibu 20-80a 20 80 
6 Ibu 20-80b 20 80 
7 Ibu 40-50a 40 50 
8 Ibu 40-50b 40 50 
9 Ibu 40-65a 40 65 
10 Ibu 40-65b 40 65 
11 Ibu 40-80a 40 80 
12 Ibu 40-80b 40 80 
*: The "a" and corresponding "b" of each number are replicates of the same formulation 
and give the mean of the dependent variables presented in Table XXV below. 
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effect. The parameters abij, acik, and bcjk are the second level coefficient of interactions, 
and eijk is the error value. 
 As already mentioned, previous studies have shown that higher order interactions 
are generally not likely to exist, and also are uninterpretable even when they are 
significant (93,244). Consequently, interactions of three or more factors were confounded 
with two-factor interactions and were assumed to be insignificant for the purposes of this 
design. Moreover, because replication (ck) had no significant effect on ten out of the 
twelve response variables, and also yielded statistically insignificant interactions with the 
main effects (ai, bj), their interaction factors (acik and bcjk) were eliminated while their 
degrees of freedom were added to that of the error factor, thereby increasing the statistical 
power of the design. The new linear equation is represented in Equation 25: 
25   Eqn.                              ijkekcijabjbiaijkY +++++= µ  
 
    2. Blending and spheronization 
 This was performed as already described in the feasibility studies (pp 88 - 92) and 
also in our published report (47).  Spheronization end point was visually assessed, based 
on experience and the fluidization pattern that gave the most acceptable product qualities. 
This has been observed to correspond to moisture content of 50 - 55% for the 
drug:Avicel® 50:50 ratios, 45 – 48% for the 65:35 ratios, and 37 – 41% for the 80:20% 
ratios, for both drug particle sizes (Table XI).  These amounts of water did not yield much 
oversized spheroids, and were recorded with regard to both the drug particle size and 
thedrug load.  Drying was performed as previously reported, with the end point achieved 
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Table XI. Binder and Time Conditions During Spheronization and Drying Processes 
 
 20 micron ibuprofen 40 micron ibuprofen 
% ibuprofen 50 65 80 50 65 80 
Binder added during 
spheronization (kg) 
1.525 ± 0.04 1.265 ± 0.08 1.085 ± 0.16 1.394 ± 0.02 1.189 ± 0.02 0.910 ± 0.03 
Total time [(spheronization  
and drying) mins] 
67.5 ± 0.95 54.5 ± 2.12 46.5 ± 2.12 75.0 ± 1.14 66.0 ±  2.83 53.1 ± 0.41 
Moisture content at end of 
spheronization 
50.69 ± 0.27 45.21 ± 0.02 37.27 ± 1.05 55.81 ± 0.56 48.45 ± 0.47 41.44 ± 0.07 
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when the product temperature reached 50 °C.  The plate gap was adjusted from 0.8 –    
1.0 cm and the air volume from 85 - 90 cfm, to ensure proper fluidization of the pellets. 
 
     3. Physical characterization of spheroids   
 These were performed as already described in the feasibility studies (pp 94 - 99).  
The yield of the granules was taken as a percentage of the ratio of the final weight 
obtained after the production processes and the initial weight of the powder blend.  The 
moisture content was measured as a function of time for all the batches, and the values at 
the end of spheronization process are shown in Table XI and Figure 36.  Microparticulate 
size distribution was determined using conventional sieve analysis.  Usable products were 
considered as granules with size ranges between 250 and 850 µm (20/60 mesh size), and 
were used in the different analyses to obtain the response variables.  The drug content and 
the dissolution assays were analyzed using the HPLC reversed phase column with 
ibuprofen monitored by UV detector at 265 nm wavelength.  The samples were filtered 
through 0.45 micron hydrophilic wolven nylon filter membrane (B. Braun Medical Inc., 
PA, USA).  The sphericity and roundness of the spheroids were determined using an 
image analyzer (Quantimet 500, Leica, USA) interfaced with a microscope (Reichert, 
Bordersen Instrument Co., Inc., Valenca). Spheroid friability, flowability, Carr's index, 
tapped and bulk densities were performed exactly as already described.  The scanning 
electron microscope analysis for studying the morphology of the spheroids was performed 




    4. Statistical analysis 
The influence of the independent variables on the characteristics of 
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto 
and interaction plots were also used as described earlier (245).  
 
b. Effects of Intermediate Size Scale-up on the Characteristics of Ibuprofen 
Microparticulates 
 Results from the drug load and drug particle size effects showed that the three 
drug loads were spheronizable, however, drug loads of 50% and 65% had similar 
characteristics and significantly affected most of the physical characteristics studied.  As 
was previously observed (157), the 80% drug load was more difficult to spheronize and 
also had high standard deviations between most of the obtained replicate values, and was 
therefore difficult to replicate. Additionally, drug particle size of 20 µm had the most 
significant effects on the spheroid qualities studied.  Therefore, 50% and 65% drug loads 
as well as 20 µm sized ibuprofen were used for further studies. 
 
    1. Experimental design 
 In order to study the scalability of the optimized product and process variables to 
semi-production size, a 2x2 full factorial design was generated using a JMP IN based 
software and consisting of two batch sizes (X1) and two drug loads (X2).  The 
experimental runs were replicated for the reasons already mentioned in the previous 
experiments.  The experimental design matrix is shown in Table XII and the different 
levels of the two factors are shown in Table XIII.  The general linear model and the 
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model deduced to increase the statistical power of the experiments are as shown in 
Equations 26 and 27 respectively.  However, ai and bj are the main effect coefficients 
(batch size and drug load) respectively. 
26    Eqn.                                      ijkejkbcikackcijabjbiaijkY +++++++= µ  
27    Eqn.                                                                   ijkekcijabjbiaijkY +++++= µ  
 
Table XII: Experimental Design Matrix for Intermediate Size Scale-up Effect on the 
Characteristics of Ibuprofen Microparticulates 
 
Number of runs Replication X1 X2 
1 -1 -1 -1 
2 1 -1 -1 
3 -1 -1 1 
4 1 -1 1 
5 -1 1 -1 
6 1 1 -1 
7 -1 1 1 
8 1 1 1 
 
X1: Batch size (kg); 1 (-1), 50 (1) 




Table XIII: Experimental Design for Intermediate Size Scale-up Effect on the 
Characteristics of Ibuprofen Microparticulates 
Number of runs Formulation name Batch Size % Drug Load 
1 1kg-50%-a 1 50 
2 1kg-50%-b 1 50 
3 1kg-65%-a 1 65 
4 1kg-65%-b 1 65 
5 50kg-50%-a 50 50 
6 50kg-50%-b 50 50 
7 50kg-65%-a 50 65 
8 50kg-65%-b 50 65 
 
*: The "a" and corresponding "b" of each number are replicates of the same formulation 
and give the means of the dependent variables presented in Table XXVII below. 
 
2. Blending and spheronization 
This was performed as already described in the feasibility studies (pp 92 and 93) 
and also in our published report (47). The FLM-15 was used for the 1 kg batches, while a 
FLN-120 having the same geometric similarities was used for the 50 kg batches. The  
specifications of both equipment are shown in Figures 18 and 20 respectively. For the 
large-scale equipment and process, the principles of dynamic geometric similarity as well 
as trial and error (137,138) were applied to obtain fluidization air volume that efficiently 
fluidized the powder bed throughout the wetting and drying periods (Equations 4 – 6; 












Figure 20. Components of the Vector FLN-120 fluid-bed machine with the numbers 
corresponding with the same equipment parts as were specified in Figure 18 (97). 
 
scale batches are shown in Table XIV. The range of the rotor speed used during the 
spheronization period corresponded to Froude’s numbers of 6.02 -17.28. Spheronization 
end point was also determined as previously reported, based on experience and acceptable 
fluidization pattern, and the results are shown in Table XV.  Drying was performed as 
previously reported, with the end point achieved when the product temperature  
reached 50 °C.   
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Table XIV: Spheronization Conditions of Scale-up Batches 
               Parameters
Batch size 1 kg 5 kg 10 kg 50 kg
Plate size 12" 19" 19" 39.5"
Centrifugal force (N) 41,667 41,667 41,667 41,667
Plate material type/contour SS/smooth SS/smooth SS/smooth SS/smooth
Teflon/waf. Teflon/waf. Teflon/waf. NA
Spraying
Air volume (cfm) A1 and A2 50 90 140 500-1500
Plate gap (mm) 0.8 3.5 6 NA
Spray rate (g/min) B1 and B2 50 90 140 470 - 500
Rotor speed (rpm) 500 300 200 130 - 135
Inlet air temperature (oC) 25 - 30 25 - 30 25 - 30 25 - 30
Product temperature (oC) 18 - 22 18 - 22 18 - 22 18 - 22
Atomization air pressure (psi) 45 45 45 45
Drying
Air volume (cfm) 85 145 220 1100 - 1300
Plate gap (mm) 1.3 5 8 NA
Rotor speed (rpm) 150 124 124 75
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Table XV. Binder and Time Conditions for Spheronization and Drying Processes of 
Intermediate Size Scale-up Ibuprofen Microparticulates 
 
3. Physical characterization of spheroids   
 These were performed as already described in the feasibility studies (pp 94 - 99). 
The yield of the granules was taken as a percentage of the ratio of the final weight 
obtained after the production processes and the initial weight of the powder blend. 
Microparticulate size distribution was determined using conventional sieve analysis.  
Usable products were considered as granules with size ranges between 250 and 850 µm  
(20/60 mesh size), and were used in the different analyses to obtain the response variables 
(Y).  The drug content and the dissolution assays were analyzed using the HPLC reversed 
phase column with ibuprofen monitored by UV detector at 265 nm wavelength. The 
samples were filtered using 0.45 micron hydrophilic wolven nylon filter membrane (B. 
Braun Medical Inc., PA, USA).  The sphericity and roundness of the spheroids were 
determined using an image analyzer (Quantimet 500, Leica, USA) interfaced with a 
microscope (Reichert, Bordersen Instrument Co., Inc., Valenca). Spheroid friability, 
Batch sizes 1 kg 50 kg 
% ibuprofen 50 65 50 65 
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flowability, Carr’s index, tapped and bulk densities were performed exactly as already 
described.  The scanning electron microscope analysis for studying the morphology of the 
spheroids was also performed exactly as described in phase 2 (page 105).
 
     4. Statistical analysis 
The influence of the independent variables on the characteristics of 
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto 




Coating and Encapsulation of Spheronized Ibuprofen Microparticulates Using 
Hard Gelatin Capsules 
 
 The results of the scale-up experiments showed that replication did not affect the 
physical characteristics of both spheroid batch sizes and that both the drug loads used and 
the rotor-disk spheronization process are scalable. Therefore, 1 kg batch size with 65% 
drug load (Table XIII, Runs #7 and 8) were pulled and used to study the effect of polymer 
film coating and hard gelatin encapsulation on the qualities of the spheroids. 
 
a. Polymer Film Coating of Spheroids 
     1. Preliminary studies using Glatt fluid-bed 
 To investigate the feasibility of coating the spheroids, the Glatt fluid-bed (Glatt 
WSG-5 Wurster column/Fluid-bed) was first used to coat 6 x 1 kg batches using three 
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coating levels each of Surelease (5, 10 and 15%) and Eudragit (8, 14 and 20%) 
polymers. The fluid-bed conditions used were almost the same for both polymers and are 
as follows: inlet air temperature (26 oC), outlet air temperature (24 - 28 oC), air of 
operation (2 mbar), air of atomization (2 - 4 mbar), flow rate (40 g/min). The batches 
were pre-warmed for 10 min before applying the film coats. Moisture content was 
analyzed before and after the pre-warming, after the polymer application and at the end of 
the process. The products were analyzed for yield, usable fraction and drug release.  
Based on the obtained results (not shown), the coating conditions and the rotor-disk 
conditions from previous studies (47,199), the levels and conditions for our rotor-disk 
fluid-bed coating were selected. These are shown in Tables IX (page 107) and XVI.   
 
     2. Experimental design for rotor-disk fluid-bed coating 
A 2x3 full factorial experimental design was generated using the JMP software, 
consisting of 2 levels of polymer film type (X1) and three coating levels (X2). The 
polymer levels were chosen based on manufacturer’ s technical literature (of the 
polymers).  Consideration of the coating levels that would allow for rotor-disk processing 
in the equipment was also made. The generated design was replicated to study the 
reproducibility of the rotor-disk coating process and also to increase the statistical power 
of the design. The experimental design matrix and the different levels of the two factors 
are shown in Tables IX (where, in this case, X1 is the polymer type and X2 the coating 
level; page 107) and XVI respectively.  A stainless steel plate (12") was used with a batch 
size of 700 g. 
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Table XVI: Experimental Design for the Coating of Spheronized Ibuprofen 
Microparticulates 
 
Number of runs Batch name Polymer type Polymer level (% 
1 SR-7.5a Surelease Low (7.5) 
2 SR-7.5b Surelease® Low (7.5) 
3 SR-10a Surelease® Medium(10) 
4 SR-10b Surelease® Medium(10) 
5 SR-12.5a Surelease® High (12.5) 
6 SR-12.5b Surelease® High (12.5) 
7 EUD-12.5a Eudragit® NE 30D Low (12.5) 
8 EUD-12.5b Eudragit® NE 30D Low (12.5) 
9 EUD-14a Eudragit® NE 30D Medium(14) 
10 EUD-14b Eudragit® NE 30D Medium(14) 
11 EUD-15.5a Eudragit® NE 30D High (15.5) 
12 EUD-15.5b Eudragit® NE 30D High (15.5) 
 
*: The "a" and corresponding "b" of each number are replicates of the same formulation 
and give the mean of the dependent variables presented in Table XXIX below. 
 
     3. Rotor-disk fluid-bed coating 
 i. Coating of spheroids with Surelease polymer 
 The Surelease product containing 25% dry polymer weight was mixed with 
appropriate amount of distilled water to bring it to 15% total solids content (174). The 
spheroids (700 g) were pre-warmed to ~ 30 oC product temperature.  The coating 
conditions and formulations are shown in Tables XVII and XVIII respectively.  The 
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Table XVII. Conditions and Process Parameters Used for the Coating of 700 g Ibuprofen Spheroids 
 
  Surelease Eudragit NE 30D 
 
Coating level (%) 7.5 10 12.5 12.5 14 15.5 
Coating  
          Air volume (cfm) 60 - 85 
 Plate gap (mm) 1.0 – 1.5 
 Rotor speed (rpm) 200 -250 
Inlet air temperature (oC) 40 - 50  
Spray rate (g/min) 5.5 -7.5 5.5 -10.0 5.5 – 10.0 5.5 -7.5 5.5 -10.0 5.5 – 10.0 
Drying        
 Air volume (cfm) 80 - 90 80 - 100 80 - 150 80 - 90 80 - 100 80 - 150 
 Plate gap (mm) 1.5 
 Rotor speed (rpm) 250 
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Table XVIII. Formulation of the Aqueous Dispersions Used for the Coating of 700 g Ibuprofen Spheroids 
 
Polymer type Surelease Eudragit NE 30D 
Coating level (%) 7.5 10 12.5 12.5 14 15.5 
 
      
Formulation       
Surelease polymeric solution (g) 210 280 350 
Surelease polymer (solids; g) 52.5 70 87.5 
Water ad (to dilute to 15% solids; g) 350 466.67 583.33 
 
NA 
    
Eudragit polymeric solution 291.67 326.67 361.67 
Eudragit polymer (solids; g) 87.5 98 108.5 
Talc (20% of dry polymer; g) 17.5 19.6 21.7 




420 470.4 520.8 
   




coating conditions were adjusted to ensure that spraying was performed continuously 
during a greater period of the process. The product temperature was maintained between 
35 and 40 oC. Spraying was intermittently interrupted to ensure proper fluidization of the 
spheroids, avoid agglomeration and minimize attrition problems. The total amount of the 
polymer shown in Table XVIII was used to obtain the theoretical percentage weight gain 
required for each of the batches. 
 
ii. Coating of spheroids with Eudragit NE 30 D polymer 
A known weight of talc (20% w/w of the total dry polymer weight) was dissolved 
in an appropriate amount of distilled water with constant stirring.  The talc solution was 
passed through a 60 mesh sieve (250 µm) to remove any undissolved particles.  Eudragit 
(30% w/w) was diluted in the talc solution to obtain 25% total solid content (Table 
XVIII), which was constantly stirred.  The spheroids (700 g) were pre-warmed to ~ 30 oC 
product temperature in the rotor-disk fluid-bed. The coating conditions are as shown in 
Table XVII, and were adjusted to ensure that spraying was performed continuously during 
a considerable period of the process. The product temperature was maintained at 30 oC. 
Although talc was added in the spraying solution to prevent agglomeration, spraying was 
intermittently interrupted to ensure proper fluidization of the spheroids. The formulation 
contents are as shown in Table XVIII. 
 
     4. Physical characterization of the coated spheroids 
 Particle size analysis was performed by the traditional sieve analysis method and 
the usable fraction was calculated as has been previously described. The geometric mean 
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and standard deviations were also calculated. The yield of the coated products was 
calculated as a percentage of the product output and the total weight of the solid content 
of the starting material [spheroids (700 g), talc, Surelease® and Eudragit®] as applied to 
specific batches (Table XVIII). The true and bulk densities, flowability, friability, 
scanning electron microscope were performed as already explained in the previous 
sections. The compressibility index was also calculated.  However, there was little to no 
volume change after several taps of the spheroids. This conforms with the reports that the 
bulk and not the tapped densities is used as a measure for calculating capsule fill weight 
and size for pellets (227). It also supports the results that compressibility is not required 
for pellet filling, thus the preference for tamp filling machine for these products over the 
dosator machines. Drug content testing was performed as already described and the 
weight of the polymer was accounted for in the calculations. Drug release studies were 
also performed as already reported, however, the time taken for 50% (T50) of the drug to 
be released was used to measure the coating efficiency and duration of release instead of 
the Q20 used for the immediate release preparations (160,248).  
 
 i. Comparison of dissolution profiles 
  Model-independent methods (Equations 13 and 14 previously shown), difference 
and similarity (f1 & f2) factors respectively, were used to compare dissolution profiles for  






























similarity. An f1 value up to 15 (0 – 15) and an f2 value between 50 and 100 showed that 
the two dissolution profiles were similar. 
 
ii. Mathematical modeling of drug release  
 The drug release data from uncoated and coated pellets were analyzed with 
square-root of time equation (Higuchi equation, Equation 7), Peppas equation (Equation 
9), zero-order kinetic (Equation 12), and first-order kinetic (Equation 28). The data were 
also fitted to a recently developed combined mechanistic release kinetics (zero-order and 
square root of time Equation 15; 177).  It was assumed that that release occurred as soon 
as the matrix is placed in contact with fluid and thus predicts an intercept at the origin. 
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    5. Statistical analysis 
 The influence of the independent variables on the characteristics of 
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto 
and interaction plots were also used as described earlier (245). 
 
 
b. Hard Gelatin Encapsulation of Spheroids 
     1. Experimental design 
 From our statistical analyses and the physical characteristics (bulk density, 
friability, flow properties and T50) of the coated spheroids, the two replicate batches 
coated with 12.5% Surelease® level were pulled for hard gelatin encapsulation. A 2x2x3 
full factorial experiment was designed consisting of two spheroid preparations, uncoated 
and coated (X1), and using two machine variables, (namely, two levels of machine 
operational speeds (X2) each operated at three different shuttle speeds (X3).  Size 0 hard 
gelatin capsules were used. A cross section of the pellet feeder assembly of the Index 
K150i series (Figure 15) used for the pellet encapsulation is shown in Figure 21A, while 
Table XIX shows the experimental matrix /design. 
The shuttle gate controls the length of time the male and female gates could 
remain open (Figures 21A & B).  These gates regulate the amount of pellets that could be 
filled into pellet feeder, which feeds the empty capsules.  It is therefore expected that the 
capsules filled at longer shuttle speed will contain higher amount of pellets since the gates 
will be left open long enough for enough pellets to be collected into the feeder.      
 In the matrix of the factorial plan represented in Table XIX, each line identifies 
the experimental condition for each batch of the factors (X1 – X3), and each experiment 
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gives a result (Y) that will be applied to a general linear model based on the algorithm of 
Yates, as shown in equation 29: 
29    Eqn.                                   ijkejkbcikackcijabjbiaijkY +++++++= µ  
where Yijk is the response variable, µ is the mean value, while ai, bj and ck are the main 
effect coefficients, type of formulation, operational speed and shuttle speed respectively.   
 
Figure 21. Cross-section of pellet feeder assembly (A) 




Table XIX Experimental Design Matrix for Encapsulation of Coated and 
Uncoated Ibuprofen Microparticulates 
Number of runs X1 X2 X3 
1 1 1 1 
2 1 1 0 
3 1 1 -1 
4 1 -1 1 
5 1 -1 0 
6 1 -1 -1 
7 -1 1 1 
8 -1 1 0 
9 -1 1 -1 
10 -1 -1 1 
11 -1 -1 0 
12 -1 -1 -1 
 
X1: Type of formulation; coated or uncoated; X2: Operational speeds; 1, 2;   
X3: Shuttle speeds; 1 – 3 
 
The parameters abij, acik, and bcjk are the second level coefficient of interactions, 
and eijk is the error value.  The experiments were not replicated due to limitations of 
materials. Consequently, the interaction factors were eliminated from the analyses to  
increase the statistical power of the error. The equation involving only the main effects 
therefore becomes:  
30    Eqn.                                       ijkekcjbiaijkY ++++= µ  
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     2. Pellet encapsulation 
 The theoretical pellet fill weight was calculated based on the drug content and 
release, and also in Equation 31. 
 
The “0”  or “00”  capsule sizes will be required to fill 430 or 600 mg respectively of our 
coated pellets that will contain 300 - 400 mg ibuprofen drug/capsule.  As stated on page 
51, the equivalent total daily dose should generally be the same in switching a patient 
from immediate release to prolonged release product, although in most cases, an effective 
response has been achieved with a lower dose of the sustained release product (168). By 
filling 300 - 400 mg/capsule, it would be easy to study the efficacy of the drug at different 
doses.  However, the available encapsulation machine did not have the capabilities 
required for filling size 00 capsules. Consequently, the highest amount of the pellets that 
could fill the “0”  capsule size was used as our target weight. This enabled extrapolation 
of results obtained to calculate the amount of pellets required to fill the “00”  capsule size, 
using the information provided in Figure 14. 
 The pellets were filled into size 0 hard gelatin capsules on a Romaco K-series 
(Figure 15) automatic tamp filling (gravity filled) machine with a 15 mm dosing disk. The 
operational speeds used were 75 and 85 rpm and the shuttle speeds were 260, 280 and 
300 milliseconds. These variables were chosen based on the flowability of the pellets, as 
well as conditions that will prevent pellet losses, considering the small batch size of the 
31   Eqn.                             
Volume
Weight
  ensity  =D
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coated pellets (~ 1 kg). Approximately 200 capsules were collected from each run and 
were stored in tight polyethylene bags for further studies. 
 
      3. Physical characterization 
 The determination of the geometric mean diameter, friability, flowability, bulk 
and true densities of the pellets have been previously reported (pp 123 and 124).  
 
i. Fill weight and coefficient of fill variation 
 The capsule fill weight and the coefficient of fill variation (CV) of 20 individual 
capsules were determined. Filled capsules were weighed on Denver Instruments balance 
and a set of 20 readings was used for calculating the average, standard deviation and 
percentage of fill weight variation (%CV). The average weight of 20 empty gelatin 
capsules was used as the blank weight.  
 
 ii. Dissolution test 
 Based on the results of the average fill weight, SD and %CV, the dissolution 
studies of the formulations encapsulated at 75 rpm and 280, 300 msecs were performed 
accordingly.  Six randomly selected capsules were used to investigate the ability of the 
capsule contents to be released. The drug release profiles were compared using difference 
and similarity factors.  The data were also fitted to Higuchi, Peppas, zero-order, first-
order, as well as the combined kinetics equations, as already described, in order to 
determine the mechanisms of drug release from the formulations. 
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     4. Statistical analysis 
 The mathematical and statistical analyses were performed with Microsoft Excel 
and JMP software packages, as already described. Studentized residuals test statistic was 
used to check for patterns and outliers while Dubin-Watson test statistic was used to test 
for possible correlations between the pairs of observations. The statistical significance 
was set at p < 0.05. 
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III. RESULTS AND DISCUSSIONS 
 
Phase 1 
Feasibility Studies in the Spheronization and Scale-up of Ibuprofen 
Microparticulates 
 
a. Drying time 
 The time it took for the product made with similar plates to reach 50oC increased 
as percentage yield and batch size increased. For the batches made with stainless steel 
smooth plates, the times were 29 – 40 minutes for the 1 kg batches and 36 – 79 minutes 
for the scale-up batches.  For teflon waffle plate batches, the drying times were 47 – 64 
minutes for the 1 kg batches and 47 – 90 minutes for the scale-up batches.  Not only are 
these results in agreement with previous reports that drying efficiency decreases with 
increased batch size (142,251), but, as mentioned earlier, the data also confirm that the 
heat conductivity of the stainless steel disk added to the overall drying efficiency of the 
process (125) while teflon had insulating effect (47).  Moreover, it has been shown that at 
any given time, the moisture content of the granules depends on wettability and 
evaporation, which in turn are controlled by liquid flow rate and inlet temperatures 
respectively (252).  Equilibrium liquid flow rate has been defined as one at which liquid 
supply is balanced by evaporation, and a critical liquid flow rate as one above which 
fluidization is impossible due to cohesion in the bed (253).  Though the liquid flow rate is 
the same in both plate types used, the insulating nature of the teflon material could hinder 
the attainment of equilibrium during processing, thereby affecting the balance between 
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liquid supply and evaporation, which in turn might have adversely affected the drying 
efficiency of these batches. 
 
b. Physical Characteristics of Developed Microparticulates 
The following physical characteristics apply to all the batch sizes, i.e., 1 kg, 5 kg 
and 10 kg, unless stated otherwise. 
 
     1. Yield of spheroids 
 i. Yield of one kilogram batches 
 The replicated eight 1 kg batches produced using FLM-1 had yield values ranging 
from 58.0% - 91.2%, however, most of the batches yielded granules varying from 74% - 
85% (Table XXA).  This could be considered satisfactory since even with starting 
materials that are “ ideal”  in formulating spheres e.g. 100% Avicel®, the process output 
was approximately 80% (249).  As already stated, the spheroid batches having 50 - 52% 
binder content at the end of the spheronization process had better product characteristics. 
Trials 4 and 7 had desirable qualities that met our set acceptance criteria (, and 
were selected for further studies.
 
 Effect of SLS and Talc: The batches spheronized without SLS (trial 2) as 
well as that containing SLS and talc (results not shown) had lower yield. The lower yield 
from trial 2 could be due to the lack of SLS that affected wetting of the powders thereby 
enhancing losses to the fluid-bed walls and filters.  The low yield obtained form the batch 
containing SLS and talc could be caused by a possible interaction between the SLS and 
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Table XXA. Physical Characteristics of 1 kg Batches (Means of replicated batches) 
Trials 
1 2 3 4 5 6 7 8 
Parameters 




Smooth disk 650/SS HPMC 500/tef 650/tef 
% Yield 73.75 ± 2.33  58.0 ± 4.24 71.45 ± 3.89 85.40 ± 6.65 70.10 ± 2.55 80.0 ± 10.32 91.2 ± 32.24 79.05 ± 1.34 
% Moisture content 1.75 ± 0.35 6.56 ± 2.34 1.66 ± 0.91 2.71 ± 1.70 2.96 ± 2.20 2.1 ± 0.43 6.85 ± 2.34 8.1 ± 4.10 
% Drug content 93.46 ± 1.17 73.77 ± 3.32 91.69 ± 2.09 94.47 ± 0.65 94.30 ± 3.88 94.3 ± 8.48 91.44 ±1.64 99.95 ± 4.08 
Geometric mean 
diameter (µm) 
438 ± 1.57 577 ± 1.43 445 ± 1.59 455 ± 1.57 363 ± 1.95 403 ± 1.63 417 ± 1.80 415 ± 1.78 
Sphericity 0.90 ± 0.00 0.92 ± 0.01 0.89 ± 0.01 0.88 ± 0.09 0.87 ± 0.04 0.84 ± 0.01 0.91 ± 0.00 0.90 ± 0.01 
Flowability (deg) 21.45 ± 1.05 23.07 ± 0.14 22.09 ± 1.88 23.36 ± 0.75 25.31 ± 1.06 24.84 ± 0.00 22.49 ± 0.83 24.37 ± 0.40 
Carr’ s index (%) 8.56 ± 0.76 6.61 ± 0.40 9.85 ± 0.21 8.92 ± 3.97 9.34 ± 0.05 11.82 ± 1.19 8.92 ± 0.53 10.14 ± 0.25 
True density (g/cm3) 1.29 ± 0.00 1.30 ± 0.00 1.29 ± 0.00 1.30 ± 0.00 1.29 ± 0.01 1.28 ± 0.01 1.31 ± 0.01 1.28 ± 0.00 
Bulk density (g/cm3) 0.67 ± 0.00 0.77 ± 0.02 0.69 ± 0.02 0.64 ± 0.08 0.67 ± 0.05 0.58 ± 0.01 0.66 ± 0.01 0.67 ± 0.00 
Tap density (g/cm3) 0.73 ± 0.00 0.82 ± 0.01 0.76 ± 0.02 0.69 ± 0.06 0.74 ± 0.05 0.65 ± 0.00 0.73 ± 0.02 0.75 ± 0.00 
Q20 (%) 86.74 ± 2.39 74.66 ± 2.92 87.47 ± 4.12 83.27 ± 5.02 90.42 ± 7.64 75.14 ± 1.85 91.75 ± 2.07 85.09 ± 1.71 
Friability (%) 0.34 ± 0.47 0.67 ± 0.48 0.17 ± 0.24 1.5 ± 1.66 1.67 ± 1.41 1.17 ± 0.71 0.33 ± 0.71 1.84 ± 0.71 
LOD: % loss on drying. 
Highlighted batches were used for further studies 
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Table XXB. Physical Characteristics of Scale-up Batches (Means of replicated batches) 
 
 
Plate material/contour Stainless steel/smooth plate Teflon/Waffle plate 
Batch size 1 kg 5 kg 10 kg 1 kg 5 kg 10 kg 
Trials 4 12 13 7 14 15 
Plate size 12”  19”  19”  12”  19”  19”  
% Yield 85.40 ± 6.65 87.16 ± 7.13 83.97 ± 2.33 91.2 ± 32.24 96.35 ± 5.5 87.84 ± 11.7 
% LOD 2.71 ± 1.70 1.85 ± 0.35 2.46  ± 0.64 6.85 ± 2.34 11.21 ± 7.62 10.65 ± 11.10 
% Drug content 94.47 ± 0.65 99.2 ± 4.90 90.52 ± 4.71 91.44 ±1.64 98.23 ± 1.89 98.65 ± 4.37 
Geometric mean diameter  (µm) 455 ± 1.57 483 ± 1.61 545 ± 1.67 417 ± 1.80 553 ± 1.54 603 ± 1.79 
Sphericity 0.88 ± 0.09 0.90 ± 0.01 0.90 ± 0.01 0.91 ± 0.00 0.89 ± 0.01 0.88 ± 0.02 
Flowability (deg) 23.36 ± 0.75 19.54 ± 1.08 24.11 ± 5.39 22.49 ± 0.83 19.29 ± 0.73 25.17 ± 7.59 
Carr's index. (%) 8.92 ± 3.97 6.71 ± 1.23 6.21 ± 4.3 8.92 ± 0.53 5.33 ± 0.19 7.84 ± 2.75 
True density (g/cm3) 1.30 ± 0.00 1.28 ± 0.01 1.28 ± 0.02 1.31 ± 0.01 1.28 ± 0.01 1.27 ± 0.01 
Bulk density (g/cm3) 0.64 ± 0.08 0.65 ± 0.03 0.64 ± 0.04 0.66 ± 0.01 0.67 ± 0.01 0.63 ± 0.00 
Tap density (g/cm3) 0.69 ± 0.06 0.70 ± 0.03 0.68 ± 0.00 0.73 ± 0.02 0.71 ± 0.04 0.69 ± 0.00 
Q20 (%) 83.27 ± 5.02 82.95 ± 12.66 85.53 ± 5.08 91.75 ± 2.10 79.47 ± 12.88 86.76 ± 13.00 
Friability (%) 1.50 ± 1.66 1.50 ± 1.65 1.50 ± 1.17 0.33 ± 0.71 1.00 ± 0.00 4.00 ± 4.71 
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talc, that also led to delayed wetting of the granules during processing, and consequently 
resulted in the powder blend losses.  
 
 Binder effect: Use of HPMC as binder improved the yield compared to the 
standard formulation (Table XXA, trial 6 vs.1), although it had higher standard deviation. 
 
 Rotor speed effect: Lower disk speed (500 rpm) produced higher yields than 
higher disk speed (650 rpm, Table XXA, trials 1 and 7 vs. 5 and 8 respectively).  This 
could be due to reduced centrifugal forces that minimized the collision of the spheres 
with the walls of the rotor container as well as losses into the cartridges.  This resulted in 
more efficiently fluidization of the spheroids, as has been reported with the traditional 
extrusion/spheronization method (250).   
 
 Rotor-disk plate material effect: Higher yield was obtained from the teflon 
waffle plate batches in comparison to those made with stainless steel waffle plate (trials 7 
and 8 vs. 1 and 5 respectively).  The yield was measured immediately after the process, 
thus, any free or residual moisture that was not dried by the drying process formed part of 
the product yield.  As can be seen from Table XXA, the moisture content for the 
formulations produced with the teflon plate ranged between 6.85 to 8.10% as compared 
to 1.75 to 2.96% of the stainless steel plate batches.  The higher moisture content for the 
teflon plate could have contributed to increase in the yield value.  The teflon disk tends to 
insulate the bed from some of the drying medium thus retaining a higher moisture level, 
and also resulting in higher yield.  In contrast, the stainless steel disk allows for better 
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conduction of heat and consequently better heat transfer and drying, resulting to reduced 
moisture content that consequently led to reduced product yield, compared to the output 
from batches made with the teflon plate.   
 
 ii. Yield of pilot scale-up batches 
 The two batches selected for scale-up (smooth stainless steel 500 rpm and waffle 
teflon 500 rpm) are highlighted in Table XXA.  The yield values were similar for 1, 5 and 
10 kg for the batches made with stainless steel smooth plate 84% - 87% (Table XXB).  
For the teflon plate, the values increased (88% -96%) compared to those of the stainless 
steel plate, though with higher LOD values as mentioned earlier.  However, student’s t-
test and one way ANOVA of the teflon plate data did not give any statistical difference 
between the yield results presented in Table XX (p < 0.05).  Nevertheless, increased 
fluidization air was used during the drying period to ensure that the LOD values of all 
future batches would be ≤ 5% at the drying end point.  There was statistically no 
difference in the LOD values of 10 kg and 5 kg or 1 kg batches made with the  
teflon plate.  
 
 Generally, the batch size did not affect the characteristics of 5 kg and 10 kg 
batches using 19”  plate, which was desirable.  In a previous report involving traditional 
extrusion/spheronization (142), it was shown that undesirable product qualities could 
result if inappropriate plate size was used relative to batch size. This is because at very 
low load, there are relatively insufficient granules to interact with each other, thereby 
leading to poor particle/particle interaction, while the opposite is true at high loads.   
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     2. Density, Carr’s index and Flowability 
 These qualities were used as indices for the flow properties of the spheroids.  The 
low values of Carr’ s index (less than 15%) signify good flowability of the granules. This 
was confirmed with the angle of repose of all the formulations being less than or equal to 
30 degrees (± 0.13 o to 7.59o SD; 240), as also shown in Tables XXA and B above.  As 
shown in Table XXA, the flowability was decreased by the use of HPMC (trial 6) and 
high rotor speed (trials 5 and 8) that could have resulted in higher level of non-spherical 
and smaller geometric mean size of granules respectively.  Use of HPMC (trial 6) and 
high speed (trials 5 and 8) also produced granules with increased tap density and percent 
compressibility and thus bad flow characteristics. 
 The results of the true densities before and after purging were practically similar, 
and almost similar results were obtained from all the batches (Tables XXA and B).  From 
these results, it could be inferred that the samples have similar moisture content, 
indicating that the LOD (apart from influencing the yield that was measured immediately 
after production), might not have affected other product characteristics determined during 
storage at ambient conditions. 
 
     3. Drug content and Dissolution analyses 
 Calibration curve 
 Good linearity (r2 = 0.9996) was obtained from the calibration curve (Figure 22)  
The percent accuracy ranged between 75 and 101% and the percent interday coefficient of 
variation (CV) ranged between 0.10 and 11% (Table XXI), with the lowest concentration 
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observed as an outlier.  These results indicate acceptable accuracy and reproducibility for 
the assay method, respectively. 
 
Figure 22: Calibration curve for HPLC analyses 
 
Drug Content Analysis: With the exception of the batch without sodium 
lauryl sulfate (SLS; Tables XXA and XXB), the mean percentages of drug content 
obtained from six replicate samples ranged between 90.52% ± 4.71% and 98.65% ± 
4.37% ibuprofen, calculated on the content of theoretical formulation.  This indicated that 
the fluid-bed processes (blending, spheronization, drying) did not affect the ratio of the 
ibuprofen drug to the Avicel RC-581 in the powder blend. It has been shown that by 
adding surfactant to a spheronization system, the interaction between the liquid and the 
powder changes (56), as a result of greater accessibility of the pore structure by the liquid 























within the powder bed. It is therefore possible that the absence of SLS delayed the 
wettability of the powder blend, leading to the loss of the lighter-weighted  
ibuprofen drug. 
 
Table XXI:  Accuracy and precision of HPLC Assay 
Concentration (µg/mL)   
Expected Obtained % Accuracy Interday CV (%) 
5 3.77 75.4 11.64 
10 8.68 86.8 3.44 
20 19.14 95.68 2.69 
40 40.45 101.12 2.14 
50 49.55 99.11 3.02 
100 102.63 102.63 1.72 
150 151.88 101.25 0.23 
200 202.12 101.06 1.3 
250 251.97 100.79 0.11 
300 295.61 98.54 0.25 
 
 
 Dissolution studies: The Q20 for all the formulations calculated using the 
obtained drug content was ≥ 80%, except the batch containing HPMC and that without 
SLS that released 75% and 74% respectively of ibuprofen at the same time (Tables XXA 
and B, and Figures 23A and B).  The variability between the replicate batches was 
generally around 5%. The slower release from granules made with HPMC as binder or in 
the absence of SLS could be attributed to densification, retardation of diffusion from the  
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Figure 23. Panel A: Profiles of 1 kg replicated batches. Panel B: Profiles of pilot scale-up 
batches. Trial 4: SS/Sm/1 kg; Trial 12: SS/Sm/5 kg; Trial 13: SS/Sm/10 kg; Trial 7: 
Tef/Waf/1 kg; Trial 14: Tef/Waf/5 kg; Trial 15: Tef/Waf/10 kg.  SS/Sm: stainless 


























































granules and larger particle size (Figure 23A) that then reduced the surface area of the 
granules respectively.  There was no difference in drug release in batches made with 
Avicel® RC and CL cellulose types contrary to previous reports in which extrusion 
spheronization technique was used (254,255). 
 
     4. Friability 
 As shown in Table XXA, the percentage weight loss from the batches was 
generally less than 5% (± 0.00 to 4.71 SD).  However, increased rotor speed (trials 5 vs. 1 
and 8 vs. 7), use of HPMC (trial 6 vs. 1), and use of different plate contours (trial 4 vs. 1) 
increased the friability due to attrition and weakly agglomerated particles.  
 
     5. Sphericity and morphology of the granules 
The sphericity of the microparticulates was in the range of 0.84 ± 0.01 to 0.92 ± 
0.01, which is close to 1.0, the optimal value for sphericity (Table XXA).  The sphericity 
was reduced by the use of HPMC as binder (Figure 24G).  HPMC increases the viscosity 
of the binder, which could influence the resistance of liquid to flow. This has been shown 
to affect the consistency of the wet powder mass, which in turn would influence the 
process ability to produce spherical pellets (56).  Moreover, a 5% HPMC solution was 
used as the binder. It could be that a lower percentage with a lesser effect on binder 
viscosity would have resulted in a more spherical product.  
Sphericity was not affected by the use of SLS although the SLS is supposed to 
enhance the wetting, which could enhance formation of spherical particles (54).  
Moreover, neither batch nor process scale-up seemed to affect the sphericity of the 
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granules (Table XXB).  The results represented in Tables XXA and XXB are the 
sphericity means of 30 - 60 pellets from replicate batches.  Figures 24A-C show the 
morphology of 1 kg, 5 kg and 10 kg batches of both plate material types (teflon and  
   
        
















Figure 24. Scanning electron micrographs (x30) of ibuprofen granules made with 













Figure 24 (Contd). Scanning electron micrographs (x30) of ibuprofen granules made with 
stainless steel plate, 1 kg (Panel A); 5 kg (Panel B); 10 kg (Panel C); and with 
Teflon/waffle plate 1 kg (Panel D); 5 kg (Panel E); 10 kg (Panel F). 1 kg batch made with 
HPMC as binder on a stainless steel plate (Panel G). 











Figure 25. Scanning electron micrographs (x200) of ibuprofen granules made with 
stainless steel plate, 1 kg (Panel A); 5 kg (Panel B); 10 kg (Panel C). 
G 
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stainless steel), and the 1 kg produced with HPMC as binder using the stainless steel 
plate. Figures 25A-C show typical morphology of the microparticulates at higher 
magnification. 
 
     6. Size distribution of granules 
Size distributions for most of the batches depicted log normal distribution (results 
not shown), with the values of the 20/60 mesh products ranging between 88 - 96%, 
except for the 1 kg batch made with stainless steel waffle plate at 650 rpm (trial 5) and 
that containing HPMC as binder (trial 6).   
For the loboratory scale batches, the presence of surfactant (SLS; trial 1 vs. 2) and 
use of water (in the standard) as binder (trial 6 vs. 1) decreased particle size (Figure 26A).  
Mean particle size increased in the absence of SLS, probably because in this situation, the 
surface energy required to reduce the particle size to what would be obtainable under 
similar conditions in the presence of the surfactant increases. It could also be due to 
decreased wettability that made these spheroids less vulnerable to attrition during drying.  
Type of Avicel hydrocolloid (trial 1 vs. 3), and disk contour type (trial 4 vs. 1) did not 
affect the distribution.  Rotor speed (650 rpm) decreased the particle size of the products 
made with stainless steel plate compared to the 500 rpm used in the standard (trial 5 vs. 
1), while plate type slightly increased the particle size at higher speed (formulations 8 vs. 
5; Figure 26A).  The geometric mean diameters of the granules together with the 
geometric standard deviations are shown in Table XXA and Figure 26A.   
The difference in size distribution between the batches could be attributed mainly 
to the formulation components and process variables, because the size distribution of the  
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Figure 26. Panel A: Geometric mean diameter of 1 kg replicated batches.  
Panel B: Geometric mean diameter of scale-up batches. The error bars did not show 































































































































starting raw materials were kept uniform by sieving the powders through a 16 mesh size 
prior to blending and spheronization. The decrease in the mean diameter with increased 
rotor speed (trial 1 vs. 5), could be due to surface defects on the pellets by the high speed, 
thereby producing more fines (7,256).  
In the scale-up batches, the particle size, especially that of the teflon plate batches, 
appeared to increase with larger batch size (Figure 26B). This is due to greater attrition by 
the smaller sized batches that are lighter, more readily fluidized, falling from higher 
heights during drying. It could also be due to increased tendency of the particles to bind 
together due to the increased surface area of the larger batch sizes.  The stainless steel 
batches had less attrition presumably because the spheroids dry up more easily than the 
products of equivalent batch sizes made with the teflon plate. Despite the increased 
particle size, the 20/60 mesh sizes yield in each of the scale-up batches was up to 85% 
thereby meeting the set acceptance criteria (page 94).  These observations however did 
not correlate with the report that the granule size is inversely related with the batch size 
(142), and will therefore be further investigated. 
 
In summary, trials 4 and 7 (Table XXA & B) were chosen as desirable 
preparations based on the acceptance criteria such as yield, drug content, dissolution and 








Optimization of the Developed Process and product Variables Using Statistically 
Designed Factorial Experiment 
 
a. Experimental Design 
Tables XXII and XXIII show the respective results of the means of replicate 
batches and p-values of the independent variables (block and main effects) obtained from 
the statistically analyzed full factorial blocked randomized design.  Table XXIV 
summarizes the qualities of the pellets by grouping them according to the used plate types 
and contours.  The effect of the main factors on spheroid qualities will be discussed in the 
sections addressing affected physical characteristics. 
 
 Binder level: The importance of water, used as binder or granulating liquid in the 
spheronization process, and the moisture content in the product, with respect to the 
physical performance of the end product have been reported in various studies (78,257).  
We have also shown that good spheroid qualities were obtained when the moisture 
content in the bed at the end of spheronization process was 50 – 52% (47), at defined 
parameters.  It is therefore evident that variation in the amount of water used for the 
production of formulations of similar composition and batch size will affect most of the 
spheroid qualities, as will be discussed in the respective sections.  Higher binder content 
implied higher yield of the spheroids and vice versa.  These results are shown in Tables 

















































Estimated effect on Geometric Mean Diameter 
Estimated effect on Yield 




















Pareto plots of effects of main factors on the specified product qualities (Contd.).  
 
Surfactant level: Surfactant level significantly affected the Q20, the geometric mean 
diameter, the LOD and the usable fraction (p < 0.05). In the presence of high binder and 


































Estimated effect on Usable fraction 
Estimated effect on Sphericity 
Estimated effect on Q20 
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decreased the Q20 of the spheroids was observed (Table XXII). Thus, in the presence of 
high amount of water as the granulating liquid, SLS appears to lose some of its surface-
active property that should reduce the particle size of the spheroids. This result was 
confirmed by the highly statistical significance observed in the interaction between the 
high binder and surfactant levels.  
 
 Plate type: As seen in Table XXIII, plate type significantly influenced the 
yield, sphericity, friability; bulk density, geometric mean diameter, the Q20 and usable  
fraction (p < 0.05).  Stainless steel smooth plate gave more consistent product quality 
especially with respect to yield, drug content, usable fraction.  The effects of plate type on 
product yield, geometric mean diameter, drug content, Q20, usable fraction and sphericity 
are also represented with the Pareto plots of some of the response variables (Figure 27).  
 
 Blocking effect: Blocking had no significant effect on eleven of the twelve 
product characteristics studied (Table XXIII), and also had no significant interactions 
with the main factors [(X1 - X3), indicating batch-to-batch reproducibility.  A significant 
blocking effect (p = 0.0014) was observed with the sphericity response variable, which 
could actually be considered insignificant.  This is because the data showed that the 
difference between the sphericity values [that should range between 0.1 (non spherical) – 
1 (most spherical)] of the two blocks was very minute such that any slight change 
appeared statistically significant.  However, although the observed difference would not 
be clinically important, this effect was tested further. 
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 To test the significance of the blocking effect, statistical analysis was performed 
on the formulations within the individual blocks.  Significant effect (p = 0.02) was 
observed only with the binder level in block 1 of Table VII, which was found to be 
insignificant for the whole model test (p > 0.05).  In block 2, significant effects were 
observed with two of the main factors, namely, binder level (p = 0.0008) and plate type 
(p = 0.0033), and there was also significant interaction between binder level and plate 
type (p = 0.013). This blocking effect could be attributed to extraneous factors like 
humidity and temperature changes which have been shown to have possible effects on 
spheroid preparation (9), since the formulations in each of the blocks were produced at 
two different periods.  However, the results from both blocks were generally within our 
set acceptance criteria and the variability between blocks was very minute.  
 
 Interaction: Some of interaction results are shown in Figure 28.  There was 
significant interaction (p < 0.05) between binder level and plate type on the drug content, 
sphericity, friability and LOD response variables. Low binder yielded lower and less 
spherical spheroids as well as reduced usable fraction with teflon plate (Formulations 7 
and 9).  There were also significant interactions between the binder and the surfactant 
levels on the drug content, true density, LOD, the Q20, usable fraction and geometric 
mean diameter response variable. High binder-High surfactant levels resulted in bigger 
spheroids for the batches made with the stainless steel plates.  Significant (p < 0.05) 
interactions were also observed between the plate type and surfactant level on the drug 








          
 






b. Physical Characteristics of the Spheroids 
     1. Scanning electron microscopy  
 As shown in Tables XXII & XXIV and Figures 29 and 30, and also as already 
explained in the interaction studies, high binder/high surfactant (HbHs) levels with 
stainless steel smooth or waffle plates (Formulations 3 and 6 respectively) produced 
spherical but very big spheroids (~1 mm). In contrast, low binder/high surfactant (LbHs) 
and high binder/low surfactant (HbLs) levels with stainless steel smooth plate 
(Formulations 5 and 11 respectively) resulted in spherical and smaller microparticulates 
within the acceptable criterion range of 0.35 –0. 5 mm.  However, batches made with low 
binder/low surfactant (LbLs) or low binder/high surfactant (LbHs) levels and with teflon 
waffle plate (Formulations 7 and 9) produced very small spheroids (0.036 and 0.130 mm) 
with low sphericity.  These results correlated with other observations and statistical 
analysis with regard to significance of binder level in the formation of well granulated 
spheroids (93,122).  Typical morphology of the three different spheroid groups is shown 
in Figures 29 and 30. 
 
     2. Moisture content determination (Loss on drying) 
 Following our observations from previous studies, the moisture content at the end 
of drying of the products was generally ≤ 5% (Table XXII).  The highest values were  
obtained with the batches (Formulations 3 and 6) made with high binder-high surfactant 
(HbHs) levels and using the stainless steel plates.  This could be due to the large sizes 
(949 and 1070 µm) of these pellets that could reduce the efficient drying of the stainless  
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Figure 29: Scanning electron micrographs (30x) of ibuprofen granules. Formulations 3 
and 6 (Panels A & B); Formulations 5 and 11 (Panels C & D); Formulations 7 and 9 










Figure 30: Scanning electron micrographs (100x) of ibuprofen granules. 
Formulations 3 (A); 11 (B); 7 (C). 
 
steel plate material.  In contrast, the formulation (#10) made with the teflon plate using 
HbHs levels at a fixed binder level had smaller sized pellets (356 µm).  This observation 
indicated that the teflon plate required higher amount of binder to yield products of 
similar sizes as those made with the stainless steel plate. The results were also supported 
by previous report that was obtained with the teflon plate.  The smaller sized pellets 
obtained with this plate must have contributed to the effects of plate type on most of the 
spheroid qualities.  In addition, these smaller sized pellets were easier to dry than the 
larger sized pellets obtained with the stainless steel plates, despite the insulating nature 
(lower drying efficiency) of the teflon material.
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TABLE XXII.  Physical Characteristics of Optimized Ibuprofen Spheroids.  
 
  
 Form. 1 Form. 2 Form. 3 Form. 4 **Form. 5 Form. 6 
Experimental variables Physical characteristics 
LbHsSS-waf LbLsSS-sm HbHsSS-sm HbLsTef-waf LbHsSS-sm HbHsSS-waf 
% Yield 80.85 ± 3.04 77.15 ± 9.83 95.85 ± 6.86 87.75 ± 7.57 89.7 ± 3.54 97.3 ± 1.56 
% Moisture content 2.10 ± 0.13 2.00 ± 0.01 5.15 ± 0.23 1.52 ± 0.56 1.55 ± 0.23 4.22 ± 0.01 
% Drug content 93.43 ± 2.17 92.57 ± 3.91 93.06 ± 1.40 96.67 ± 3.38 98.74 ± 0.81 92.76 ± 3.47 
Geometric mean diameter  (µm) 350 ± 1.55 354 ± 1.42 949 ± 1.40 460 ± 1.41 396 ± 1.35 1070 ± 1.40 
Sphericity 0.87 ± 0.01 0.87 ± 0.00 0.89 ± 0.02  0.88 ± 0.00 0.89 ± 0.03 0.89 ± 0.02 
Flowability (deg) 18.76 ± 0.54 20.38 ± 0.33 17.85 ± 0.00 17.92 ± 1.94 17.60 ± 1.95 19.14 ± 0.65 
Carr’s index. (%) 7.43 ± 1.55 9.12 ± 2.35 3.00 ± 0.59 7.48 ± 1.86  8.11 ± 0.24 3.78 ± 0.09 
True density (g/cm3) 1.30 ± 0.00 1.25 ± 0.01 1.22 ± 0.02 1.29 ± 0.01 1.29 ± 0.01 1.23 ± 0.00 
Bulk density (g/cm3) 0.63 ± 0.01 0.61 ± 0.09 0.78 ± 0.01 0.65 ± 0.07  0.64 ± 0.01 0.77 ± 0.00 
Q20 (%) 89.85 ± 1.48 91.00 ± 1.13 47.55 ± 7.14 84.35 ± 5.02 89.90 ± 0.28 47.25 ± 0.49 
Friability (%) 0.67 ± 0.00 0.67 ± 0.94  0.33 ± 0.00 0.67 ± 0.47 0.67 ± 0.47 0.5 ± 0.24 
Usable fraction (%) 92.00 ± 2.83 81.00 ± 7.07 54.00 ± 14.14 93.00 ± 1.41 97.00 ± 1.41 43.00 ± 1.41 
 
Low binder (Lb), High binder (Hb) 
Low surfactant (Ls), High surfactant (Hs) 
Stainless steel smooth (SS-sm), Stainless steelwaffle (SS-waf), Teflon waffle (Tef-waf) 
Form.: Formulation 
**The highlighted formulations showed the most acceptable spheroid qualities 
 158 
TABLE XXII.  Physical Characteristics of Optimized Ibuprofen Spheroids (Contd.). 
 
 
 Form. 7 Form. 8 Form. 9 Form. 10 **Form. 11 Form. 12 
Experimental variables Physical characteristics 
LbLsTef-waf HbLsSS-waf LbHsTef-waf HbHsTef-
waf 
HbLsSS-sm LbLsSS-waf 
% Yield 68.65 ± 6.29 104.00 ± 9.9 60.4 ± 2.26 92.65 ± 18.87 92.10 ± 0.99 71.85 ± 4.6 
% Moisture content 0.37 ± 0.13 0.44 ± 0.13 2.60 ± 0.30 1.69 ± 0.13 1.80 ± 0.43 2.50 ± 0.28 
% Drug content 89.24  ± 2.18 99.96 ± 6.75  92.66 ± 0.94 99.79 ± 3.20  96.80 ± 0.47 93.96 ± 5.20 
Geometric mean diameter  (µm) 130 ± 2.54 417 ± 1.47 36 ± 5.93  356 ± 1.74 386 ± 1.48 384 ± 1.61 
Sphericity 0.84 ± 0.01 0.88 ± 0.02 0.84 ± 0.00 0.89 ± 0.02 0.88 ± 0.01 0.88 ± 0.01 
Flowability (deg) 24.36 ± 1.41  18.42 ± 0.44 26.47 ± 3.57 20.52 ± 1.88 20.93 ± 1.8 18.95 ± 1.85 
Carr’s index. (%) 10.85 ± 0.48 7.42 ± 1.39 18.61 ± 13.95  9.24 ± 0.86  8.07 ± 2.44 7.63 ± 1.41 
True density (g/cm3) 1.31 ± 0.00 1.28 ± 0.00 1.27 ± 0.04 1.28 ± 0.02 1.29 ± 0.00 1.29 ± 0.00 
Bulk density (g/cm3) 0.56 ± 0.02 0.65 ± 0.02 0.54 ± 0.05 0.60 ± 0.02 0.62 ± 0.03 0.65 ± 0.06 
Q20 (%) 88.90 ± 5.23 88.95 ± 6.01 89.25 ± 1.48 91.80 ± 2.12 92.45 ± 3.61 87.35 ± 3.61 
Friability (%) 0.37 ± 0.24 0.44 ± 0.24 7.62 ± 2.76 0.50 ± 0.71 1.00 ± 0.00  0.67 ± 0.94 
Usable fraction (%) 37.00 ± 15.56 95.00 ± 1.41  13.00 ± 7.07 78.00 ± 19.80 94.00 ± 0.00  87 00 ± 9.90 
Low binder (Lb), High binder (Hb) 
Low surfactant (Ls), High surfactant (Hs) 
Stainless steel smooth (SS-sm), Stainless steelwaffle (SS-waf), Teflon waffle (Tef-waf) 
Form.: Formulation 
**The highlighted formulations showed the most acceptable spheroid qualities 
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Bold: indicates the few NS results obtained with the binder level factor in comparison to those obtained with the plate type and 
surfactant level factors. 
Dependent 
                  Independent variables Interactions
variables Blocking Plate type Binder level Surf. level
1 2 3 4 2*3 2*4 3*4
Yield NS S (0.03) S (<.0001) NS NS NS NS
Drug cont. NS NS S (<.0001) NS S (0.0291) S (0.0011) S (0.0036)
Q20 NS S (0.0198) S (0.0003) S (0.0071) NS NS (0.055) S (0.0007)
Carr’s Index NS NS (0.06) S (0.03) NS NS NS NS
Flowability NS NS (0.067) NS NS NS NS NS
Friability NS S (0.0001) S (0.0001) NS S (0.0001) NS NS
Bulk density NS S (0.0046) S (0.0017) NS (0.08) NS S (0.0522) S (0.0572)
True density NS NS NS NS (0.06) NS NS S (0.0468)
Geom. m. diam. NS S. (0.0006) S (<.0001) S (0.0066) NS S (0.011) S (0.0023)
Moisture content NS NS NS (0.0857) S (0.0026) S (0.0049) NS S (0.0007)
Usable fraction NS S (0.0037) NS S (0.0063) S (<.0001) NS S (0.0088)
Sphericity S  (0.0014) S (0023) S (0.0003) NS S (0.0058) NS NS
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TABLE XXIV:  Summary of the Optimized Ibuprofen Spheroid Qualities 
 
Plate type  Form.  Form.                                         Physical Charateristics
number vars
Yield (%) Q20 (%) Geom. Mean Usable 
diam. (mm) fraction (%)
12 Lb-Ls 71.85 ± 4.6 87.35 ± 3.61 384 ± 1.61 87.00 ± 9.90
SS-Waf 1 Lb-Hs 80.85 ± 3.04 89.85 ± 1.48 350 ± 1.55 92.00 ± 2.83
8 Hb-Ls 104.00 ± 9.9 88.95 ± 6.01 417 ± 1.47 95.00 ± 1.41 
6 Hb-Hs 97.3 ± 1.56 47.25 ± 0.49 1070 ± 1.40 43.00 ± 1.41
2 Lb-Ls 77.15 ± 9.83 91.00 ± 1.13 354 ± 1.42 81.00 ± 7.07
5 Lb-Hs 89.7 ± 3.54 89.90 ± 0.28 396 ± 1.35 97.00 ± 1.41
SS-Sm 11 Hb-Ls 92.1 ± 0.99 92.45 ± 3.61 386 ± 1.48 94.00 ± 0.00 
3 Hb-Hs 95.85 ± 6.86 47.55 ± 7.14 949 ± 1.40 54.00 ± 14.14
7 Lb-Ls 68.65 ± 6.29 88.90 ± 5.23 130 ± 2.54 37.00 ± 15.56
9 Lb-Hs 60.4 ± 2.26 89.25 ± 1.48 36 ± 5.93 13.00 ± 7.07
Tef-Waf 4 Hb-Ls 87.75 ± 7.57 84.35 ± 5.02 460 ± 1.41 93.00 ± 1.41
10 Hb-Hs 92.65±18.87 91.80 ± 2.12 356 ± 1.74 78.00 ± 19.80
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TABLE XXIV: Summary of the Optimized Ibuprofen Spheroid Qualities (Contd.) 
 
 
P late type  Form .  Form .                                  Physical characteristics
num ber vars
D rug cont. C arr’s Sphericity
(% ) index (% )
12 Lb-Ls 93.96 ± 5 .20 7.63 ± 1 .41 0.88 ± 0 .01
SS-W af 1 Lb-H s 97.3 ± 1 .56 7.43 ± 1 .55 0.87 ± 0 .01
8 H b-Ls 99.96 ± 6 .75 7 .42 ± 1 .39 0.88 ± 0 .02
6 H b-H s 92.76 ± 3 .47 3.78 ± 0 .09 0.89 ± 0 .02
2 Lb-Ls 92.57 ± 3 .91 9.12 ± 2 .35 0.87 ± 0 .00
5 Lb-H s 98.74 ± 0 .81 8.11 ± 0 .24 0.89 ± 0 .03
SS-Sm 11 H b-Ls 96.80 ± 0 .47 8.07 ± 2 .44 0.88 ± 0 .01
3 H b-H s 93.06 ± 1 .40 3.00 ± 0 .59 0.89 ± 0 .02 
7 Lb-Ls 89.24  ± 2 .18 10.85 ± 0 .48 0.84 ± 0 .01
9 Lb-H s 92.66 ± 0 .94 18.61 ± 13.95 0 .84 ± 0 .00
T ef-W af 4 H b-Ls 96.67 ± 3 .38 7.48 ± 1 .86 0 .88 ± 0 .00
10 H b-H s 99.79 ± 3 .20 9 .24 ± 0 .86 0 .89 ± 0 .02
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 The statistical analyses also showed that surfactant level significantly affected the 
moisture content of the products (p = 0.0026).  This might have led to the significant 
interaction (p = 0.0007) between these two factors that resulted in the yield of oversized 
granules.  The same reasons already given for the stainless steel and teflon plates might 
have led to the significant interaction (p = 0.0049) observed  between plate type and 
binder level.   
 
     3. Yield and usable fractions of spheroids 
The yield of the formulations ranged from 60.4 ± 2.26% - 104 ± 9.9% with the 
usable fractions (250 - 850 µm) ranging between 37 ± 15.56% - 97 ± -1.41% respectively 
(Table XXII). 
Comparing batches made with similar plates, the formulations with low binder 
level gave lower yield values (1 and 12 vs. 6 and 8 respectively; 2 and 5 vs. 11 and 3 
respectively; 7 and 9 vs. 4 and 10 respectively).  The lower yield obtained from the low 
binder batches could be attributed to insufficient amount of binder being added to the 
powder blend leading to the production of more fines that were lifted up by the 
fluidization air into the filters, and also coated the walls of the fluid-bed.  These 
observations were made more apparent from the results obtained with the geometric mean 
diameter (see below).  
 By comparing different batches made with plate material types of similar contours 
[Teflon waffle (TW) and stainless steel waffle (SSW)], it was observed that the latter 
yielded more products than the former (Formulations 4 vs. 8; 10 vs. 6; 9 vs. 1; 7 vs. 12). 
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This could be attributed to the production of more fines by the teflon material than the 
stainless steel material that could also lead to more losses, as already explained.  
Plate contour was affected by the binder and (more or less) by the surfactant 
levels. At low binder level, the stainless steel smooth contour yielded higher 
microparticulates and more usable fractions than the SSW plate irrespective of the 
surfactant levels (Formulations 5 vs. 1 and 2 vs. 12). This could be due to the loss of 
products in the waffle contour, as previously explained (47).  However, at higher binder 
levels, the SSW plate yielded more products and more or less equal usable fractions 
(Formulations 6 vs. 3 and 8 vs. 11) than the SS-smooth plate. The latter observation could 
be due to the formation of large sized spheroids that were neither lost in the filters nor in 
the waffle contours. The high binder-high surfactant batches are however practically 
unusable within our set acceptance criteria. 
 The results from Tables XXII & XXIV are supported by those of the p-values 
obtained using the JMP® software analyses (Table XXIII).  These show that binder level 
and plate type significantly affected the product yield (p < 0.0001 and p = 0.0311 
respectively). However, there was no significant interaction observed between any of the 
main factors (p > 0.05) on the yield product variable.   
 
     4. Drug content 
 Binder level significantly affected this response variable (p < 0.0001).  Low 
binder levels generally resulted in reduced drug content, probably due to some losses that 
could occur from insufficient wetting of the product at any stage of its development. As 
already explained, there was also significant interaction between plate type and binder 
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level (p = 0.0291), plate type and surfactant level (p = 0.0011) and also binder and 
surfactant levels (p = 0.0036) on this spheroid quality.  However, the results obtained 
from all the formulations are within our set acceptance criteria (≥ 85%), as shown in 
Table XXII.   
 
     5. Friability 
As shown in Table XXII, the percentage weight loss from all the formulations was 
generally < 1%, except that of the batch made with teflon plate and low binder 
(formulation 9) that also produced the smallest sized spheroids (geometric mean diameter 
36 ± 5.93) and the lowest usable fraction (13 ± 6.7%).   It was observed that both binder 
level and plate type significantly affected this response variable (p < 0.0001), and there 
was also significant interaction observed between these two factors (p < 0.0001).  
Generally, low binder content produced more friable spheres.  These results could 
be related to the explanations given under the LOD section.  At low binder levels there 
will not be enough binder for particle-particle contact and adhesion that will lead to the 
formation of primary and strong secondary nuclei (76), thereby forming friable spheroids.  
 
     6. True density and compressibility 
 The statistical analyses showed that none of the main factors significantly affected 
the true density of the microparticulates.  The closest was the effect of the surfactant level 
(p = 0.06) and its interaction with binder level (p = 0.048).  Different binder and 
surfactant levels might have led to different pellet sizes, which might have affected the 
true density of the pellets. Bulk density was significantly affected by plate type  
 165 
(p = 0.0046) and binder level (p = 0.0017), however, no significant interaction was 
observed between these factors (p > 0.05).  Our results correspond with previous reports 
(using the traditional extrusion-spheronization process) that bulk density which greatly 
influences the packing properties of spheres is greatly dependent on the diameter of the 
pellets (134,258).  Thus, there would be no change in the volume occupied by pellets of 
high geometric mean diameter leading to high bulk density of the microparticulates 
(Formulations 3 and 6).  For true density that directly affects the compactness of 
substances, high geometric mean diameter is indicative of larger air pockets, and 
consequently, lower true density. However, we observed the lowest true density values 
for the spheroids with the highest geometric mean diameter (Table XXII), as was also 
observed by other authors (259).  This is probably due to larger air pockets entrapped by 
these bigger microparticulates that are practically open porous structures, as shown in 
Figure 30 above, and therefore would result in low true density (low compactedness) 
spheroids. 
 The percent compressibility (Carr’s index) was significantly affected by binder 
level (p = 0.032). It has been shown that during spheronization, agglomerates grow by 
coalescence (44), which depends on plastic deformability of the wet material mass. 
Sufficient binder is therefore required for the powder materials to achieve plastic 
deformation, which is related to the compressibility of the product, Hence the observed 
statistically significant effect at two binder levels. The p-value for plate type was 0.0642 
but there was no significant interaction observed. The results of the Carr’s index 
(generally < 15%) indicate that the granules have acceptable bulk and true densities for 
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the production of unit dosage forms except for formulation 9, which also has the lowest 
usable fraction, smallest geometric mean diameter and the poorest flowability  
(Table XXII).   
 Flowability was slightly affected by plate type (p = 0.067), though not statistically 
significant (p > 0.05), which could be attributed to the higher fines produced by the teflon 
plate material as already discussed.   
 
     7. Sphericity of the granules 
 The sphericity values of most of the microparticulates were within our set 
acceptance criterion (≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table 
XXII).  The sphericity was reduced by the use of teflon waffle plate except in the 
presence of high binder levels (Formulations 7 and 9 vs. 4 and 10).  This could be due to 
the production of more fines in the presence of low binder levels by this plate type, thus 
producing less spheronized microparticulates, and also indicating the need for higher 
binder level by this plate type. Statistically, it was observed that binder level and plate 
type significantly affected this response variable (p = 0.003 and 0.023 respectively), and 
there was also significant interaction between these factors (p = 0.0058). Batch 
replication (blocking) was also observed to affect the sphericity of the batches  






     8. Size distribution of granules 
 The geometric mean diameter of the microparticulates ranges from 36 ± 5.93 µm -
1070 ± 1.14 µm (Table XXII; Figure 31) respectively.  Three groups can be distinguished 
from the observed experimental results. The first group comprised of formulations 3 an6 
that present very large spheroid sizes caused probably by the simultaneous use of high 
binder and high surfactant levels, which could lead to excessive agglomeration (260).  
The second group included formulations 7 and 9 with very small spheroid sizes due to 
low binder level with the teflon plate material which tends to produce more fines than 
similar batches made with the stainless steel plates.  The results from both groups are in  
 

































accordance with previous experiments that showed that the higher the amount of binder, 
the more spherical the particles and the larger their sizes, and vice versa (261).   
The last group consisting of intermediate sizes (e.g. Formulations 5 and 11) with 
geometric mean diameter ranging from 350 ± 1.55 µm - 460 ± 1.41 µm respectively are 
mostly results of low levels of either the binder or the surfactant.  This group, with usable 
fractions mostly > 85% fell within our set acceptance criteria and comprised our most 
acceptable formulations. 
 As explained in various sections, the statistical data show that the three main 
factors significantly affected this response variable (Table XXIII), namely, binder level  
(p < 0.0001), plate type (p = 0.0006) and surfactant level (p = 0.0066).  There was  
significant interaction between plate type and surfactant level (p = 0.011) and also binder 
and surfactant levels (p = 0.0023).  Both effects could be related to our observation of the 
smaller pellets obtained with the different binder and surfactant levels when used with the 
different plate types.  Thus, the simultaneous presence of high binder and surfactant 
levels in the formulation made with teflon plate material (Formulation 4) did not lead to 
the production of big sized spheres (Table XXII; Figure 31), as seen with formulations 3 
and 6. This could be attributed to the hydrophobic nature of the teflon material that 
prevented fast spreading of the hydrophilic binder. Consequently higher amount of binder 






     9. Ibuprofen release from granules 
 All the formulations released > 80% of the drug within 20 minutes (Q20), except 
the batches with large sizes (Formulations 3 and 6) that consequently reduced the surface 
area of the granules (Table XXII; Figures 32A & B).  These formulations consisted of  
HbHs levels and made with stainless steel smooth and waffle plates respectively. 
Statistically, it was observed that plate type (p = 0.0198), binder level (p = 0.0003) and 
 
Figure 32: Dissolution profiles of experimentally designed replicated batches. 
















































surfactant level (p = 0.0071) significantly affected this response variable (Table XXIII), 
which could be related to their effects on the spheroid sizes. As already explained, there 
was significant interaction between binder and surfactant levels (p = 0.0007).  High 
binder level might have resulted in reduced surface active properties of SLS that 
ordinarily would result in smaller particle sizes.  Consequently, larger spheroids were 
produced.  The interaction between plate type and surfactant level (p = 0.0554) should 
also be noted though not statistically significant (p > 0.05). 
 
Based on the results of the statistical analyses (effects of binder, SLS and plate 
type) and our set acceptance criteria such as yield, drug content, dissolution and sphericity 
studies, Formulation 11 (Tables XXII and XXIV) was chosen as the optimized 
preparation and was subsequently used to study the effects of particle size and drug load 
on spheroid qualities. 
 
Phase 3 
The Effects of Drug particle Size, Drug Loading and Intermediate Size Scale-up on 
the Characteristics of Ibuprofen Microparticulates 
 
a. Effects of drug particle size and drug loading 
     1. Experimental design 
 Drug micron size: Drug particle size significantly (p < 0.05) affected some of 
the physical characteristics studied, namely, moisture content (p = 0.0203), bulk density 
(p = 0.0088), flowability (p = 0.0028), sphericity (p = 0.0034) and usable fractions  
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(p = 0.0214). These results are as expected as similar observations have been previously 
reported necessary for most of these variables (52,153).  The bigger micron sized 
ibuprofen (40 µm) resulted in higher LOD, lower sphericity and lower bulk density.  The 
latter two observations could be a result of the bigger sizes breaking up during drying, 
leading to lower bulk density of the spheres. These outcomes would affect the sphericity 






Figure 33. Pareto plots of effects of main factors on the specified product qualities. 









Estimated effect on Geometric mean diameter 



















Drug load: Drug load significantly affected most of the qualities of the 
spheroids, except the yield, flowability and Carr’s index.  The insignificant effect on 
Carr’ s index was not expected since the bulk and tapped densities (p < 0.001) from which 
it was calculated were significantly affected by drug load (Tables XXV and XXVI).  
However, these observations conform with the reports that there may be other factors 
such as GMD and LOD contributing to the qualities of the finished product.  The 
observed increase in GMD with increased drug load could be due to the reduced amount 
of Avicel® RC-581 (a spheronization enhancer) in the system, which might have exposed 
the products to be easily over granulated.   
 
 Replication: Replication had no significant effect on ten of the twelve product 
characteristics studied (Table XXVI), as well as no significant interactions with the main 
effects [(drug load & drug micron size); results not shown], indicating batch-to-batch 
reproducibility.  The result obtained with the drug content response variable could be 
considered statistically significant (p = 0.0446).  However, this result falls on the 
borderline of our set level of significance (p = 0.05). In addition, the drug contents of all 
the response variables were > 90% (above our set acceptance criteria). Although 
statistical significance (p = 0.0069) was observed with friability, the friability values of 
all the response variables could be considered negligible (< 2%).  
 
 Interaction: There was significant interaction (p < 0.05) between drug micron 
size and drug load on the flowability (p = 0.0371) and Q20 (p = 0.0303) variables (Table 




Figure 34. Interaction plots of the effects of main factors on specified qualities. 
 
2. Physical characterization of granules   
 i. Scanning electron microscopy  
 Figure 35 shows typical morphology of the spheroids obtained from the three drug 
loads.  As shown in Table XXV and Figure 35, the size of the microparticulates increased 
with increased drug load. This could be due to the reduced amount of Avicel®, the water 












Figure 35: Scanning electron micrographs (30x) of ibuprofen formulations (20 µm drug 
size and 1 kg batch) for the different drug loads, A (50%); B (65%); and C (80%). 
 
ii. Moisture content/Loss on drying analyses  
 Binder amount: As expected, the amount of binder needed for 
spheronization of the different drug levels was inversely related to drug load (Table XI).  
This indicates that, as previously reported (44,49), Avicel® acted as molecular sponge that 
absorbed water, thus the requirement for higher amount of binder as Avicel®  level 
increased.  It was also observed that at each drug level, less binder was required to  






Table XXV. Physical Characteristics of Drug Micron Size/Drug Load Batches (Means of replicated batches) 
 20 micron size ibuprofen 40 micron size ibuprofen 
% ibuprofen 50 65 80 50 65 80 
Physical characteristics       
% Yield 90.85 ± 7.99 87.7 ± 1.56 76.35 ± 10.11 85.60 ± 0.00 94.27 ± 0.07 93.6 ± 2.83 
% Moisture content 1.7 ± .14 0.89 ± 0.01 0.71 ± 0.28 1.72 ± 0.14 1.69 ± 0.15 0.94 ± 0.20 
% Drug content 98.55 ± 5.08 98.79 ± 0.95 91.57 ± 1.27 94.96 ± 1.10 99.13 ± 1.11 94.81 ± 1.12 
Geometric mean diameter  (µm) 485 ± 1.52 605 ± 1.45 697 ± 1.98 456 ± 1.37 528 ± 1.42 802 ± 1.35 
Sphericity 0.91 ± 0.00 0.91 ± 0.01 0.88 ± 0.01 0.871 ± 0.017 0.882 ± 0.00 0.873 ± 0.00 
Flowability (deg) 22.15 ± 0.00 21.43 ± 1.16 23 72 ± 1.73 20.63 ± 0.11 19.88 ± 0.11 17.95 ± 0.21 
Carr’s index. (%) 8.03 ± 1.67 6.02 ± 0.06 7.23 ± 1.38 6.79 ± .32 6.83 ± 0.92 8.43 ± 5.29 
True density (g/cm3) 1.29 ± 0.02 1.24 ± 0.00 1.18 ± 0.00 1.29± 0.00 1.21 ± 0.04 1.18 ± 0.01 
Bulk density (g/cm3) 0.69 ± 0.01 0.63 ± 0.01 0.58 ± 0.03 0.64 ± 0.02 0.57 ± 0.01 0.57 ± 0.00 
Q20 (%) 83.94 ± 4.00 86.87 ± 1.34 82.80 ± 6.19 89.48 ± 4.93 88.38 ± 3.73 67.04 ± 0.26 
Friability (%) 0.50 ± 0.24  0.50 ± 0.24 1.17 ± 0.71 0.84 ± 0.23 1.00 ± 0.47 1.17 ± 0.23 
Usable fraction (%) 91.00 ± 1.41 85.00 ± 1.41 59.00 ± 7.07 97.00 ± 1.41 92.00 ± 0.00 70.00 ± 5.66 
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Dependent variables Independent variables  
Physical characteristics Replication  
 
[1, 2] 
Micron size (MS) 
 
[20 µm, 40 µm] 
Drug load (DL) 
 
[50%, 65%, 80%] 
Interactions  
 
(MS * DL) 
     
Yield NS NS NS NS (0.0681) 
Moisture content S (0.0446) NS S (0.0108) NS (0.0777) 
LOD NS S (0.0203) S (0.003) NS (0.0689) 
Q20 NS NS S (0.0124) S (0.0303) 
Geometric mean diameter NS NS S (0.0196) NS 
True density NS NS  S (0.0003) NS 
Bulk density NS S (0.0088) S (0.001) NS 
Carr’ s index NS NS NS NS 
Flowability NS S (0.0028) NS  S (0.0371) 
Friability S (0.0069) NS (0.0584) S (0.0315 NS 
Sphericity NS S (0.0034) S (0.0282) NS (0.0613) 
Usable fraction NS S (0.0214) S (0.0004) NS 
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Moisture content in the fluid-bed: A plot of the moisture content for both drug 
particle sizes during spheronization and drying processes in function of time (Figure 36) 
showed that, as stated above, with the two drug micron sizes, the amount of the liquid 
binder needed for the spheronization of the powder blends decreased as the drug load 
increased.  It was also observed that the products containing 20% Avicel® or 80% drug 
load were easily overspheronized, resulting in larger particle sizes.  This is in accordance 
with the report that the lower the amount of Avicel® in the spheronization of most model 
drugs, the more difficult the spheronization process (49).  The moisture content at the end 






























Figure 36: The moisture content profile of 20 micron ibuprofen as a function of time  
(1 & 2 represent replicate batches). 
 
  iii. Yield and usable fractions of spheroids 
 The yield of the formulations ranged from 76.35 ± 10.11% - 94  ± 0.07% with the 
usable fractions (250 - 850 µm) ranging between 59 ± 7.07%– 97 ± 1.41% respectively 
(Table XXV).  Comparing batches made with 20 micron sized ibuprofen, the percent 
yield decreased as drug load increased.  This could be attributed to the poor wettability of 
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the batch due to increased ibuprofen that led to more losses in the system.  The 40 micron 
sized ibuprofen yielded slightly more products although this was not statistically 
significant (Table XXVI).   
 The usable fraction was significantly affected by both drug micron size  
(p = 0.0004) and drug load (p = 0.0214).  As shown in Table XXV, the fraction 
decreased as drug load increased, possibly due to greater percentage of oversized fraction 
that increased with increased drug load.  
 
 iv. Drug content 
 Although drug content was significantly affected by replication (p = 0.0446) and 
drug load (p = 0.0108), all the formulations had drug contents > 90% thereby meeting   
our set acceptance criteria (≥ 85%).  The lower drug content obtained with the 80% drug 
loaded 20 micron sized batch supports the hypothesis that the poor wettability of this 
more micronized drug size led to more losses of the drug to the fluid-bed walls, and 
consequently to decreased drug content. 
 
 v. Friability 
 As shown in Table XXV, the percentage weight loss from all the formulations 
was generally less than 2%, indicating that all the formulations could withstand 





 vi. True density and compressibility 
 In both particle sizes, bulk and true densities decreased with increased drug loads. 
Considering the nature or composition of the blend, Avicel® is bulkier and has higher 
particle density than ibuprofen. Consequently, increasing the amount of ibuprofen, i.e. 
decreasing Avicel® content should lead to decreased bulk and true densities as observed.  
In addition, at each drug level, the densities of the 20 micron sized ibuprofen are higher 
than those of the 40 micron sizes.  These could be explained by the higher geometric 
mean sizes obtained from the 20 micron sizes, as already explained on page 168.  The 
50% drug loads of both drug micron sizes have almost similar GMDs and consequently 
slightly similar densities.  These results are supported by those of the statistical analyses 
shown in Table XXVI.  It was observed that drug load (p = 0.0003) significantly affected 
the true density of the microparticulates.   
Bulk density was also significantly affected by drug load (p = 0.001) as well as 
micron size (p = 0.0088), however, no significant interaction was observed between these 
factors (p > 0.05).  The percent compressibility (Carr’s index) was generally < 15%, 
indicative of the acceptable flowability of the spheroids as well as good bulk and true 
densities for the production of both single unit- (tablets) and multi unit (capsules) dosage 
forms. 
 
 vii. Flowability 
 The finer sized ibuprofen resulted in lower flowability (Table XXV). These 
results were as previously reported (52,153). 
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 viii. Sphericity of the granules 
 The sphericity of most of the microparticulates fell within our set acceptance 
criteria (≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table XXV).  The 
sphericity of the 20 micron sized ibuprofen batches were slightly higher than the 40 
micron sized batches.  This could be explained by the smaller size of the particles that 
could form less porous bond with Avicel®, thereby leading to smoother surface texture.  
Statistically, sphericity was significantly affected by drug load (p = 0.0282) and micron 
size (p = 0.0034), but no significant interaction was observed between these factors. 
 
 ix. Size distribution of granules 
 The geometric mean diameter of the microparticulates ranged from 456 ± 1.37 µm 
- 802 ± 1.35 µm (Table XXV; Figure 37) respectively.  Within the batches made of the 
two ibuprofen micron sizes, the GMD increased with increased drug load, which could be 
either due to overgranulation or improved bonding due to higher amount of ibuprofen.  
This observation was also found to be statistically significant (p = 0.0196), as already 
discussed on page 168. 
 
x. Ibuprofen release from granules 
 All the formulations released more than 80% of the drug within 20 min, except 
the batch containing 80% ibuprofen spheronized using the 40 micron sized drug.  This 
could be due to the bigger GMD that consequently reduced the surface area of the 




Figure 37: Geometric mean diameters of drug particle size/drug load batches. 
   
Figure 38. Dissolution profiles of drug particle size/drug load batches. 
 
Statistically, it was observed that drug micron size (p = 0.0034) and drug load  
(p = 0.0282) significantly affected this response variable (Table XXVI).  There was also 
interaction between these main factors, although this was not statistically significant  
(p = 0.0613) based on our set significant level (p < 0.05). 
 In addition, the 65% drug loaded formulation of the 20 µm ibuprofen had similar 
characteristics with the previously optimized 50% and had the most significant positive 

































































b. Effect of Intermediate Size Scale-up on the Characteristics of Ibuprofen 
Microparticulates 
     1. Experimental design 
 Batch size: Batch size significantly (p < 0.05) affected some of the physical 
characteristics studied, namely, bulk density (p = 0.0072), tapped density (p = 0.0124), 
friability (p = 0.0146) and usable fractions (p = 0.0009).  These results were as expected 
as similar observations have been reported for most of these variables (101,140).  
Increased batch size led to higher densities, lower friability and lower usable fractions.  
The latter could be due to increased spheroid size as it affected only the 1 kg batches that 
have considerably big differences in their particle sizes.  These results are shown in 
Tables XXVII and XXVIII and in the Pareto plots (Figure 39). 
 
Drug load: Drug load significantly (p < 05) affected the densities of the 
spheroids (Table XXVIII).  This is due to the difference in the densities of the powder 
blends used in the formulations, which contained different percentages of Avicel®  and 
the drug. As was previously obtained, higher drug loads resulted in lower bulk                
(p = 0059), tapped (p = 0071) and true (p = 0022) densities. 
 
Replication: Replication had no significant effect (p > 0.05) on all twelve 
product characteristics studied (Table XXVIII), as well as no significant interactions with 










Figure 39. Pareto plots of effects of main factors on the specified product qualities. 
 
Interaction: The interaction results are shown in Figure 40.  There was 
significant interaction (p < 0.05) between batch size and drug load on the LOD               
(p = 0.0178) and usable fraction (p = 0.0255) variables (Table XXVIII; Figure 40).   



































Estimated effect on Tapped density 
Estimated effect on True density 
Estimated effect on Friability 
Estimated effect on LOD        
Estimated effect on Usable fraction   
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          Figure 40. Interaction plots of the effects of main factors on specified qualities. 
 
Considering the significant interaction obtained with the usable fraction, and the fact that 
significant effect was obtained from batch size alone, it can be inferred that increased 
batch size resulted in decreased usable fraction.   
 However, the results obtained are within our set acceptance criteria that were 
based on published results from other reporters (6,9). 
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2. Physical characteristics of pellets 
 i. Scanning electron microscopy  
 Figure 41 shows typical morphology of the spheroids obtained from the two drug 
loads (Figures 41A & B) and the two batch sizes (Figures 41B & C).  As shown in Table 
XXVII and Figure 41, the size of the microparticulates increased with increased drug load 
at the 1 kg level.  This effect was not pronounced at the scale-up level. This could be due 
to the fact that although the percentage of Avicel® present in the fluid-bed is the same in 
both batch sizes, the increased batch size of Avicel® might have enhanced   







Figure 41: Scanning electron micrographs (30x) of ibuprofen formulations (20 µm drug 
particle size) containing different drug loads, A (1 kg, 50%); B (1 kg, 65%),  









Batch size 1 kg 50 kg 
% ibuprofen 50 65 50 65 
Physical characteristics     
% Yield 90.85  7.99 87.7  1.56 95.70  0.18 91.38  0.76 
% Moisture content 1.7  .14 0.89  0.01 1.50  0.27 1.74  0.35 
% Drug content 98.55  5.08 98.79  0.95 101.5  2.16 102.09  0.06 
Geometric mean diameter (mm) 485  1.52 605  1.45 522.00  2.04 538.00  1.95 
Sphericity 0.91  0.00 0.91  0.01 0.91  0.00 0.91  0.01 
Flowability (deg) 22.15  0.00 21.43  1.16 22.99  0.47 20.84  0.46 
Carr’s index. (%) 8.03  1.67 6.02  0.06 6.14  0.16 6.85  1.94 
True density (g/cm3) 1.287  0.02 1.235  0.00 1.27  0.01 1.22  0.00 
Bulk density (g/cm3) 0.69  0.01 0.63  0.01 0.77  0.02 0.68  0.01 
Tapped density 0.75  0.02 0.67  0.01 0.82  0.02 0.73  0.00 
Q20 (%) 83.1  1.68 83.1  1.68 83.1  1.68 87.45  1.05 
Friability (%) 0.50  0.24 0.50  0.24 0.00  0.00 0.00  0.00 




  TABLE XXVIII: P-values of Independent Variables of Batch Size/Drug Load Batches 
 
 
Dependent variables Independent variables Interactions 
Physical characteristics Replication Batch size Drug load Interactions 
 1 2 3 2 * 3 
Yield NS NS NS NS 
Drug content NS NS NS NS 
LOD NS NS (0.0602) NS (0.0813) S (0.0178) 
Q20 NS NS NS NS 
Geometric mean 
diameter 
NS NS NS NS 
True density NS NS (0.0753) S (0.0022) NS 
Bulk density NS S (0.0072) S (0.0059) NS 
Tapped density NS S (0.0124) S (0.0071) NS 
Carr’ s index NS NS NS NS 
Flowability NS NS NS (0.0774) NS 
Friability NS S (0.0146 NS NS 
Sphericity NS NS NS NS 
Usable fraction NS S (0.0009) NS S (0.0255) 
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ii. Moisture content/Loss on drying analyses  
 Binder amount: As expected and also as was previously observed, the 
amount of binder needed for spheronization of the different drug levels was inversely 
related to drug load (Table XV), although the amount used for the 50 kg-65% drug load 
appeared to be high. This could be due to some human error as both the total time used 
for spheronization and the percent moisture at the end of the spheronization process 
reflect an inverse relationship to the drug load.  These results indicated that, as previously 
stated, Avicel® acts as molecular sponge that absorbed water.  Additionally, the amount 
of binder needed for the process also decreased as the batch size increased.  From Table 
XV, it is apparent that a processing time was reduced by 13x for intermediate batch 
compared to the small scale batch irrespective of the drug load used (Equations 32 and 
33).  This confirmed the reproducibility of the process.  
 
For the 50% drug load:  
32 Eqn.                 13 
batches) kg 50  theof batches for two  value(Averagemin  246
 50 * batches) kg 1  theof batches for two  value(Averagemin  67
=  
 
For the 65% drug load:  
33 Eqn.                 13 
batches) kg 50  theof batches for two  value(Averagemin  198
 50 * batches) kg 1  theof batches for two  value(Averagemin  5.54
=  
  
Moisture content in the fluid-bed: A plot of the moisture content for both batch 
sizes during spheronization and drying processes in function of time (Figure 42) showed 
that with the two sizes, the amount of the liquid binder needed for the spheronization of  
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the powder blends decreased as the drug load increased.  These correlated with previous 
reports and our earlier explanations about the function of microcrystalline cellulose as a 
molecular sponge for water absorption.  The moisture content at the end of drying of the 
products was generally < 2% (Table XXVII). 
 
Figure 42: The moisture content profile of scale-up batches as a function of time. 
(1 & 2 represent replicate batches). 
 
 iii. Yield and usable fractions of spheroids 
 The yield of the formulations ranged from 87.7 ± 1.56% - 95.7 ± 0.18% with the 
usable fractions (250 - 850 µm) ranging between 69.8 ± 2.12% - 91 ± 1.41% respectively 
(Table XXVII).  Comparing the two batch sizes, increased batch resulted in increased 
product output, which could be attributed to decreased amount lost as a percentage of the 
initial powder blend input. Comparing the two drug loads within each of the batch sizes, 
increased load resulted in decreased product output, as was observed in the previous 























the larger drug load formulation. However, the analysis showed that these observations 
were not statistically significant (Table XXVIII). 
 The usable fraction was influenced by both batch size and drug load (Table 
XXVII). The fraction decreased as drug load increased, however, increased batch size 
appeared to have positively affected the usable fraction since the 50 kg-65% batch yielded 
slightly higher amount than the 50 kg-50% formulation.  These results were supported by 
the statistical results that showed a significant effect (p = 0.0009) of the batch size on this 
variable, as well as a significant interaction effect (p = 0.0255).  
 
 iv. Drug content 
All the formulations had drug contents > 90% thereby meeting our set acceptance 
criteria (≥ 85%).   
 
 v. Friability 
 As shown in Table XXVII, the percentage weight loss from all the formulations 
was generally less than 1. Thus, although the statistical results show a significant effect of 
batch size on friability (p = 0.0146), this effect was obtained between 0 and 0.5% values 
and could be considered clinically unimportant.  
 
 vi. True density and compressibility 
 In both batch sizes, bulk, tapped and true densities decreased with increased drug 
loads, which could be due to the reasons explained in the previous section. In addition, at 
each drug level, the true densities were similar as could be expected, being the same 
 191 
formulation and moreover, true density is indicative of the importance of compactness of 
substances.  However, the bulk and tapped densities, which reflect the packing properties 
of spheres, increased with increased batch size. These could be as a result of other 
product qualities including pellet sizes.  The percent compressibility (Carr’s index) was 
generally < 15%, indicative of the acceptable flowability of the spheroids as well as good 
bulk and true densities for the production of both single unit- and multi unit  
dosage forms. 
 
 vii. Flowability 
 The flowability of the products fall within our set acceptance criteria (θ < 30o). In 
addition, no significant effect was observed on this variable by the main factors.  
 
 viii. Sphericity of the granules 
 The sphericity of all the microparticulates fall within our set acceptance criteria  
(≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table XXVII).   
 
 ix. Size distribution of granules 
 The geometric mean diameters of the microparticulates range from 485 ± 1.52 µm 
- 605 ± 1.45 µm (Table XXVII; Figure 43).  Within the 1 kg batches, the GMD increased 
with increased drug load, which could either be due to over granulation or improved 
bonding due to higher amount of ibuprofen.  For the 50 kg batches, the effect of drug load 
on GMD appeared to be improved with the increased batch size, although these results 
were statistically insignificant (p > 0.05). 
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Figure 43: Geometric mean diameters of batch size/drug load batches. 
 
 x. Ibuprofen release from granules 
 All the formulations released more than 80% of the drug within 20 min. As 
observed by other reporters, the Q20 was higher for the higher drug loaded batches at each 
batch size, despite the larger GMD of the 1 kg batch containing 65% drug load (Table 
XXVII; Figures 43 & 44).  
Figure 44. Dissolution profiles of batch size/drug load batches. 
 
 In summary, increased batch size reduced the processing time at both drug loads 
and also improved some spheroid qualities such as geometric mean diameter (Table XVII 
and Figure 43). The dissolution of the 65% drug load 50 kg batch size was the most 


























































Coating and Encapsulation of Spheronized Ibuprofen Microparticulates Using 
Hard Gelatin Capsules 
 
a. Effects of coating  
     1. Experimental design 
 Polymer type:  Polymer type significantly (p < 0.05) affected most of the 
qualities of the spheroids, except the T50, geometric mean diameter (GMD), the friability 
and the sphericity.  The core pellets used in this experiment were similar for both 
Eudragit® and Surelease®.  The levels were chosen such that the medium level in each 
case represented the company recommended level to obtain satisfactory coating.  It is 
therefore evident from our results that these recommended levels are somehow equivalent 
in the coating capacities of the two polymers.  However, the polymer level necessary to 
achieve the objective (prolonged drug release) is formulation-dependent.  These results 
are shown in Tables XXIX and XXX and also in the Pareto plots in Figure 45. 
 
 Polymer level:  Polymer level significantly (p < 0.05) affected some of the 
physical characteristics studied, namely, yield (p = 0.0370), T50 (p = 0.0165), bulk 
density (p = 0.0462), true density (p = 0.0072), flowability (p < 0.0001), and usable 
fractions (p = 0.0071). Most of these results were as expected.  Drug release has been 
variously reported to decrease with increased polymer level (175,176).  Increased polymer 
level was also expected to increase particle size/geometric mean diameter, which will 
affect the flowability and densities of the formulations, as already explained in previous  
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Figure 45. Pareto plots of effects of main factors on the specified product qualities. 
 
sections.  The discrepancy observed within the batches coated with the Eudragit® polymer 
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tubing that might have altered most of the results expected from this polymer type and 
levels. Possible explanations with regard to this observation will be discussed at the 
various sections of the product quality variables.  The statistical results obtained with this 
variable are shown in Tables XXIX and XXX and also in the Pareto plots in Figure 45. 
 
 Replication: Replication had no significant (p > 0.05) effect on all the product 
characteristics studied (Table XXIX), as well as no significant interactions with the main 
effects [(polymer type and level); results not shown].  Although these results support 
batch-to-batch reproducibility of the process, some effort and experience with the fluid-
bed are required in order to achieve this goal. 
 
Interaction: There was no significant interaction (p > 0.05) between polymer type and  
 
Figure 46. Interaction plots of the effects of main factors on specified qualities. 
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polymer level.  There were also no significant interactions between these main factors and  
replication. These results, some of which are presented in Figure 46 support the feasibility 
of the process.  
        
     2. Physical characterization of granules   
 i. Scanning electron microscopy  
 The size of the microparticulates increased directly with coating Table XXIX and 
Figures 47 & 48.  The pore size decreased, suggestive by the smoother surface of the 
coated pellets.  Thus, the particle size distribution and drug release were subsequently 












Figure 47: Scanning electron micrographs (30x) of ibuprofen granules (65 % drug load). 

















Figure 48: Scanning electron micrographs (100x) of ibuprofen granules (65 % drug load). 
Uncoated ibuprofen (A); Surelease® 12.5% (B); Eudragit®  NE 30D 15.5% (C).  
 
 ii. Yield and usable fractions of spheroids 
 The yield of the formulations ranged from 82.36 ± 0.53% – 98.05 ± 1.47% with 
the usable fractions (250 - 850 µm) ranging between 68 ± 2.83% – 83 ± 2.82% 
respectively (Table XXIX).  The percent yield of the batches coated with Surelease® was 
greater than that of the Eudragit® batches.  The percent yield was calculated based on the 
ratio of the product output to the total weight of solids present in the fluid-bed.  This, as 




TABLE XXIX. Physical Characteristics of Coated Ibuprofen Spheroids (Means of replicated batches) 
 
Polymer type  Surelease Eudragit 
% Coating level 0 (Uncoated) 7.5 10 12.5 12.5 14 15.5 
                                                          Physical characteristics 
% Yield 91.38 ± 0.76 93.35 ± 2.35 98.05 ± 1.47 96.76± 0.54 82.36 ± 0.53 88.31 ± 4.76 90.76 ± 2.81 
% LOD 1.74 ± 0.35 0.66 ± .21 0.76 ± 0.21 0.81 ± 0.14 0.87 ± 
0.0.07 
1.25 ± 0.19 1.29 ± 0.28 
% Drug content 102.09 ± 0.06 108.22 ± 
0.25 









diameter  (µm) 
538.00 ± 1.95 643 ± 0.04 680 ± 0.06 685 ± 0.05 725 ± 0.00 670 ± 0.01 669 ± 0.02 
Sphericity 0.91 ± 0.01 0.85 ± 0.026 0.86 ± 0.05 0.87 ± 0.01 0.86 ± 0.01 0.88 ± 0.01 0.88 ± 0.01 
Flowability (deg) 20.84 ± 0.46 21.06± 0.35 22.78 ± 0.00 23.75 ± 0.00 26.57 ± 0.00 28.73 ± 0.12 29.47 ± 0.30 
True density g/cm3) 1.22 ± 0.00 1.14 ± 0.01 1.12 ± 0.02 1.11 ± 0.01 1.19± 0.00 1.12 ± 0.01 1.15 ± 0.01 
Bulk density g/cm3) 0.68 ± 0.01 0.63 ± 0.01 0.62 ± 0.02 0.63 ± 0.01 0.60 ± 0.00 0.57 ± 0.00 0.60 ± 0.00 
T50 (min) < 15 45 ± 7.07 75 ± 21.21 105 ± 21.21 60 ± 0 105 ± 21.21 100 ± 14.14 
Friability (%) 0.00 ± 0.00 0.33 ± 0.00  0.34 ± 0.47 0.17 ± 0.23 0.17 ± 0.23 0.33 ± 0.00 0.33 ± 0.00 
Usable fraction (%) 73.75 ± 2.19 80.00 ± 0.00 86.00 ± 2.82 83.00 ± 4.24 68.00 ± 2.83 81.00 ± 1.41 80.00 ± 0.00 
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TABLE XXX: P-values of Independent Variables of Coated Ibuprofen Spheroids 
 
Dependent variables Independent variables Interactions 
(PT*PL) 
Physical characteristics Replication (2x) Polymer type (PT) 
[Surelease, Eudragit] 
Polymer level (PL) 
[Low, Medium, High] 
 
 1 2 3 2 * 3 
Yield NS S (0.0016) S (0.0370) NS 
Drug content NS S (0.0269) NS NS 
LOD NS S (0.0248) NS NS 
t50 NS NS S (0.0165) NS 
Geometric mean 
diameter 
NS NS NS NS 
True density NS S (0.0008) S (0.0072) NS 
Bulk density NS S (0.0013) S (0.0462) NS 
Carr’ s index NS NS NS NS 
Flowability NS S (<.0001) S (<.0001) NS 
Friability NS NS NS NS 
Sphericity NS NS NS NS 
Usable fraction NS S (0.0083) S (0.0071) NS 
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confirmed with the fact that within the batches coated with Eudragit®, the percent yield 
increased with the theoretical coating level and increased solid content. The talc effect 
would be more pronounced on the batches coated with the lower polymer level as any 
effect on the ratios (used for yield calculation) would have greater effect on the lower  
polymer level.    
 The usable fractions were mostly < 85% of the product output. This could be 
attributed to some amount of agglomeration that led to increased particle size.  However, 
values as lower than this have been reported acceptable usable fraction in literature (9). 
 
 iii. Drug content 
 The drug content ranged between 105 ± 1.13% – 109 ± 1.34%. Although these are 
greater than 100%, they fell within the USP recommended range for drug content. 
Additionally, standard solution analyzed with these samples (without the extraction 
process) also gave a drug content greater than 100%. The results could be due to some 
random analytical errors. 
 
 iv. Friability 
 During coating, pellets are subjected to appreciable frictional forces, thus friable 
pellets generate significant amount of fines, which can mix with the coating solution and 
affect the topography of the coated pellets. The pellets to be coated must therefore 
withstand the vigorous agitation that occurs in the coating chamber. As shown in Table 
XXIX, the percentage weight loss from the uncoated ibuprofen formulation used for 
coating was zero, indicating its suitability for the coating processes.  The percentage 
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weight losses from all the coated formulations were also less than 2%.  These 
formulations are therefore suitable for the hard gelatin encapsulation process that will be 
subsequently performed.   
 
 v. Densities 
 Coating with both polymers decreased both the bulk and true densities (Table 
XXIX). This could be attributed to increased pellet sizes due to coating. There were 
generally no significant difference between the densities of pellets coated with the same 
polymer, except with the batch coated with 14% Eudragit®.  The inconsistencies observed 
with this polymer could be due to the presence of talc as has already been explained, that 
made it difficult to calculate the actual amount of polymer in the batches. This 
inconsistency was also made obvious with the release pattern observed with these 
Eudragit® batches, as will be shown below. 
 It was not possible to calculate the tapped density of the batches because the 
volume of most of the formulations increased with successive taps, thus making the 
tapped density higher than the bulk density.  This phenomenon was not problematic for 
future (encapsulation) study as it has been reported that the bulk and not the tapped 
density is used to calculate the fill weight for pellets. Consequently, the compressibility 
index could also not be calculated. 
 
 vi. Flowability 
 The flowability of the products fell within the generally acceptable flowability 
criterion (θ < 30o). However, flowability decreased with increased polymer level. 
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Considering the batches coated with Surelease®, the flowability trend could be due to 
increased diameter of the pellets that retarded flow properties, while the reduced flow 
within the Eudragit® batches could be due to increased tackiness with increased polymer 
caused by the absence of the sedimented talc in the products. This tackiness must have 
led to the difference in the flowability between the two polymer types that resulted in high 
significant level observed from this variable with both polymer type (p < 0.0001) and 
level (p < 0.0001). It could therefore be better to add the talc directly to the fluid-bed 
instead of dissolving it in the coating solution. 
 
 vii. Sphericity of the granules 
 The sphericity of both the coated and uncoated spheroids fell within our set 
acceptance criteria (≥ 0.85; Table XXIX).  No significant difference was observed 
between the results obtained from these analyses. However, the pellets coated with 
Surelease® appeared to be better spheres visually. 
 
 viii. Size distribution of granules 
 The geometric mean diameters of the microparticulates ranged from 643 ± 0.04 
µm - 725 ± 0 - 0.00 µm (Table XXIX; Figure 49). As expected, all the coated batches 
were larger than the uncoated formulation, confirming an increased diameter of the 
pellets due to the coating levels.  Within the batches coated with Surelease®, there was 
slight but statistically insignificant increase in diameter as the coating level increased. 
This indicated the consistency of this coating material.  With the batches coated using 
Eudragit® polymer, a discrepancy in the geometric diameter was observed. The batch 
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with the theoretical lowest polymer level was larger than the batches coated with higher 
polymer levels. Most of these pellets appeared to be agglomerated. 
 
Figure 49: Geometric mean diameters of uncoated and coated ibuprofen pellets. 
 
 ix. Ibuprofen release from pellets 
 The uncoated formulation released 50% (T50) of its drug content within 15 min.  
On the contrary, the release rates of the coated formulations were retarded (Table XXIX 
and Figure 50).  The T50 of the replicate batches of these coated formulations ranged 
between 45 ± 7.07 min - 105 ± 21.21 min, depending on the coating level.   
 Several factors affected the release rate of modified release formulations 
(175,176,262). These include the type of equipment used for coating, the porosity of the 
products, surface area, type of dissolution medium, coating level, physical characteristics 
























































sizes have been reported as among the major factors affecting their release characteristics.  
Potter et al. (263), showed that at the same coating level using Surelease®, the T50 of 
chloropheniramine pellets was 40 min (500 – 600 µm), 3 hrs (850 – 1000 µm) and 5 hrs 
(1000 – 1400 µm).  The mean diameter of our pellets was between 642 – 725 µm (Figure 
49), with the mode value lying generally at 425 µm.  Pellet size could therefore explain 
the results obtained from our dissolution analysis. 
 As shown in Figure 50, the release rates of the formulations decreased as the 







Figure 50. Dissolution profiles of ibuprofen pellets. Uncoated pellet and pellets coated 
with Surelease® polymer (Panel A), Uncoated pellet and pellets coated with Eudragit® 








































with Surelease® polymer.  The batches coated with 14% and 15.5% Eudragit® released  
equivalent amount of drugs till 60% of their contents were released, consistent with the  
discrepancy that has been observed in the product qualities of these batches.  However, at 
the highest polymer coating level for both polymers, a prolonged release was  
observed generally. 
 
 x. Kinetics of drug release  
Kinetically, the decreased drug release observed with increased polymer levels is 
due to simultaneous increase in coating thickness and length of diffusion pathway 
(175,188).  These confirmed that the coating process was successfully achieved.  With 
uncoated pellets as well as at low coating levels, pores exist at the pellet surface or at 
pellet-coating interface of the latter due to the coating imperfections achieved at these 
levels. Drugs readily diffuse through these pores, thus the cumulative drug release in this 
case is linear with the square root of time (Equation 7).  The pores are sealed as coating 
levels increase so that drug is released through an intact membrane and consequently 
follow the zero order release kinetics (Equation 12). The transition point where drug 
release is defined by the zero order kinetics is called the critical coating level. Drug 
release has also been shown to follow first order kinetics (Equation 28).  Our data were 
therefore fitted to these equations, to Peppas empirical equation (Equation 9) and to a 
recently proposed combined mechanistic kinetics (Equation 15; 177).  The Peppas 
equation constant incorporates the structural and geometric characteristics of the release 
device (264).  The combined mechanistic equation constants incorporate the Higuchi and 
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zero-order release kinetics.  The results of these studies are shown in Figures 51, 52 and 
Table XXXI. 
 









Uncoated pellets: Drug release from uncoated beads can be described by the 
pore controlled release model, and mathematically by the square root equation (Equation 
7).  Figure 51 shows plots of cumulative percent drug release vs. square root of time of all 
the formulations.  Table XXXI shows the results of the parameters of the drug release 
equations. The best correlation coefficients were achieved with the combined mechanistic 
and Higuchi equations. Howere, the release rate of uncoated formulation depicted by the 
Higuchi constant (kH) shows a high linear release constant compared to the coated pellets. 
These indicate that the uncoated pellets follow an inner matrix (Higuchi) release model. 
 
 Coated pellets: As previously discussed, Surelease® and Eudragit® 
polymers form water permeable but insoluble polymeric membranes that allow controlled  
7 Eqn.                                               2
1
ktQ =
12 Eqn.                                   
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Table XXXI. Results of Regression Equations for Drug Release from Uncoated and 
Coated Pellets According to Equations 7, 12, 28, 15, and 9 Respectively. 
 
Formulations                     Kinetic models




Uncoated 0.9543 19.491 0.7445 3.7974 0.9358 0.0395
SR 7.5% 0.9639 5.6918 0.7977 0.3163 0.9545 0.0034
SR 10% 0.9815 5.2065 0.8473 0.2955 0.9553 0.0026
SR 12.5% 0.9899 5.1117 0.908 0.2991 0.9794 0.0024
EUD 12.5% 0.9796 5.6065 0.8494 0.319 0.9698 0.003
EUD 14% 0.9892 5.1572 0.9183 0.3036 0.9833 0.0024
EUD 15.5% 0.9821 4.9152 0.8811 0.2844 0.9609 0.0022
Formulations                     Kinetic models
Combined mechanistic equation           Peppas equation
R2 k0 kH R
2 kP n
Uncoated 0.9997 3.03 32.55 0.8594 0.2303 1.5443
SR 7.5% 0.9959 0.23 9.27 0.9041 0.304 0.7648
SR 10% 0.9938 0.13 7.22 0.935 0.2428 0.7578
SR 12.5% 0.99 0.01 5.28 0.9758 0.1431 0.7722
EUD 12.5% 0.9904 0.13 7.63 0.9414 0.2313 0.7746
EUD 14% 0.9893 0.01 4.96 0.9828 0.1153 0.7812
EUD 15.5% 0.9843 0.05 5.72 0.9708 0.1477 0.7677
 
 
release of the model drug. Drug release from such systems can either be dissolution-
controlled (Equation 7), membrane-controlled (Equation 12) or a combination of both  
processes (Equation 15), depending on the coating levels (265,266).  As shown in the 
scanning electron micrographs in Figures 47 & 48, the uncoated pellets used for coating 
have pores.  If all the pores of the core ibuprofen pellets are blocked by permeable coating 
































Figure 52: First order release profiles from uncoated (Unctd) and coated ibuprofen pellets 
 
the coating film.  The release rate will depend on the polymer film/dissolution medium 
partition coefficient and zero order kinetics will be followed. Table XXXI shows that the 
highest correlation coefficient was achieved with the combined mechanistic and Higuchi  
equations. The correlation coefficients obtained with the first order kinetics appeared to 
be better than those of the zero order kinetics. However, the n values from the Peppas 
equation were > 0.75 for all the coated formulations, an inclination towards the zero order 
release mechanism.  These results, together with the first order plot shown in Figure 52 
exclude first order kinetics from the release mechanism of the coated pellets.  
Figure 51 also shows that although good correlation was obtained with the coated 
pellets for the Higuchi model, the coated pellets did not follow pure Higuchi mechanism. 
Therefore, the kinetics of drug release from these coated pellets follows either a complex 
system or a combination of square root of time and zero-order kinetics (Equation 15). 
Thus, a non-Fickian diffusion through the polymer films (0.5<n<1) was followed. 
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xi. Comparison of in vitro dissolution profiles using difference and similarity factors 
Drug release decreased as polymer levels increased. Table XXXII lists some time 
points and (their respective) percentage dissolution of both the uncoated and coated pellet 
formulations. Table XXX shows the p-values of some of the product qualities.  The time 
taken for both 50% (p = 0.0165) and 80% dissolutions (T50 and T80 respectively) varied 
for the different formulations, and were significantly affected by the coating levels.  
Results from difference and similarity factors calculations (Table XXXIII) showed that 
the profile of the uncoated pellets was different from those of all the coated pellets         
(f1 > 15 and f2 < 50). These indicated that the release was dependent on the coating level.  
 
TABLE XXXII: Mean Percent Dissolution of Ibuprofen Spheroids at the Specified 
Time Points 
 Time (min) 10 20 60 120 240 480 
Batches  Mean percent dissolution ± SD 
Uncoated 75.32  











Surelease® 7.5% 21.55  















































































TABLE XXXIII: Values of Difference and Similarity Factors (f1 and f2 respectively)  
for Uncoated and Coated Pellets 
Reference formulation Test formulation F1 value F2 value 
Uncoated Surelease® 7.5% 32.04 23.10 
Uncoated Surelease® 10% 40.81 19.25 
Uncoated Surelease® 12.5% 47.95 16.2 
Surelease® 7.5% Surelease® 10% 12.91 54.44 
Surelease® 7.5% Surelease® 12.5% 23.42 41.71 
Surelease® 10% Surelease® 12.5% 12.06 58.68 
 
Uncoated Eudragit® 12.5% 37.72 19.9 
Uncoated Eudragit® 14% 47.89 15.89 
Uncoated Eudragit® 15.5% 48.68 16.13 
Eudragit® 12.5% Eudragit® 14% 16.33 50.65 
Eudragit® 12.5% Eudragit® 15.5% 17.59 49.87 
Eudragit® 14% Eudragit® 15.5% 1.51 71.75 
 
 For the pellets coated with Surelease®, the f2 values indicate that the batch coated 
with 7.5% was similar (f2 > 50) to the profile of 10% coating level batch, but was 
significantly different (f2 < 50) from the pellets coated with 12.5% polymer. The same 
trend of f2 values was obtained from the batches coated with Eudragit®, although to a very 
limited level. The f2 values indicated that the batch coated with 12.5% polymer level was 
not significantly different from those coated with 14% (f2 = 50.65) and was slightly 
different (f2 = 49.87) from the batch coated with 15.5% polymer.  However, the  
results of the 15.5% coating level showed some discrepancies, as already observed from 
other product variables.   
Generally, f1 values confirmed the results of the f2 factor. However, the results of 
comparisons between Eudragit® 12.5% and 14% and Eudragit® 12.5% and 15% appeared 
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to be on a borderline. Thus, the more generally accepted results from f2 factor were 
considered more conclusive in these cases. The batch coated with 12.5% Surelease® was 
therefore chosen to study the effects of encapsulation on the uncoated and coated 
spheroids.  
 
b. Effect of Encapsulation on the Characteristics of Ibuprofen Microparticulates 
     1. Experimental design and Physical characteristics of pellets 
 A major objective of encapsulated formulations is to ensure that each capsule 
provides the expected dose of drug and that the drug should be released from the 
capsule to ascertain its bioavailability.  Tables XXXIV and XXXV show the 
respective results of the effects of encapsulation on pellet qualities and the p-values of 
the independent variables obtained from the statistically analyzed factorial design.  
 
 i. Formulation type 
 Fill weight: Formulation type significantly (p < 0.05) affected the average fill 
weight of the pellets (Figure 53).  As has been previously reported by other authors, this 
could be due to the effects of factors, e.g. flowability of the pellets (224,225,228). Based 
on the results of the angle of repose of the pellets before encapsulation, (Table XXIX), 
the XQFRDWHGSHOOHWV  oZHUHPRUHIORZDEOHWKDQWKHFRDWHGSHOOHWV  o), 
and consequently resulted in higher fill weights within the experimentally specified time 
(Table XXXIV).  Studentized residuals test statistic showed some likely pattern, however, 
based on Dubin-Watson there was no correlation between the observations (p < 0.05). 
The result causing the observed pattern could therefore be an outlier.
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TABLE XXXIV: Effects of Encapsulation Variables on Uncoated and Coated Ibuprofen Spheroids 
 
 
Operational Shuttle speed                   Uncoated                  Coated  
speed (rpm)  (msecs) Average fill SD %CV  Drug ~ T50 Average fill SD %CV  Drug ~ T50
weight (mg) content (mg) (mins) weight (mg) content (mg) (mins)
260 517.03 16.95 3.28 - - 467.8 14.97 3.2 - -
75 280 528.2 8.87 1.68 358.47 7 463.15 12.92 2.79 292.25 90
300 528.35 7.24 1.37 363.24 6 483.2 10.78 2.23 302.65 120
260 511.51 10.22 2 - - 460.7 18.48 4.01 - -
85 280 503.91 16.58 3.29 - - 470.33 18.32 3.89 - -
300 487.24 26.8 5.51 - - 471.58 11.63 2.47 - -
Unencapsulated 528.35 352.23 5 483.2 300.68 120
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Figure 53. Pareto plots of effects of main factors on the specified product qualities
 
TABLE XXXV: P-values of Independent Variables of Encapsulated and 
Unencapsulated (Uncoated and Coated) Ibuprofen Spheroids 
Dependent  variables Independent variables 
Physical characteristics Formulation type Operational speed Shuttle speed 
Average Fill weight S (0.0004) NS NS 
SD NS NS NS 
%CV NS NS NS 
 
 Standard deviation and coefficient of fill weight variation: The more flowable 
uncoated pellets resulted in lower standard deviations and consequently in lower fill 
weight variations. The bar diagram presented in Figure 54 shows that with the two 
formulation types (uncoated and coated), the SD and %CV were generally lower for the 
uncoated than with the coated pellets. The highest variability was however observed with 
the uncoated pellets encapsulated at the highest operational and shuttle speeds. This result 












Estimated effect on SD 







could be due to some interactions between the flowability of the pellets and these 
different factors. There was no pattern observed with this variable and autocorrelation 
result was also not significant (p > 0.05). 
 
ii. Operational speed 
 Although the operational speed was observed to be statistically insignificant (p > 
0.05), Table XXXIV shows that within each formulation type at different operational 
speeds, the average fill weight was slightly higher for the lower speed than the higher 
speed.  Figure 53 also shows that the lower speed (75 rpm) contributed more to the 
operational speed effect than the higher speed (85 rpm). This implied that for 
formulations of similar flowability, a certain amount of speed is required for machine 
operation as to achieve a desirable fill weight for the capsules. 
As can be seen from the Pareto plots (Figure 53) and Table XXXIV, the 
operational speed had more effect on the standard deviation and consequently on the 
coefficient of fill variation than the other factors.  Although these results were observed to 
be statistically insignificant (p > 0.05), they were similar to those obtained previously in 
literature with tamp filling machines using powders (216).  Higher speeds generally led to 
higher SD and %CV. This could be because with high operational speed, there was 
insufficient time to achieve consistent fill weight and reproducibility, thereby introducing 
more filling errors.  There was no pattern observed with this variable and autocorrelation 




 iii. Shuttle speed 
The results obtained with the shuttle speed (which regulates how long the feeder 
assembly stays open to fill the capsules) varied for each formulation type. For the 
uncoated pellets with very good flow properties, there was no difference between fill 
weight at the medium and highest shuttle speeds.  This indicated that 280 msecs was 
sufficient for maximum fill weight of this formulation (Figure 5).  For the coated batches, 
the highest fill weight was also obtained at the lowest operational speed. However, higher 
shuttle speed (300 msecs) was required to achieve higher fill weights compared to those 
obtained with the lower shuttle speeds (260 and 280 msecs).  These results were as 
expected because higher shuttle speed allows more time for the capsule feeder to obtain 
Figure 54. Average fill weight (± SD) of ibuprofen pellets at different shuttle sizes 
and operational speeds. 
Uncted: Uncoated pellets; Cted: Coated pellets 
75, 85: Operational speeds, 75 rpm and 85 rpm 










































































more pellets that will be fed into the capsules. The results obtained with the high shuttle 
speed at high operational speed might therefore be due to possible interactions between 
the product qualities, e.g. flowability, and these different factors. 
 Apart from the uncoated formulation filled at high operational (85 rpm) and 
shuttle (300 msecs) speeds, the SD and %CV decreased as shuttle speed increased (Table 
XXXIV).  A possible explanation to this has been given above, i.e. there was enough time 
for sufficient pellets to fill the gelatin capsules, leading to filling consistency and 
reproducibility.  This could lead to reduced variability in the capsule fill weight.  These 
observations shown in Figures 54 and 55, were however statistically insignificant  
(p > 0. 05).  
Figure 55. %CVs of the fill weight of ibuprofen pellets at different shuttle sizes and 
operational speeds. 
Uncted: Uncoated pellets; Cted: Coated pellets 
75, 85: Operational speeds, 75 rpm and 85 rpm 




































































 In summary, formulation type had significant effect on the average capsule fill 
weight.  Within similar formulation types, high operational speed generally led to 
increased SD and CV.  Additionally, with the two formulation types and using the lower 
speed (75 rpm), high shuttle speed resulted in higher fill weight, lower SD and 
consequently to reduced %CV. The formulations encapsulated at low operational speed 
(75 rpm) and at the medium (280 msecs) and high (300 msecs) shuttle speeds were 
therefore selected to study the content uniformity and release profiles of the encapsulated 
pellets.  
 
iv. Drug content 
 The drug content was calculated as the amount of drug / capsule content used for 
the dissolution experiments. Table XXXIV shows that the drug content was directly 
related to the fill weight of the capsules, with the drug content of the uncoated pellets 
being higher than that of the coated pellets per capsule.  These results confirm the 
reproducibility of the processes involved in the spheronization and encapsulation steps.  
 
       v. Ibuprofen release from granules 
 The percent drug release was normalized for drug content.  The uncoated 
formulations (encapsulated and unencapsulated) consistently released more than 80% of 
the drug within 20 min. As was observed before encapsulation, the T50 of the coated 
formulation was ~ 120 min.  The T50 of the pellets encapsulated at 300 msecs was higher 
than that encapsulated at 280 msecs, although the former had more ibuprofen content. 
Although the gelatin capsules dissolved within 5 min of the dissolution analysis, the 
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pellets remained undispersed throughout the analytical period. Thus, the release of the 
capsules containing higher amount of pellets might have been retarded by the higher 
packing of the content (Table XXIV and Figure 56).   
Figure 56 also show that while the uncoated pellets released almost all their drug 
contents within 40 min, the coated pellets sustained ibuprofen release up to 12 hr. This 
confirmed that encapsulation had no undesirable effect on the formulated ibuprofen 









Figure 56. Dissolution profiles of encapsulated and unencapsulated (uncoated and coated) 
ibuprofen spheroids. 
 
Uncted: Uncoated pellets;  
Cted: Coated pellets;  
Unencap: Unenapsulated pellets 
75, 85: Operational speeds; 75 rpm and 85 rpm;  
























 vi. Drug release kinetics 
 The release mechanism also showed similar results with the unecnapsulated 
pellets (Table XXXVI). However, encapsulation of the uncoated pellets, especially at 75 
rpm and 300 msecs yielded higher correlation coefficients.  The Higuchi release constant 
was however comparatively unaffected. It is possible that smoother release profile was 
achieved by adding the encapsulated pellets in the dissolution baskets, than by pouring  
 
Table XXXVI. Results of Regression Equations for Drug Release from 
Encapsulated and Unencapsulated (Uncoated and Coated) Pellets According to 
Equations Equations 7, 12, 28, 15, and 9 Respectively. 
 
Formulations                     Kinetic models




Uncted-Unencap 0.9543 19.491 0.7445 3.7974 0.9358 0.0395
Uncted-75/280 0.9981 18.402 0.8848 3.82 0.9925 0.0359
Uncted-75/300 0.9985 18.149 0.9255 3.85 0.0361 0.9975
Cted-Unencap 0.9899 5.1117 0.908 0.2991 0.9794 0.0024
Cted-75/280 0.9698 5.4677 0.8712 0.3166 0.9563 0.0026
Cted-75/300 0.9873 5.0532 0.8954 0.294 0.9697 0.0023
Formulations                     Kinetic models
Combined mechanistic equation            Peppas equation
R2 k0 kH R
2 kP n
Uncted-Unencap 0.9997 3.03 32.55 0.8594 0.2303 1.5443
Uncted-75/280 0.999 0.3924 20.09 0.899 0.1878 1.5209
Uncted-75/300 1 0.4966 16.01 0.9103 0.1751 1.5128
Cted-Unencap 0.99 0.01 5.28 0.9758 0.1431 0.7722
Cted-75/280 0.9717 0.05 6.3212 0.9792 0.0451 0.8242
Cted-75/300 0.9882 0.03 5.5603 0.9755 0.1368 0.7753
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them in the basket.  For the coated pellets, encapsulation, especially at the same 
conditions (75 rpm, 300 msecs) yielded results that were very similar to the 
unencapsulated spheroids. The n values of Peppas equation were also > 0.75, thereby 
depicting a non-Fickian diffusion through the polymer film membrane. 
 
vii. Comparison of in vitro dissolution profiles using difference and similarity factors  
 Table XXXVII shows some time points and (their respective) percentage 
dissolution of both the uncoated and coated, unencapsulated and encapsulated pellet  
formulations. 
Results from difference and similarity factors calculations (Table XXXVIII) 
showed that the profiles of all the batches of each formulation type (uncoated and coated) 
were similar (f1 < 15 and f2 > 50). However, the profiles of all the uncoated pellets were 
different from those of all the coated pellets (f1 > 15 and f2 < 50).  These show that the 
ibuprofen release profile depended on the formulation type (coated vs. uncoated). These 
results also confirmed that encapsulation did not alter the release properties of the pellets. 
Consequently, the encapsulated pellets could be used for immediate (uncoated) and 
controlled (coated) delivery of ibuprofen. 
  
Using capsule size 0, the results showed that the highest fill weight and least 
variabilities were obtained in both coated and uncoated ibuprofen pellets with operational 
speed 75 rpm and shuttle speed 300 msecs on the K150i (tamp filling) encapsulation 
machine.  The encapsulation process did not affect the drug content and release profiles 
of the pellets (Table XXXIV and Figure 56). Under these conditions, about 530 mg of 
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TABLE XXXVII: Mean Percent Dissolution of Encapsulated and Unencapsulated (Uncoated and Coated) Ibuprofen 
Spheroids at the Specified Time Points 
 
 
Time (min) 10 20 60 120 240 480
Formulation type                              Mean percent dissolution
Uncoated-Unencapsulated 66.55 81.95 96.16 96.00 - -
*Uncoated-75/280 60.89 81.41 91.49 94.72 - -
*Uncoated-75/300 55.68 81.48 90.09 91.97 - -
Coated-Unencapsulated 4.19 12.27 36.00 54.76 72.13 83.84
*Coated-75/280 5.92 15.11 40.97 61.11 73.93 81.61
*Coated-75/300 9.6 18.60 37.52 56.26 71.36 82.29
 
 
*: Encapsulated batches 
 75, 85: Operational speeds; 75 rpm and 85 rpm 
 280, 300: Shuttle speeds; 280 msecs, 300 msecs. 
 223 
TABLE XXXVIII: Values of Difference and Similarity Factor (f1 and f2) for 













Bold: The release profiles of reference and test formulations were different. 
1. Uncoated and unencapsulated; 2. Uncoated and encapsulated at 75 rpm and 280 msecs 
3. Uncoated and encapsulated at 75 rpm and 300 msecs; 4. Coated and unencapsulated 
5. Coated and encapsulated at 85 rpm and 280 msecs 
6. Coated and encapsulated at 85 rpm and 300 msecs
 
 
uncoated ibuprofen spheroids could be filled into this capsule size while about 485 mg 





F1VALUE F2 VALUE 
1 2 3.57 74.68 
1 3 6.29 63.22 
1 4 68.53 15.75 
1 5 63.86 17.11 
2 3 2.83 78.7 
2 5 62.52 18.32 
2 6 64.85 17.80 
3 5 61.43 19.18 
3 6 61.79 19.32 
4 5 5.87 70.56 
4 6 4.73 71.49 
5 6 1.08 72.69 
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results of the drug content, these pellet weights contained 365 and 302 mg ibuprofen 
respectively.  
Thus, the following information could be deduced using the information in Figure 
14: Uncoated pellets; capsule size “ 0” , 0.68 mL contained 365 mg ibuprofen/capsule, 
therefore, capsule size “ 00” , 0.95 mL could hold 510 mg ibuprofen/capsule theoretically. 
Coated pellets; capsule size “ 0”  contained 302 mg ibuprofen/capsule, therefore, 420 mg 
ibuprofen could be encapsulated into the “ 00”  size capsule.  
It is expected that ≥ 25% of the content of the coated pellets will be released 
within 15 min of delivery to achieve a therapeutic level for the drug. The use of 
microparticulate system would also facilitate dose adjustment by varying capsule sizes 
and fill weights without reformulating the product (9). It is also possible to mix coated 
and uncoated pellets at different levels.  The initial burst effect will be achieved with drug 
release from the uncoated pellets, while sustained delivery will be maintained with the 
coated pellets (177).  
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Ibuprofen spheres with good physical characteristics were developed using the 
rotor-disk fluid-bed technology, a one-step closed process that did not require additional 
unit processes.  Based on plate radius and centrifugal force used as similarity factors for 
scale-up, the batch size and process could be scaled up to 5x and 10x. An attempt to 
simultaneously characterize spheronized ibuprofen granules, as well as process and batch 
scale-up was made.  Consequently, further efforts were centered on experimental design 
for critical study of important process variables and formulation, on scale-up and coating 




Experimentally designed studies on different process and product variables, and 
based on our set acceptance criteria showed that the formulations spheronized using low 
binder level, high surfactant level, stainless steel smooth plate (Formulation 5) and also 
that produced with high binder level, low surfactant level, stainless steel smooth plate 
(Formulation 11) were most acceptable.  The statistical design or approach also 
highlighted complexity and interplay of various variables in the outcome or predicted 
characteristics. It also showed the importance of rational approach in product 
development especially in multivariable unit process, as the case of rotor-disk fluid-bed 
operated. In consideration of the obtained data as well as previous reports 
(134,249,252,257) in which binder level had significant effect on most of the desirable 
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spheroid characteristics, with low binder level forming spheroids with low product 
quality, the conditions set in formulation 11 were used for further studies.  
 
Phase 3 
 Using the optimized formulation to study some of the major formulation variables 
in rotor-disk fluid-bed technology, such as drug load, drug particle size and scale-up, our 
results showed that both particle sizes of ibuprofen are spheronizable at the different drug 
levels studied. Although the time and amount of binder required for the formulations 
decreased with increased drug concentration while spheroid size increased, there were 
generally no differences observed in the physical characteristics of equivalent load of 
both ibuprofen particles.  The reduced surface area due to increased size slowed the rate 
of drug release with the highest drug load, while the low and medium sized drug loads 
showed very similar characteristics.   
 Intermediate size (50 kg) scale-up of the 65% drug load showed that, in contrast to 
the 1 kg batches, increased batch size reduced the effects of drug load on spheroid size 
and drug release, possibly due to an observed interaction between these two factors (batch 
size and drug load).  Statistical analysis showed that true and bulk densities were 
significantly affected by both ibuprofen drug load and batch size, while replication did 
not alter the physical characteristics of both spheroid batch sizes, showing batch-to-batch 
reproducibility.   
 However, in future work, process parameters, e.g. rate of binder addition and end 
point for the binder addition will need to be optimized. These might solve the problem 
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encountered with spheronization processes using increased drug loads.  From the results, 
it can be inferred that the rotor-disk spheronization process is scalable. 
 
Phase 4 
  Coating of 0.7 kg batches of the scaled-up formulation showed that ibuprofen 
product characteristics, e.g.  pellet size, drug release, bulk density, etc. depended on the 
coating levels. As previously reported, we observed slower release with increased coating 
level. This confirmed the successfulness of the coating process. The average fill weight of 
the encapsulated spheroids was mostly affected by the formulation types. Encapsulation 
of the microparticulates had no undesirable effect on the qualities of both formulation 
types.  Therefore, the formulation has a lot of pharmaceutical market potentials (70).    
 
 We have statistically studied the effects of various formulation and product 
variables on the development of spheronized microparticulates using the rotor-disk fluid-
bed technology. Our experience showed that a tighter spheroid fraction would be obtained 
if an in-process means of monitoring moisture content in the fluid-bed is introduced. This 
is because the moisture content is closely associated with the spheroid size and size 
distribution (44).  
Although ibuprofen was used as the model drug, the process could be extended to 
other poorly water soluble drugs. Additionally, with careful manipulation of the variables 
and parameters studied in this work, the process could be applied to water soluble drugs 
as well. These will aid in the production of several pharmaceutical products with reduced 
cost e.g. amount of excipients and production time. 
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Figure 57.  Log-Probability Profiles for Sieve Analysis of 1 kg Replicated 
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Mean micron siz v No SLS 
Mean micron siz v Smooth disk 
Mean micron siz v HPMC 
Mean micron siz v 500/teflon 
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Figure 58.  Log-Probability Profiles for Sieve Analysis of Pilot Size Scale-up 



































Mean micron siz v SS\Sm\1 kg 
Mean micron siz v SS\Sm\5 kg 
Mean micron siz v SS\Sm\10 kg 
Mean micron siz v Tef\Waf\1 kg 
Mean micron siz v Tef\Waf\5 kg 
Mean micron siz v Tef\Waf\10 kg 
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Table XXXIX.  Sphericity Analysis of SS/Sm/1 kg (Trial 4) Batch from 
Feasibility Studies 
Sample # Area Perimeter Roundness Sphericity
1 172440.77 1596.66 1.11 0.85
2 85836.72 1095.65 1.05 0.90
3 140054.00 1397.66 1.04 0.90
4 145441.75 1425.75 1.05 0.90
5 117719.24 1278.26 1.04 0.91
6 129925.26 1362.54 1.07 0.88
7 171147.28 1545.15 1.04 0.90
8 135543.20 1369.57 1.03 0.91
9 161336.42 1495.99 1.04 0.91
10 88412.76 1102.68 1.03 0.91
11 91745.16 1135.45 1.05 0.89
12 159993.59 1505.35 1.06 0.89
13 138333.00 1378.93 1.03 0.91
14 145737.72 1421.07 1.04 0.91
15 118678.41 1287.63 1.04 0.90
16 144636.05 1460.87 1.10 0.85
17 125809.09 1374.25 1.12 0.84
18 114332.04 1292.31 1.09 0.86
19 110314.52 1259.53 1.08 0.87
20 95691.42 1208.03 1.14 0.82
21 171695.36 1627.09 1.15 0.82
22 87930.44 1133.11 1.09 0.86
23 97401.47 1177.59 1.06 0.88
24 113997.70 1322.74 1.15 0.82
25 106412.10 1261.87 1.12 0.84
26 115866.70 1294.65 1.08 0.87
27 101599.85 1238.46 1.13 0.83
28 122586.31 1474.92 1.33 0.71
29 129963.63 1385.95 1.11 0.85
30 95691.42 1208.03 1.14 0.82
Average 124542.45 1337.26 1.09 0.87
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Table XL.  Sphericity Analysis of SS/Sm/5 kg (Trial 12) Batch from 
Feasibility Studies 
 
Sample # Area Perimeter Roundness Sphericity
1 99462.30 1186.96 1.06 0.89
2 335744.80 2172.58 1.05 0.89
3 121013.30 1311.04 1.06 0.88
4 181539.10 1601.34 1.06 0.89
5 121375.00 1311.04 1.06 0.89
6 115614.60 1275.92 1.05 0.89
7 137582.10 1409.36 1.08 0.87
8 162777.90 1526.42 1.07 0.88
9 100925.70 1179.93 1.03 0.91
10 151536.50 1449.16 1.04 0.91
11 139423.70 1388.29 1.03 0.91
12 99462.30 1186.96 1.06 0.89
13 388208.20 2380.94 1.09 0.86
14 162777.90 1526.42 1.07 0.88
15 100925.70 1179.93 1.03 0.91
16 141687.31 1404.68 1.04 0.90
17 178617.77 1582.61 1.05 0.90
18 277367.50 1947.83 1.02 0.92
19 281505.70 1964.21 1.03 0.92
20 185627.88 1638.80 1.08 0.87
21 187502.34 1603.68 1.03 0.92
22 172588.80 1540.47 1.03 0.91
23 124493.66 1325.08 1.05 0.89
24 158585.00 1479.60 1.03 0.91
25 218655.91 1734.78 1.03 0.91
26 288532.20 1996.99 1.03 0.91
27 172210.58 1545.15 1.04 0.91
28 180048.30 1570.90 1.03 0.92
29 166417.20 1512.38 1.03 0.91
30 148330.20 1449.16 1.06 0.89
Average 176684.65 1546.09 1.05 0.90
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Table XLI.  Sphericity Analysis of SS/Sm/10 kg (Trial 13) Batch from 
Feasibility Studies  
Sample # Area Perimeter RoundnessSphericity
1 233279.02 1805.02 1.04 0.90
2 258869.44 1898.66 1.04 0.90
3 312812.66 2128.09 1.08 0.87
4 349101.84 2217.06 1.05 0.89
5 212555.64 1734.78 1.06 0.89
6 350811.91 2221.74 1.05 0.89
7 199445.28 1666.89 1.04 0.90
8 183276.56 1603.68 1.05 0.90
9 183276.56 1603.68 1.05 0.90
10 332516.59 2151.51 1.04 0.90
11 211388.20 1709.03 1.03 0.91
12 211892.45 1711.37 1.03 0.91
13 269036.53 1938.46 1.04 0.90
14 191865.16 1652.84 1.06 0.88
15 291963.25 2032.11 1.06 0.89
16 153180.81 1467.89 1.05 0.89
17 114600.60 1261.87 1.04 0.90
18 143265.83 1442.14 1.09 0.87
19 121281.84 1292.31 1.03 0.91
20 93252.41 1151.84 1.06 0.88
21 110166.53 1245.49 1.05 0.89
22 104943.22 1210.37 1.04 0.90
23 104406.09 1224.42 1.07 0.88
24 156935.25 1533.45 1.12 0.84
25 87376.86 1130.77 1.09 0.86
26 109262.18 1238.46 1.05 0.90
27 158848.08 1488.96 1.04 0.90
28 135252.72 1367.22 1.03 0.91
29 101621.77 1205.69 1.07 0.88
30 102005.45 1222.07 1.10 0.86
Average 186283.02 1585.26 1.06 0.89
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Table XLII.  Sphericity Analysis of Tef/Waf/1 kg (Trial 7) Batch from 
Feasibility Studies 
Sample # Area Perimeter Roundness Sphericity
1 186444.53 1624.75 1.06 0.89
2 128922.25 1332.11 1.03 0.91
3 154353.73 1479.60 1.06 0.89
4 91410.82 1144.82 1.07 0.88
5 149968.98 1442.14 1.04 0.91
6 89010.17 1116.72 1.05 0.90
7 117576.74 1282.94 1.05 0.90
8 92523.45 1142.48 1.06 0.89
9 100350.20 1186.96 1.05 0.90
10 132906.88 1367.22 1.05 0.89
11 144986.83 1423.41 1.05 0.90
12 107053.38 1238.46 1.07 0.88
13 128418.01 1343.81 1.05 0.89
14 106116.13 1238.46 1.08 0.87
15 124970.51 1350.84 1.09 0.86
16 122476.69 1313.38 1.05 0.89
17 220431.72 1805.02 1.11 0.85
18 112090.34 1238.46 1.02 0.92
19 133619.41 1376.59 1.06 0.89
20 118267.34 1289.97 1.05 0.89
21 136255.72 1390.64 1.06 0.89
22 169672.91 1540.47 1.05 0.90
23 157368.23 1479.60 1.04 0.90
24 93756.66 1156.52 1.07 0.88
25 147201.13 1449.16 1.07 0.88
26 102789.21 1184.62 1.02 0.92
27 137543.73 1428.09 1.11 0.85
28 158530.19 1481.94 1.04 0.91
29 94140.32 1144.82 1.04 0.90
30 109547.19 1254.85 1.08 0.87
Average 128956.78 1341.63 1.06 0.89
 235 
Table XLIII.  Sphericity Analysis of Tef/Waf/5 kg (Trial 14) Batch from 
Feasibility Studies  
 
Sample # Area Perimeter Roundness Sphericity
1 79599.43 1058.19 1.05 0.89
2 104449.93 1229.10 1.08 0.87
3 88133.23 1121.41 1.07 0.88
4 123797.59 1315.72 1.05 0.90
5 120646.06 1318.06 1.08 0.87
6 223632.58 1797.99 1.08 0.87
7 233322.86 1826.09 1.07 0.88
8 78300.45 1048.83 1.05 0.89
9 123797.59 1315.72 1.05 0.90
10 139051.00 1418.73 1.08 0.87
11 85102.28 1121.41 1.11 0.85
12 103989.54 1219.73 1.07 0.88
13 108933.33 1250.17 1.07 0.88
14 137335.47 1400.00 1.07 0.88
15 141479.05 1402.34 1.04 0.90
16 365150.00 2277.93 1.06 0.88
17 234342.31 1797.99 1.03 0.91
18 211985.63 1706.69 1.03 0.91
19 287041.38 2067.22 1.11 0.84
20 295553.25 2039.13 1.05 0.89
21 335103.59 2160.87 1.04 0.90
22 205118.03 1716.05 1.07 0.88
23 206789.72 1697.32 1.04 0.90
24 361494.22 2289.63 1.08 0.87
25 210999.06 1725.42 1.06 0.89
26 307726.38 2076.59 1.05 0.90
27 214605.50 1760.54 1.08 0.87
28 226740.27 1788.63 1.06 0.89
29 282135.94 2013.38 1.07 0.87
30 334314.31 2214.72 1.10 0.86
Average 199022.33 1639.19 1.06 0.88
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Table XLIV.  Sphericity Analysis of Tef/Waf/10 kg (Trial 15) Batch from 
Feasibility Studies  
Sample # Area Perimeter Roundness Sphericity
1 259647.72 1926.76 1.07 0.88
2 247162.19 1879.93 1.07 0.88
3 181413.05 1580.27 1.03 0.91
4 277932.09 2008.70 1.09 0.87
5 215515.34 1758.19 1.07 0.88
6 233465.36 1816.72 1.06 0.89
7 276194.63 1999.33 1.08 0.87
8 192506.42 1631.77 1.03 0.91
9 368345.38 2259.20 1.04 0.91
10 230390.56 1774.58 1.02 0.92
11 244279.22 1849.50 1.05 0.90
12 243468.05 1863.55 1.07 0.88
13 270680.81 1957.19 1.06 0.89
14 242169.06 1837.79 1.04 0.90
15 186296.55 1624.75 1.06 0.89
16 153202.73 1491.30 1.09 0.87
17 109240.26 1252.51 1.07 0.88
18 105579.00 1231.44 1.07 0.88
19 87338.49 1121.41 1.08 0.87
20 94743.22 1172.91 1.09 0.87
21 80569.56 1062.88 1.05 0.90
22 122997.38 1376.59 1.15 0.82
23 148702.91 1474.92 1.09 0.86
24 114496.46 1292.31 1.09 0.86
25 105688.63 1273.58 1.15 0.82
26 119275.83 1322.74 1.10 0.86
27 94798.03 1172.91 1.09 0.87
28 159730.52 1514.72 1.07 0.87
29 115921.50 1285.28 1.07 0.88
30 129936.22 1374.25 1.09 0.86
Average 180389.57 1572.93 1.07 0.88
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Table XLV.  Dissolution Data for Ibuprofen Release of Pilot Size Scale-up 













Time (mins)                         % Ibuprofen Released (S.D.)
SS/Sm/1 kg SS/Sm/5 kg SS/Sm/10 kg
5 62.02 (21.29) 60.35 (22.25) 63.64 (10.37)
10 75.73 (13.92 72.89 (19.62) 77.53 (12.88)
20 83.27 (5.02) 82.95 (12.66) 85.53 (5.08)
40 85.86 (1.03) 88.97 (6.74)  87.61 (2.45)
60 86.27 (0.92) 90.18 (4.79) 87.79 (2.38)
120 86.41 (0.54) 90.06 (4.15) 87.96 (4.1)
Time (mins)                            % Ibuprofen Released (S.D.)
Tef/Waf/1 kg Tef/Waf/5 kg Tef/Waf/10 kg
5 61.28 (5.42) 60.43 (24.86) 63.64 (10.37)
10 82.82 (5.83) 70.56 (21.64) 77.53 (12.88)
20 91.75 (2.07) 79.47 (12.88) 85.53 (5.08)
40 94.30 (1.64) 85.64 (5.30) 87.61 (2.45)
60 94.68 (1.66) 87.75 (1.65) 87.79 (2.38)
120 94.69 (2.01) 89.55 (0.07)  87.96 (4.10)
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Figure 59.  Log-Probability Profiles for Sieve Analysis of Experimentally 
Designed Replicated Batches  
Particle size (micron)































Mean micron siz v HbHsSS-sm 
Mean micron siz v LbHsSS-sm 
Mean micron siz v HbHsSS-waf 
Mean micron siz v LbLsTef-waf 
Mean micron siz v LbHsTef-waf 
Mean micron siz v HbLsSS-sm 
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Table XLVI.  Sphericity Analysis of LbHSSS-sm (Formulation 5) Spheroids 
from Experimentally Designed Batches  
 
Sample # Area Perimeter Roundness Sphericity
1 224969.938 1751.17 1.019 0.92
2 191974.781 1620.067 1.022 0.92
3 164076.891 1510.033 1.039 0.90
4 99791.148 1172.91 1.031 0.91
5 86921.945 1102.676 1.046 0.90
6 251371.531 1865.886 1.035 0.91
7 124669.055 1315.719 1.038 0.91
8 179505.688 1566.221 1.022 0.92
9 124669.055 1315.719 1.038 0.91
10 179505.688 1566.221 1.022 0.92
11 176228.094 1549.833 1.019 0.92
12 83973.211 1081.605 1.041 0.90
13 170566.297 1533.445 1.031 0.91
14 118683.891 1271.237 1.018 0.92
15 116913.547 1266.555 1.026 0.92
16 207814.641 1723.077 1.068 0.88
17 190445.594 1662.207 1.085 0.87
18 174304.281 1580.267 1.071 0.88
19 253969.484 1908.027 1.072 0.88
20 219083.422 1765.217 1.063 0.88
21 289814.719 2022.742 1.055 0.89
22 241209.906 1847.157 1.057 0.89
23 130884.422 1353.177 1.046 0.90
24 84373.313 1095.652 1.064 0.88
25 184137.063 1631.772 1.081 0.87
26 104707.539 1236.12 1.091 0.86
27 189130.188 1659.866 1.089 0.86
28 226405.938 1828.428 1.104 0.85
29 259472.328 1959.532 1.106 0.85
30 293201.938 2081.271 1.104 0.85
Average 178092.52 1561.46 1.05 0.89
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Table XLVII.  Sphericity Analysis of HbLsSS-sm (Formulation 11) 
Spheroids from Experimentally Designed Batches  
 
Sample # Area Perimeter Roundness Sphericity
1 83627.906 1069.9 1.023 0.92
2 137658.844 1390.635 1.05 0.89
3 123797.586 1339.13 1.083 0.87
4 73005.883 1004.348 1.033 0.91
5 68259.406 962.207 1.014 0.93
6 62997.719 952.843 1.077 0.87
7 76069.719 1046.488 1.076 0.87
8 125474.75 1325.083 1.046 0.90
9 77160.422 1041.806 1.052 0.89
10 110078.844 1240.803 1.046 0.90
11 110034.992 1243.144 1.05 0.89
12 72337.211 994.983 1.023 0.92
13 152857.438 1456.187 1.037 0.91
14 110150.094 1247.826 1.057 0.89
15 251678.469 1931.438 1.108 0.85
16 207814.641 1723.077 1.068 0.88
17 190445.594 1662.207 1.085 0.87
18 174304.281 1580.267 1.071 0.88
19 253969.484 1908.027 1.072 0.88
20 219083.422 1765.217 1.063 0.88
21 219083.422 1765.217 1.063 0.88
22 241209.906 1847.157 1.057 0.89
23 130884.422 1353.177 1.046 0.90
24 84373.313 1095.652 1.064 0.88
25 259472.328 1959.532 1.106 0.85
26 184137.063 1631.772 1.081 0.87
27 104707.539 1236.12 1.091 0.86
28 149108.484 1470.234 1.084 0.87
29 189130.188 1659.866 1.089 0.86
30 226405.938 1828.428 1.104 0.85
Average 148977.31 1424.43 1.06 0.88
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Table XLVIII.  Dissolution Data for Ibuprofen Release of Experimentally 
Designed Replicated Batches  
Time (mins)                         % Ibuprofen Released (S.D.)
LbHsSS-waf LbHsSS-sm HbHsSSwaf
(Formulation 3) (Formulation 5) (Formulation 6)
5 21.93 (3.20) 69.20 (2.06) 22.48 (0.19)
10 31.76 (3.66) 83.52 (0.59) 32.29 (0.64)
20 47.56 (7.17) 89.87 (0.30) 47.23 (0.47)
40 61.62 (4.58) 91.19 (0.68) 63.98 (0.06)
60 72.66 (3.20) 90.325 (1.20) 77.86 (1.19)
120 86.12 (1.57) 91.11 (2.48) 90.15 (0.04)
Time (mins)                        % Ibuprofen Released (S.D.)
LbsTef-waf LbHsTef-waf HbLsSS-sm
(Formulation 7) (Formulation 9) (Formulation 11)
5 82.08 (3.26) 77.04 (2.75) 78.89 (4.95)
10 86.62 (4.27) 84.46 (2.09) 89.02 (1.37)
20 88.90 (5.25) 89.23 (1.45) 92.47 (3.61)
40 89.53 (3.91) 92.44 (1.03) 93.23 (3.30)
60 90.30 (3.54) 93.51 (0.15) 93.63 (3.87)
120 90.08 (3.17) 93.83 (0.83) 93.67 (3.56)
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Figure 60.  Log-Probability Profiles for Sieve Analysis of Drug Load/Drug Particle 
Size Replicated Batches  
Particle size (micron)
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Mean micron siz v Ibu 40-80 
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Table XLIX.  Sphericity Analysis of Ibuprofen Spheroids from Drug Load/Drug 
Particle Size Replicated Batches (1kg, 20 Micron Size, 65% Drug Load) 
Sample # Area Perimeter Roundness Sphericity
1 158058.83 1517.06 1.09 0.86
2 169914.06 1531.10 1.03 0.91
3 169914.06 1531.10 1.03 0.91
4 289491.34 2008.70 1.04 0.90
5 140152.66 1383.61 1.02 0.92
6 230428.92 1779.26 1.03 0.91
7 281631.69 2004.01 1.07 0.88
8 301708.31 2076.59 1.07 0.88
9 348685.31 2195.99 1.03 0.91
10 317049.44 2137.46 1.08 0.87
11 81495.83 1053.51 1.02 0.92
12 275821.94 2004.01 1.09 0.86
13 258737.89 1912.71 1.06 0.89
14 270735.63 1924.42 1.02 0.92
15 207376.17 1706.69 1.05 0.89
16 149810.05 1428.09 1.02 0.92
17 258710.48 1877.59 1.02 0.92
18 295262.75 2015.72 1.03 0.91
19 174254.95 1552.17 1.03 0.91
20 190966.30 1606.02 1.01 0.93
21 260650.73 1889.30 1.02 0.92
22 313782.78 2069.57 1.02 0.92
23 192122.77 1622.41 1.02 0.92
24 206559.52 1699.67 1.05 0.90
25 236112.64 1797.99 1.02 0.92
26 174814.02 1549.83 1.03 0.91
27 224536.94 1758.19 1.03 0.91
28 239203.89 1816.72 1.03 0.91
29 216945.86 1718.40 1.02 0.92
30 279384.53 1950.17 1.02 0.92
Average 230477.34 1770.60 1.04 0.91
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Table L.  Sphericity Analysis of Ibuprofen Spheroids from Drug Load/Drug Particle 
Size Replicated Batches (1kg, 40 Micron Size, 65% Drug Load) 
Sample # Area Perimeter Roundness Sphericity
1 200963.48 1673.91 1.04 0.90
2 249179.16 1901.00 1.08 0.87
3 223007.77 1793.31 1.08 0.87
4 154370.17 1467.89 1.04 0.90
5 314402.13 2118.73 1.07 0.88
6 260267.06 1933.78 1.07 0.87
7 171350.06 1568.56 1.07 0.88
8 261467.39 1908.03 1.04 0.90
9 133838.64 1397.66 1.09 0.86
10 274462.66 1985.28 1.07 0.88
11 206882.89 1706.69 1.05 0.89
12 218940.92 1765.22 1.06 0.88
13 146461.20 1444.48 1.07 0.88
14 185342.86 1624.75 1.07 0.88
15 188143.61 1638.80 1.07 0.88
16 157439.48 1495.99 1.06 0.88
17 207469.34 1711.37 1.06 0.89
18 232955.64 1821.41 1.07 0.88
19 120207.59 1301.67 1.05 0.89
20 196173.17 1664.55 1.06 0.89
21 112950.84 1271.24 1.07 0.88
22 193257.31 1648.16 1.05 0.89
23 319822.78 2153.85 1.08 0.87
24 287644.28 2029.77 1.07 0.88
25 268543.25 1961.87 1.07 0.88
26 144334.61 1444.48 1.08 0.87
27 164712.67 1540.47 1.08 0.87
28 126686.03 1339.13 1.06 0.89
29 189530.28 1636.46 1.06 0.89
30 178075.16 1594.31 1.07 0.88
Average 202962.75 1684.76 1.07 0.88
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Table LI.  Dissolution Data for Ibuprofen Release of Drug Load/Drug Particle Size 
Replicated Batches  
 
Time (mins)                         % Ibuprofen Released (S.D.)
Ibu 20-50 Ibu 20-65 Ibu 20-80
5 48.82 (7.73) 54.21 (6.32) 54.51 (14.00)
10 65.36 (10.95) 70.31 (6.17) 67.78 (12.92)
20 83.94 (4.00) 86.87 (1.34) 82.80 (6.19)
40 88.98 (2.67) 88.49 (0.69) 89.02 (5.04)
60 90.34 (2.13) 90.29 (0.12) 91.61 (3.95)
120 91.00 (0.90) 91.20 (0.11) 95.55 (0.78)
Time (mins)                            % Ibuprofen Released (S.D.)
Ibu 40-50 Ibu 40-65 Ibu 40-80
5 61.21 (6.38) 56.25 (3.55) 39.92 (3.46)
10 75.10 (6.03) 71.78 (2.36) 54.14 (4.75) 
20 89.48 (4.93) 88.38 (3.73) 74.34 (0.50)
40 91.35 (2.84) 92.13 (3.18) 86.07 (7.21)
60 94.04 (5.60) 93.09 (2.67) 93.33 (7.61)
120 94.01 (4.82) 93.22 (3.04) 99.65 (7.16)
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Figure 61.  Log-Probability Profiles for Sieve Analysis of Intermediate Size Scale-up  
Replicated Batches  
Particle size (micron)
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Table LII.  Sphericity Analysis of Intermediate Scale-up Ibuprofen Replicated 
Batch (20 Micron, 50% Drug Load, 50kg Batch Size)
Sample # Area Perimeter Roundness Sphericity
1.00 84844.67 1069.90 1.01 0.93
2.00 114019.63 1243.14 1.01 0.93
3.00 113783.95 1264.21 1.05 0.89
4.00 110330.96 1243.14 1.05 0.90
5.00 196485.58 1645.82 1.03 0.91
6.00 122125.91 1296.99 1.03 0.91
7.00 128538.59 1329.77 1.03 0.91
8.00 140432.19 1407.02 1.05 0.89
9.00 133444.02 1355.52 1.03 0.91
10.00 132287.53 1357.86 1.04 0.90
11.00 105030.91 1219.73 1.06 0.89
12.00 125524.08 1327.43 1.05 0.90
13.00 85677.77 1079.26 1.02 0.92
14.00 137757.50 1376.59 1.03 0.91
15.00 78053.81 1037.12 1.03 0.91
16.00 132638.31 1357.86 1.04 0.90
17.00 93652.52 1140.13 1.04 0.91
18.00 122800.06 1292.31 1.02 0.92
19.00 126883.34 1322.74 1.03 0.91
20.00 248844.83 1856.52 1.04 0.91
21.00 147168.23 1411.71 1.01 0.93
22.00 130418.54 1350.84 1.05 0.90
23.00 84948.81 1086.29 1.04 0.90
24.00 107332.90 1210.37 1.02 0.92
25.00 178338.25 1582.61 1.05 0.89
26.00 161254.20 1500.67 1.04 0.90
27.00 116546.33 1271.24 1.04 0.91
28.00 88801.90 1109.70 1.04 0.91
29.00 139873.14 1383.61 1.02 0.92
30.00 80673.70 1067.56 1.06 0.89
Average 125617.07 1306.59 1.03 0.91
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Table LIII.  Sphericity Analysis of Intermediate Scale-up Ibuprofen Replicated 
Batch (20 Micron, 65% Drug Load, 50 kg Batch Size) 
Sample # Area Perimeter Roundness Sphericity
1.00 83874.56 1079.26 1.04 0.90
2.00 86752.04 1095.65 1.03 0.91
3.00 211404.64 1702.01 1.02 0.92
4.00 183040.88 1599.00 1.04 0.90
5.00 83677.23 1067.56 1.02 0.92
6.00 218343.50 1727.76 1.02 0.92
7.00 150763.72 1432.78 1.02 0.92
8.00 132517.73 1348.50 1.03 0.92
9.00 177647.64 1563.88 1.03 0.91
10.00 130933.75 1339.13 1.02 0.92
11.00 126905.27 1334.45 1.05 0.90
12.00 213525.77 1704.35 1.02 0.92
13.00 178880.86 1587.29 1.05 0.89
14.00 209552.09 1690.30 1.02 0.92
15.00 102071.21 1182.27 1.02 0.92
16.00 158650.77 1486.62 1.04 0.90
17.00 113285.18 1259.53 1.05 0.90
18.00 283385.59 1973.58 1.03 0.91
19.00 83046.93 1076.92 1.04 0.90
20.00 170878.70 1554.52 1.06 0.89
21.00 108401.68 1236.12 1.05 0.89
22.00 114836.28 1275.92 1.06 0.89
23.00 129788.23 1336.79 1.03 0.91
24.00 348723.66 2205.35 1.04 0.90
25.00 150089.58 1446.82 1.04 0.90
26.00 137012.09 1378.93 1.04 0.91
27.00 117193.08 1282.94 1.05 0.89
28.00 231903.30 1788.63 1.03 0.91
29.00 120931.06 1304.01 1.05 0.89
30.00 129788.23 1336.79 1.03 0.91
Average 156260.18 1446.59 1.04 0.91
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Time (mins)                         % Ibuprofen Released (S.D.)
1 kg-50% 1 kg-65% 50 kg-50% 50 kg-65%
5 48.82 (7.73) 54.21 (6.32) 50.09 (2.7) 62.25 (2.44)
10 65.36 (10.95) 70.31 (6.17) 63.74 (2.94) 75.32 (1.22)
20 83.94 (4.00) 86.87 (1.34) 83.10 (1.68) 87.43 (0.03)
40 88.98 (2.67) 88.49 (0.69) 88.02 (1.13) 90.82 (0.75)
60 90.34 (2.13) 90.29 (0.12) 91.29 (0.02) 92.36 (0.28)
120 91.00 (0.90) 91.20 (0.11) 93.01 (0.67) 93.63 (0.52)
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Figure 62.  Log-Probability Profiles for Sieve Analysis of Uncoated and Coated 
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Table LV.  Sphericity Analysis of SR 12.5% Coated Ibuprofen Spheroids 
Replicated Batches)
Sample # Area Perimeter Roundness Sphericity
1 157675.17 1493.65 1.06 0.89
2 128461.85 1348.50 1.06 0.89
3 170889.67 1554.52 1.06 0.89
4 337635.75 2205.35 1.08 0.87
5 167897.09 1545.15 1.06 0.88
6 116551.81 1275.92 1.04 0.90
7 212122.66 1734.78 1.06 0.89
8 170675.92 1563.88 1.07 0.88
9 96869.82 1165.89 1.05 0.90
10 122701.41 1299.33 1.03 0.91
11 117160.20 1287.63 1.06 0.89
12 99506.14 1170.57 1.03 0.91
13 196518.47 1669.23 1.06 0.89
14 208329.84 1727.76 1.07 0.88
15 123753.74 1296.99 1.02 0.92
16 257696.52 1903.34 1.05 0.89
17 106362.77 1212.71 1.03 0.91
18 220705.77 1748.83 1.04 0.91
19 106554.61 1217.39 1.04 0.90
20 181604.88 1573.24 1.02 0.92
21 192084.39 1634.11 1.04 0.90
22 114047.03 1257.19 1.04 0.91
23 78448.44 1037.12 1.03 0.92
24 157318.91 1463.21 1.02 0.92
25 233640.75 1814.38 1.05 0.89
26 135334.92 1374.25 1.04 0.90
27 72852.41 1018.40 1.06 0.88
28 185293.53 1634.11 1.08 0.87
29 171311.70 1547.49 1.05 0.90
30 227239.03 1781.61 1.04 0.90
Average 162241.51 1485.22 1.05 0.90
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Table LVI.  Sphericity Analysis of EUD15.5% Coated Ibuprofen Spheroids 
(Replicated Batches)
Sample # Area Perimeter Roundness Sphericity
1 154222.19 1486.62 1.07 0.88
2 113175.56 1250.17 1.03 0.91
3 89514.42 1140.13 1.09 0.87
4 198398.42 1659.87 1.04 0.91
5 199023.25 1662.21 1.04 0.91
6 141895.59 1402.34 1.04 0.91
7 143622.08 1411.71 1.04 0.91
8 142427.25 1418.73 1.06 0.89
9 93318.18 1165.89 1.09 0.86
10 93531.94 1140.13 1.04 0.90
11 154863.45 1486.62 1.07 0.88
12 148034.22 1437.46 1.04 0.90
13 186488.38 1636.46 1.07 0.88
14 186581.55 1624.75 1.06 0.89
15 191624.00 1664.55 1.08 0.87
16 154249.59 1481.94 1.06 0.88
17 145228.00 1430.44 1.05 0.89
18 141199.52 1395.32 1.03 0.91
19 97823.50 1170.57 1.05 0.90
20 91202.55 1140.13 1.07 0.88
21 125255.52 1320.40 1.04 0.90
22 154249.59 1481.94 1.06 0.88
23 179127.50 1582.61 1.05 0.90
24 242728.13 1840.13 1.04 0.90
25 191624.00 1664.55 1.08 0.87
26 107376.74 1224.42 1.04 0.90
27 321406.75 2135.12 1.06 0.89
28 267617.00 1964.21 1.08 0.87
29 146159.75 1428.09 1.04 0.90
30 278809.03 1973.58 1.04 0.90
Average 162692.59 1494.04 1.05 0.89
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Table LVII.  Dissolution Data for Ibuprofen Release Coated Replicated Batches  
Time (mins)                                    % Ibuprofen Released (S.D.)
Uncoated SR 7.5% SR 10% SR 12.5%
5 62.25 (2.44)
10 75.32 (1.22) 21.55 (0.67) 16.36 (0.93) 11 (0.35)
20 87.43 (0.03) 31.80 (0.37) 24.19 (1.78) 16.56 (0.40)
40 90.82 (0.75) 47.39 (1.46) 37.27 (3.05) 28.53 (0.98)
60 92.36 (0.28) 56.94 (4.43) 46.82 (3.76) 37.23 (2.96)
90 66.88 (6.58) 56.17 (5.78) 48.29 2.28)
120 93.63 (0.52) 72.91 (9.25) 62.41 (7.56) 55.24 3.44)
150 77.14 (7.59) 68.64 (8.63) 61.96 4.06)
180 80.26 (7.91) 70.01 (8.44) 66.92 (4.52)
240 93.9 (0.46) 85.61 (8.30) 76.98 (4.72) 72.66 (3.09)
360 90.76 (6.89) 84.12 1.46) 79.77 (3.95)
480 91.00 (6.16) 87.47 (3.38) 83.63 (2.41)
720 93.9 (0.20) 93.63 (5.39) 90.2 (4.01) 86.14 (3.27)
Time (mins)                         % Ibuprofen Released (S.D.)
Uncoated EUD 12.5% EUD 14% EUD 15.5%
5 62.25 (2.44)
10 75.32 (1.22) 16.26 (2.37) 9.43 (1.80) 11.18 (0.93)
20 87.43 (0.03) 22.91 (4.07) 15.76 (3.11) 15.28 (2.35)
40 90.82 (0.75) 39.88 (1.34) 27.67 (5.78) 30.09 (2.49)
60 92.36 (0.28) 50.62 (0.98) 37.30 (5.16) 39.05 (3.35)
90 58.97 (0.21) 47.38 (6.80) 49.47 (4.75)
120 93.63 (0.52) 66.69 (1.25) 53 (2.77) 55.44 (3.97)
150 71.49 (1.44) 60.11 (4.75) 60.34 (3.69)
180 75.20 (2.07) 68.43 (9.38) 61.64 (0.16)
240 93.9 (0.46) 82.06 (4.21) 73.13 (4.10) 71.12 (4.26)
360 88.42 (0.55) 81.68 (5.30) 74.87 (1.74)
480 92.09 (0.01) 88.04 (6.14) 80.39 (0.90)
720 93.9 (0.20) 96.61 (2.58) 93.80 (6.65) 89.22 (2.28)
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Table LVIII. Fill Weight and Statistical Parameters of Uncoated Ibuprofen 
Spheroids Encapsulated at 75 rpm and 280 msecs 
 
Sample # Wt. capsule + Av. wt. 20 empty Fill wt. spheroids
spheroids (mg) capsules (mg) (mg)
1 622.19 94.88 527.31
2 624.65 94.88 529.77
3 635.32 94.88 540.44
4 629.86 94.88 534.98
5 624.57 94.88 529.69
6 627.08 94.88 532.20
7 631.62 94.88 536.74
8 631.95 94.88 537.07
9 624.08 94.88 529.20
10 625.21 94.88 530.33
11 622.86 94.88 527.98
12 610.10 94.88 515.22
13 629.29 94.88 534.41
14 634.01 94.88 539.13
15 623.22 94.88 528.34
16 625.39 94.88 530.51
17 601.91 94.88 507.03
18 609.91 94.88 515.03
19 616.29 94.88 521.41
20 612.11 94.88 517.23
Average fill weight (mg) 528.20
Standard deviation 8.87
Coefficient of variation (%) 1.68
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Table LVIX. Fill Weight and Statistical Parameters of Uncoated Ibuprofen 
Spheroids Encapsulated at 75 rpm and 300 msecs 
 
Sample # Wt. capsule + Av. wt. 20 empty Fill wt. spheroids
spheroids (mg) capsules (mg) (mg)
1 617.23 94.88 522.35
2 608.26 94.88 513.38
3 611.68 94.88 516.80
4 617.65 94.88 522.77
5 625.15 94.88 530.27
6 626.09 94.88 531.21
7 630.84 94.88 535.96
8 629.47 94.88 534.59
9 621.19 94.88 526.31
10 627.60 94.88 532.72
11 629.39 94.88 534.51
12 616.45 94.88 521.57
13 620.57 94.88 525.69
14 628.66 94.88 533.78
15 624.45 94.88 529.57
16 613.77 94.88 518.89
17 632.14 94.88 537.26
18 625.23 94.88 530.35
19 635.21 94.88 540.33
20 623.54 94.88 528.66
Average fill weight (mg) 528.35
Standard deviation 7.24
Coefficient of variation (%) 1.37
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Table LX. Fill Weight and Statistical Parameters of Coated Ibuprofen Spheroids 
Encapsulated at 75 rpm and 280 msecs 
Sample # Wt. capsule + Av. Wt. 20 empty Fill wt. spheroids
spheroids (mg) capsules (mg) (mg)
1 552.89 94.88 458.01
2 547.78 94.88 452.90
3 569.09 94.88 474.21
4 554.30 94.88 459.42
5 536.72 94.88 441.84
6 536.67 94.88 441.79
7 573.11 94.88 478.23
8 581.93 94.88 487.05
9 566.62 94.88 471.74
10 554.00 94.88 459.12
11 537.81 94.88 442.93
12 551.14 94.88 456.26
13 552.14 94.88 457.26
14 557.43 94.88 462.55
15 560.84 94.88 465.96
16 574.71 94.88 479.83
17 556.03 94.88 461.15
18 574.26 94.88 479.38
19 565.69 94.88 470.81
20 557.52 94.88 462.64
Average fill weight (mg) 463.15
Standard deviation 12.92
Coefficient of variation (%) 2.79
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Table LXI. Fill Weight and Statistical Parameters of Coated Ibuprofen 
Spheroids Encapsulated at 75 rpm and 300 msecs 
Sample # Wt. capsule + Av. Wt. 20 empty Fill wt. spheroids
spheroids (mg) capsules (mg) (mg)
1 587.86 94.88 492.98
2 577.59 94.88 482.71
3 589.83 94.88 494.95
4 578.74 94.88 483.86
5 583.14 94.88 488.26
6 564.94 94.88 470.06
7 569.66 94.88 474.78
8 563.18 94.88 468.30
9 585.63 94.88 490.75
10 573.47 94.88 478.59
11 591.24 94.88 496.36
12 583.00 94.88 488.12
13 558.88 94.88 464.00
14 570.62 94.88 475.74
15 596.40 94.88 501.52
16 571.49 94.88 476.61
17 571.94 94.88 477.06
18 566.51 94.88 471.63
19 587.53 94.88 492.65
20 590.02 94.88 495.14
Average fill weight (mg) 483.20
Standard deviation 10.78
Coefficient of variation (%) 2.23
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Table LXIIA.  Dissolution Data for Ibuprofen Release of Encapsulated and 
Unencapsulated (Uncoated) Spheroids  
Time (mins)                                 % Ibuprofen Released (S.D.)
Uncoated-Unencapd. Uncoated-Unencapd. Uncoated-Unencapd. 
(75/280) (75/300) 
5 51.71 (0.00) 41.59 (0.00) 38.18 (0.00)
10 66.55 (0.00) 60.89 (0.01) 55.68 (0.00)
20 81.95 (0.00) 81.41 (0.01) 81.48 (0.00)
40 88.69 (0.00) 87.34 (0.01) 87.24 (0.00)
60 96.16 (0.00) 91.49 (0.00) 90.09 (0.00)
90






720 99.03 (0.01) 97.9 (0.00) 95.06 (0.00)
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Table LXIIB.  Dissolution Data for Ibuprofen Release of Encapsulated and 
Unencapsulated (Coated) Spheroids 
 
Time (mins)                         % Ibuprofen Released (S.D.)
Coated-Uncapd. Coated-Encapd. Coated-Encapd.  
 (75/280) (75/300)
10 4.19 (0.01) 5.92 (0.00) 9.6 (0.00)
20 12.27 (0.00) 15.11 (0.00) 18.6 (0.00)
40 25.87 (0.01) 30.44 (0.00) 28.62 (0.00)
60 36.00 (0.01) 40.97 (0.00) 37.52 (0.00)
90 45.83 (0.00) 52.36 (0.01) 48.1 (0.00)
120 54.76 (0.01) 61.11 (0.01) 56.26 (0.00)
150 60.12 (0.01) 64.63 (0.01) 62.18 (0.00)
180 66.48 (0.01) 69.16 (0.00) 65.8 (0.00)
240 72.13 (0.01) 73.93 (0.01) 71.36 (0.00)
360 79.19 (0.01) 80.93 (0.00) 80.29 (0.00)
480 83.84 (0.01) 81.61 (0.00) 82.29 (0.00)
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VII. ABSTRACT 
The aim was to develop uncoated and coated ibuprofen microparticulates in a one-step 
fluid-bed machine with rotor-disk insert, for immediate and prolonged drug delivery. 
Feasibilty studies using ibuprofen:Avicel® (RC-581; 50:50), sodium lauryl sulfate (1%) 
as surfactant and water as binder in FLM-15 Vector Flo-coater with 12”  stainless-steel 
and waffle-disk inserts showed that amount of binder, plate type and the presence of 
surfactant affected most of spheroid characteristics. These variables were used in a 2x2x3 
full factorial (replicated) experiment. Blocking was used to study batch-to-batch 
reproducibility of the process and product variables. Our results confirmed that the binder 
amount, plate-type and the presence of surfactant were important variables in rotor-disk 
spheronization. The amount of binder was the most critical. The batch with the most 
acceptable product characteristics was chosen as the optimized formulation, and used to 
statistically study the effects of other formulation variables viz, drug particle size (20 µm, 
40 µm) and drug load (50%, 65%, 80%) in a 2x3 factorially designed (replicated) 
experiment.  The two ibuprofen particle sizes and the three drug loads were 
spheronizable.  However, spheronization of the higher drug load was more difficult and 
yielded larger sized microparticulates that consequently retarded drug release. The 65% 
drug load was therefore used for intermediate size scale-up, which resulted in spheroids 
with good product characteristics.  
The optimized scaled-up batch was used in a 2x3 factorially designed (replicated) 
experiment to study the effects of polymer type (Surelease®, Eudragit® NE-30D) and 
level (low, medium, high) on the developed microparticulates. Coating level was found to 
be inversely related to the drug release. The batch coated with the highest Surelease® 
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level yielded the most acceptable spheroid characteristics, including most prolonged 
release. The latter and the uncoated spheroids were encapsulated using a 2x2x3 
experiment in Romaco Index-K150i machine. The average fill-weight of the encapsulated 
spheroids was mostly affected by the formulation type. Encapsulation of the 
microparticulates had no undesirable effects on the qualities of both the uncoated and 
coated pellets.   
This study provides spheronized ibuprofen microparticulates that can be sold as 
ready-to-use modified ibuprofen to pharmaceutical companies owing to their lots of 
pharmaceutical market potentials. 
 
